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Prostate cancer is a major cause of cancer-related mortality in Australia men. Mortality 
is primarily due to metastasis and the development of resistance to therapy. While 
prostate cancer is primarily driven by the androgen receptor signalling, a number of other 
factors play important roles in its growth and progression. In particular, small non-coding 
RNA molecules called microRNAs (miRNAs) are known to be key regulators of 
progression in prostate cancer. Our group previously identified one specific miRNA, 
miR-194-5p (miR-194), as an important driver of prostate cancer metastasis; however, 
the molecular mechanisms by miR-194 mediates these effects is not fully understood. My 
PhD project aimed to identify target genes and pathways that miR-194 regulates in order 
to better understand its role in prostate cancer.  
I used cutting-edge genomic techniques and bioinformatics to identify 163 miR-194 
target genes in prostate cancer. In Chapter 3, I used this data to identify a new role for 
miR-194 in prostate cancer. More specifically, I found that miR-194 activity was 
inversely correlated with androgen receptor (AR) activity in clinical samples, an 
observation explained mechanistically by AR-mediated repression of miR-194 
expression. In concordance with these findings, miR-194 activity was significantly 
elevated in treatment-induced neuroendocrine prostate cancer (NEPC), an aggressive 
AR-independent subtype of prostate cancer. Furthermore, miR-194 can enhance 
transdifferentiation of epithelial LNCaP cells to neuroendocrine-like cells, a function 
mediated at least in part by its ability to target the FOXA1 transcription factor. 
Importantly, targeting miR-194 effectively inhibited the growth of aggressive models of 
NEPC, including patient-derived organoids.  
By integrating the miR-194 “targetome” with transcriptomic data, my work has provided 
important insights into miRNA function in cancer cells (Chapter 4). Specifically, I have 
found that miR-194 functions potently through canonical interactions and can mediate 
co-operative repression through targeting multiple sites in the same mRNA transcript. 
Further, I have demonstrated that miR-194 is associated with widespread non-canonical 
interactions that can regulate gene expression, albeit to a lesser extent than canonical 
sites.   
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Finally, in Chapter 5 I have demonstrated that miR-194 has dichotomous effects on 
proliferation and invasion in breast and prostate cancer despite both cancers having 
several underlying biological similarities. Furthermore, in breast cancer I have found that 
miR-194 inhibits estrogen receptor expression, potentially by targeting FOXA1.  
Overall, my work has provided unique insights into the pathobiology of miR-194, 
demonstrated its role as a potential therapeutic target in aggressive AR-independent 
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1.1 The prostate gland 
 
1.1.1 Anatomy of the prostate gland 
 
The prostate is a small, glandular male reproductive organ located within the pelvis. It is 
situated below the bladder, in front of the rectum and surrounds the first part of the 
urethra. Structurally, the prostate consists of glandular and stromal components enclosed 
by a fibromuscular pseudocapsule (Ayala et al. 1989; McNeal 1988).  
The prostate is divided into four histologically distinct zones: three glandular zones - 
central, peripheral, transitional - and the non-glandular anterior fibromuscular stromal 
zone (Figure 1.1) (McNeal 1981). The distal urethral segment receives the majority of 
ducts from prostate glandular tissue (McNeal 1988). The peripheral zone, situated at the 
posterior of the gland, comprises approximately 70% of total prostatic glandular tissue 
(McNeal 1981). The peripheral zone is most predisposed to the development of cancer, 
with the majority (70-80%) of prostatic intraepithelial neoplasia and carcinomas arising 
here (McNeal et al. 1988). The central zone makes up 25% of total prostate glandular 
tissue and is histologically markedly different from the peripheral zone (McNeal 1981). 
The ejaculatory ducts are located within the central zone and the seminal vesicle duct 
fuses with the urethra in this region (McNeal 1988). The transitional zone, comprising 
only 5% of total prostate glandular tissue, is located directly below the bladder (McNeal 
1988). Approximately 25% of cancers arise in the transition zone (McNeal et al. 1988). 
Non-malignant benign prostatic hyperplasia (BPH) typically occurs due to enlargement 
of glandular and stromal tissues in the transitional zone (McNeal 1978). The anterior 
fibromuscular region consists of bundles of smooth muscle fibres (McNeal 1988). 
 




















1.1.2 Histology of the prostate gland 
 
The prostate gland is a highly lobulated structure composed of ducts and acini 
interspersed in a fibromuscular stroma (McNeal 1988). The ducts and acini are lined with 
epithelial cells, mainly luminal secretory and basal cells as well as other stem, progenitor 
or intermediate cells (Figure 1.2). Columnar secretory cells line the lumen whereas 
flattened basal cells are situated peripherally, separating the secretory cells from the 
stroma (McNeal 1988; Packer & Maitland 2016). Neuroendocrine (NE) cells are a rare 
population of cells found in the normal prostate. NE cells have a hybrid of neural and 
epithelial characteristics and comprise less than 1% of the prostatic epithelium 
(Abrahamsson & di Sant'Agnese 1993). The prostate epithelium represents a spectrum of 
differentiation from undifferentiated stem cells to fully mature luminal, basal or 
neuroendocrine cells. At least 3 models have been proposed for epithelial cell hierarchy 
in the prostate (Figure 1.3) (Taylor, Toivanen & Risbridger 2010). The linear hierarchal 
model (Figure 1.3A) hypothesizes that stem cells in the basal layer divide asymmetrically 
into a stem cell and a progenitor cell. Progenitor cells translocate towards the lumen, 
differentiating into an intermediate cell that proliferates and terminally differentiates into 
luminal or neuroendocrine cells (Isaacs & Coffey 1989) (Van Leenders & Schalken 
2001). In the non-linear or bidirectional model (Figure 1.3B), stem cells give rise to 
lineage-specific progenitors that ultimately differentiate into terminal cell lineages 
(Taylor, Toivanen & Risbridger 2010; Wang et al. 2001). A more recent model (Figure 
1.3C) suggests that multiple progenitors (e.g. basal stem cells or castration-resistant 
Nkx3.1-expressing cells (CARNS), a rare population of prostatic epithelial cells) give 
rise to differentiated cells (Taylor, Toivanen & Risbridger 2010; Wang et al. 2009). These 
progenitors may also be bi-potent, giving rise to opposite lineages (Wang et al. 2009). 
The terminally differentiated luminal cells express the androgen receptor (AR), described 
below, and prostate-specific markers such as prostate specific antigen (PSA), prostate-
specific acid phosphatase (PAP), prostate-specific membrane antigen (PSMA) and the 
prostate specific epithelial marker Nkx-3.1 (Shah & Zhou 2012). Mature basal cells are 
characterized by expression of cytokeratins and p63 and lack AR expression (Shah & 
Zhou 2012). NE cells, which also lack AR expression, are considered to be fully 
differentiated and typically express markers such as neural specific enolase, 
chromogranin A, synaptophysin and CD56 (Abrahamsson 1999). Prostate cancers are 
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primarily luminal in origin, although a small percentage arise from neuroendocrine cells 










    
 








         
Figure 1.3: Models for prostate epithelial cell hierarchy (A) Linear hierarchical model 
(B) Non-linear or Bidirectional model (C) Independent arrangement model (Taylor, 




1.2 Androgen receptor (AR): Structure and function  
 
Androgen hormones and androgen receptor (AR) signalling are critical for normal 
prostatic development as well as prostate carcinogenesis (Heinlein & Chang 2004; 
Lonergan & Tindall 2011). The AR, a member of the nuclear receptor superfamily, is a 
ligand-activated transcription factor that is encoded by the AR gene on the X chromosome 
(Lubahn et al. 1988; Van Laar et al. 1989). The AR protein is 110 kDa, made up of 917 
amino acids encoded by 2757 nucleotides on eight exons (Brinkmann et al. 1992; Tilley 
et al. 1989). Similar to other nuclear receptors, the AR protein consists of an N-terminal 
activation domain (NTD), a DNA binding domain (DBD), a hinge region and a C-
terminal ligand binding domain (CTD) (Brinkmann et al. 1989; Jenster et al. 1991).  
AR function is modulated by the binding of agonists or antagonists to the CTD. 
Unliganded AR is generally considered inactive and localised predominantly in the 
cytoplasm associated with molecular chaperones, co-chaperones and tetratricopeptide 
repeat (TPR)–containing proteins (Prescott & Coetzee 2006). Androgens such as 
testosterone and its more active metabolite, dihydrotestosterone (DHT), bind to the AR, 
which induces conformational changes, dissociation from chaperones, dimerization and 
translocation to the nucleus (Grino, Griffin & Wilson 1990; Jenster, Trapman & 
Brinkmann 1993; Wong et al. 1993). In the nucleus, the androgen-bound AR complex 
binds to specific DNA sequences called AR response elements (AREs) in the regulatory 
regions of target genes (Claessens et al. 1996).  
During embryonic development, the presence of androgens (especially DHT) and a 
functional AR is necessary for prostate morphogenesis (Bardin et al. 1973; Siiteri & 
Wilson 1974; Wilson, Griffin & Russell 1993). During early prenatal development, the 
AR is expressed in the urogenital sinus mesenchyme but not in epithelial cells; AR 
regulated signals from the mesenchyme promote bud formation, ductal branching, 
proliferation and differentiation of the prostatic epithelium (Cooke, Young & Cunha 
1991). Expression of epithelial AR commences during late prenatal or early neonatal 
development (Donjacour & Cunha 1993).  
During puberty, androgen receptor signalling promotes growth of the prostate to its 
mature size (Banerjee et al. 2018). Post-puberty, AR signalling maintains homeostasis of 
the prostatic epithelium, promoting differentiation and maintaining a balance between 
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proliferation and apotosis, thereby preventing overgrowth of the prostate (Mirosevich et 
al. 1999). The AR is expressed in both stromal and epithelial cells in the prostate. While 
stromal cells do not appear to require AR for survival, the release of paracrine factors 
mediated by AR activity in stromal cells is necessary for the differentiation, growth, 
survival and function of epithelial cells (Donjacour & Cunha 1993; Prins & Birch 1993). 
Androgens also act directly via epithelial AR, targeting genes that include those 
promoting survival of the secretory epithelia, seminal fluid proteins, factors involved in 
epithelial differentiation and metabolic pathway components (Balk 2014).  
 
1.3 AR co-regulators and pioneer factors 
 
AR activity is modulated by a host of co-regulator proteins, with co-activators enhancing 
transcriptional activation and co-repressors reducing transactivation (Heinlein & Chang 
2002). AR co-regulatory molecules include molecular chaperones, histone modifiers, 
transcriptional coordinators and chromatin modifiers (Chmelar et al. 2007). 
Besides coregulators, pioneer factors play a key role in AR transactivation.  Binding of 
AR to its response elements requires access to DNA, which is mediated by pioneer factors 
(Mayran & Drouin 2018). Pioneer factors bind to condensed chromatin, initiate 
chromatin opening and allow AR to access its regulatory elements (Zaret & Carroll 
2011). FOXA1, a member of the FOX family of transcription factors, is a pioneer factor 
for AR and other members of the steroid hormone receptor family, opening chromatin to 
allow receptor recruitment to genomic loci (Jozwik & Carroll 2012). In the normal 
prostate, FOXA1 is required for AR gene activation in the prostatic epithelium and for 
the differentiation of epithelium into mature luminal cells (Gao et al. 2005; Gao et al. 
2003). The equilibrium between FOXA1 and AR, important for maintaining the AR 











Prostate cancer (PCa) is the second most frequently occuring malignancy and the fifth 
leading cause of cancer-related mortality in men worldwide (Bray et al. 2018). In 
Australia, which has one of the highest estimated PCa incidence rates worldwide (86.4 
per 100,000), PCa is estimated to be the most commonly diagnosed cancer and the 
second-leading cause of cancer mortality in 2019 (Bray et al. 2018; AIHW 2019).  
1.4.2 Diagnosis of PCa 
 
Two major tests that assist in the diagnosis of PCa are the serum prostate specific antigen 
(PSA) test and the digital rectal exam (DRE). PSA is encoded by the human kallikrein 3 
gene (KLK3) and is a well characterised AR target gene in prostate epithelial cells. PSA 
is generally present at low levels in serum with levels between 0-4ng/ml considered 
normal. A rise in PSA levels may be due to PCa and or non-malignant conditions like 
prostatitis and benign prostatic hyperplasia (Kim & Coetzee 2004). PSA or DRE results 
that are indicative of PCa will often lead to histopathological examination of tissue 
obtained by biopsy, which is the definitive diagnostic tool for PCa.  
Besides being used for diagnosis, PSA levels are also used to monitor patients following 
surgery or radiation treatment for PCa. A rise in PSA levels following treatment, known 
as biochemical recurrance (BCR), is used as an indicator of treatment failure, disease 
progression or metastases (Stephenson et al. 2006). 
1.4.3 Gleason grading 
 
The Gleason grading system, based on specific histological patterns of cells, assigns a 
score to histological sections that is indicative of the aggressiveness of the tumour and its 
prognosis. The original sytem of clasification, developed in the 1960s, describes 5 
histological growth patterns graded from 1 to 5 (Figure 1.4) (Gleason 1992). Gleason 
grade 1 represents well differentiated cell architecture that is close to normal and 
associated with favourable prognosis. Grade 5 is indicative of poor differentiation and is 
correlated with poor prognosis. Since tumours are heterogenous and often contain more 
than one grade, the two most prevalent grades are added to generate the Gleason score 
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(Gleason 1992). If only one grade is present or the secondary grade is present in less than 
3% of tissue, the primary grade is doubled to give Gleason score (Humphrey 2004). 
Gleason scores range from 2-10, and have been linked with a number of histopathological 
and clinical endpoints, including tumour size, pathological stage, margin status, 
biochemical recurrence, metastasis and survival (Humphrey 2004). The Gleason score 
remains a powerful prognostic predictor and is used to guide treatment strategies and 
clinical disease management. 
Despite its prognositic utility, the classical Gleason scoring system does have some 
limitation. For instance, the lowest Gleason score currently assigned to tumours is 6, with 
scores of 2-5 not being used due to under grading, poor reproducibilty and a lack of 
correlation between biopsy and prostetectomy samples (Cury, Coelho & Srougi 2008; 
Epstein 2000). Another drawback is that tumours with patterns 3+4 or 4+3 both have an 
overall Gleason score of 7 although tumours with primary pattern 4 are likely to be more 
aggressive (Burdick et al. 2009). To overcome these limitations, modifications have 
recently been made to the classical Gleason scoring sytem whereby Gleason scores are 
assigned into grade groups that more accurately predict disease progression (Gordetsky 


















                        





1.4.4 Tumour staging 
 
Tumour staging classifies tumours based on the extent of spread of disease (Reese 2016). 
The TNM system is widely used for PCa and evalutes the extent of primary tumour (T), 
lymph node involvement (N) and presence or absence of metastasis (M) (Figure 1.5). 
TNM staging in combination with Gleason grade and PSA levels is used to assign patients 
into prognositic stage groups that guide treatment decisions (Buyyounouski et al. 2017). 
1.4.5 Risk stratification 
 
Men with localized or locally advanced PCa, where the cancer is confined within the 
capsule that surrounds the prostate gland or has extended into surrounding organs, are 
stratified at diagnosis into groups based on their risk of disease progression. The 
D’Amico risk stratification system is commonly used for PCa and assesses risk of 
biochemical recurrance over a 5 year period following treatment (D'Amico et al. 1998). 
The D’Amico classifier uses pre-treatment, PSA, Gleason score and TNM stage to assign 










1.5 Treatment of localized and locally advanced PCa 
 
At diagnosis, approximately 93% of men have clinically localized or locally advanced 
disease (National Cancer Control Indicators 2019).With appropriate treatment, localized 
and locally advanced disease is associated with >98% 5-year overall survival rates in 
Australia (National Cancer Control Indicators 2019). 
Management and treatment decisions for localized and locally advanced PCa are based 
on disease risk stratification. Low-risk cancers are often slow growing, clinically 
insignificant and may not require intervention (O’Donnell & Parker 2008). Active 
surveillance i.e. regular monitoring of disease with selective intervention when there are 
signs or symptoms of disease progression, is a commonly recommended approach for 
low-risk tumours (Bellardita et al. 2015; Dall'Era et al. 2008). Active surveillance is also 
an option for a subset of patients who have favourable intermediate risk PCa (defined as 
a single intermediate risk factor, Gleason grade of 3 + 4 = 7 or less and <50% of cancer 
containing biopsies (Zumsteg et al. 2013)), but this carries a higher risk of disease 
progression (Ward et al. 2015). 
Treatment options for intermediate and high-risk PCa include radiation therapy and 
surgery to remove the prostate and some surrounding tissue (i.e radical prostatectomy). 
Radiation therapy may involve either external beam radiation therapy (EBRT) or 
brachytharapy, where radiation source (“seeds”) are implanted near the cancer. Both 
radiation or surgery are effective treatments, with no significant difference in survival 
irrespective of treatment option (Hamdy et al. 2016). Within the high risk group however, 
patients with locally advanced disease are at higher risk of treatment failure. For these 
patients, radical prostatectomy in combination with radiation therapy improves overall 
survival (Jang et al. 2018).  
 
1.6 Treatment of recurrent and metastatic prostate cancer  
 
Despite high post-treatment survival rates, a subset of men (20-40% post radical 
prostatetctomy, 30-50% post radiation therapy) experience BCR within 10 years, either 
due to local disease recurrance or metastasis (Artibani et al. 2018). Local disease 
recurrance involves the presence of cancer cells in the prostatic bed or pelvic area whereas 
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metastatic prostate cancer manifests in distant anatomic sites such as bones, lymph nodes, 
lungs, liver and brain (Logothetis & Lin 2005). Appoximately 10-20% of men develop 
metastatic disease after treatment, although approximately 5% of men also have 
metastatic disease at diagnosis (Merseburger et al. 2013; National Cancer Control 
Indicators 2019). Men with recurrent and metastatic PCa are treated with androgen 
deprivation therapy (ADT), chemotherapy, radiotherapy, immunotherapy or a 
combination of these treatments (Miller et al. 2016).  
AR is the primary driver of primary and metastatic PCa. The AR-regulated transcriptional 
program switches from regulating cell differentiation and homeostatsis in the normal 
prostate to promoting cell proliferation and survival in PCa, resulting in continuous 
growth (Zhou, Bolton & Jones 2015). Hodges and Huggins first demonstrated that PCa 
was dependent on androgen hormones in 1941 and supressing AR signalling has since 
been a mainstay treatment for PCa since that time (Huggins & Hodges 1941). ADT 
supresses prostate tumour growth by reducing levels of circulating androgens and/or 
directly blocking the action of the AR with antagonists. ADT is the primary treatment for 
metastatic PCa and is used as an adjunct to radiotherapy in high-risk and locally advanced 
disease, where it improves disease-free and overall survival (Kauffmann & Liauw 2017).  
Historically, ADT was achieved by orchiectomy (i.e. surgical removal of the testes, 
which produce the majority of androgens), or chemically using oral estrogen, which 
supresses testicular androgen production via negative feedback with the hypothalamic–
pituitary–testicular axis (Figure 1.6) (Phillips et al. 2014; Turo et al. 2014). Both 
orchiectomy and oral estrogen have now been replaced in favour of luteinizing hormone 
releasing hormone (LHRH) agonists and antagonists, and inhibitors of steroid hormone 
synthesis. LHRH agonists, also known as gonadotrophin-releasing hormone (GnRH) 
analogues, bind to their receptors in the pituitary, causing an increase in lutenizing 
hormone (LH) and follicule stimulating hormone (FSH), which act to stimulate 
testosterone production in the testes. This continuous stimulation of LHRH receptors 
ultimately downregulates LH/FSH production leading to suppression of testosterone 
levels (Labrie et al. 1980; Labrie et al. 2005). The rise in serum testosterone levels or 
‘flare’ on initial exposure to LHRH agonists can be detrimental to some patients 
(Thompson 2001). By contrast, LHRH antagonists competitively bind to LHRH receptors 
to prevent the release of LH/FSH and are not associated with a flare (Gordon & Hodgen 
1992). Since the ‘flare’ phenomenon is associated with several side effects including hot 
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flashes, ureteral obstruction, urinary retention, erectile dysfunction, anaemia and muscle 
wasting, LHRH antagonists represent a safer therapeutic approach compared to LHRH 
agonists for treatment of PCa.  
In addition to therapeutics that surgically or chemically prevent production of androgens, 
anti-androgens (also called AR antagonists) are also used to treat advanced PCa. Anti-
androgens are a class of steroidal or non-steroidal molecules that inhibit AR signalling 
by competitively preventing binding of endogenous androgens to the AR (Chen, Clegg 
& Scher 2009). First generation anti-androgens include such as Flutamide, Bicalutamide 
and Nilutamide (more accurately termed selective AR modulators (SARMS) (Culig et al. 
1999; Kemppainen & Wilson 1996). Antiandrogens can be used in combination with 
surgical or chemical castration to improve treatment efficacy (Yang et al. 2019).  
Castration based therapy and first generation anti-androgens invariably fail, normally 
after a period of 2-3 years, resulting castration-resistant prostate cancer (CRPC) (Pienta 
& Bradley 2006; Scher et al. 2004). More than 80% of patients with CRPC develop 






















Figure 1.6: Production of androgens by the testes and adrenal glands. Adapted from 




1.7 Treatment of CRPC  
 
The emergence of CRPC due to the failure of first line treatments has led to the 
development of second generation anti-androgens (Tran et al. 2009). These include 
Enzalutamide and Apalutamide, which bind to the AR with high affinity, prevent 
translocation of receptor into the nucleus and inhibit AR-DNA interaction (Antonarakis 
2013; Rathkopf et al. 2017). These anti-androgens significantly improve overall survival 
and progression free survival in men with CRPC (Chong, Oh & Liaw 2018; Linder et al. 
2018).  
Although the majority of androgen is produced by the testes, about 1% is produced by 
the adrenal glands via the corticotropin-releasing hormone (CRH) and 
adrenocorticotropic hormone (ACTH) signalling axis (Figure 6). Adrenal androgens such 
as dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS) and 
androstenedione act as precursors for the production of testosterone or DHT and thus 
contribute to activation of AR signalling. Drugs such as abiraterone acetate are used to 
inhibit the cytochrome P450 family of enzymes involved in adrenal and gonadal 
androgen synthesis (Friedlander & Ryan 2010; Mostaghel 2013; Mostaghel & Plymate 
2011).  
Additional treatment modalities for CRPC and mCRPC includes chemotherapy, 
radiopharmaceuticals and immunotherapy. These treatments are also used in combination 
with castration or ADT to aggressively treat non-CRPC metastases for improved clinical 
outcomes (Sweeney et al. 2015). Commonly used chemotherapeutic agents used for 
CRPC include docetaxel, cabazitaxel and mitoxantrone. For bone metastasis, the 
radiopharmaceutical radium-223 dichloride has been found to be effective at improving 
overall survival (Parker et al. 2013). Radium-223 is a calcium mimetic that is 
incorporated in stroma formed by bone metastases where it emits cytotoxic alpha 
radiation (Parker et al. 2013). Immunotherapy, using a dendritic cell vaccine (Sipuleucel-
T) is used to treat asymptomatic or minimally symptomatic CRPC.  
Despite being incurable, emerging therapies have improved median survival for patients 
with CRPC. This longer life expectancy is associated with cancer-related complications, 
particularly related to the urinary tract and skeletal system if bone metastases has 
occurred. In these instances, palliative treatments are used for symptomatic relief and to 
improve quality of life (Piper et al. 2014). 
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1.8 Mechanisms of resistance to ADT 
 
1.8.1 Reactivation of AR signalling 
 
Persistent AR signalling in spite of castrate levels of circulating testosterone  is the main 
driver of CRPC growth in ~70-85% of cases (Bluemn et al. 2017; Coutinho et al. 2016). 
Persistent AR signalling in CRPC is frequently due to AR gene amplification, which 
occurs at low frequency (~1%) in primary tumours but at high frequency (45-54%) in 
CRPC (Abida et al. 2019; Cancer Genome Atlas Research 2015; Chen et al. 2004; Grasso 
et al. 2012; Koivisto et al. 1997; Robinson et al. 2015; Taplin et al. 1995; Visakorpi et al. 
1995). Increased AR expression promotes resistance to ADT by sensitizing cells to low 
levels of serum androgen (Visakorpi et al. 1995). AR gene point mutations, which occur 
in a proportion of CRPC tumour cells, are also important in resistance to ADT (Steinkamp 
et al. 2009). AR mutations are found in 5-30% of tumours post-treatment but infrequently 
in primary PCa prior to treatment (Coutinho et al. 2016). CRPC-associated AR mutations 
mostly occur within the ligand binding domain of the AR where they promote 
promiscuous binding and activation by alternative ligands such as estrogens, 
progesterone or anti-estrogens (Eisermann et al. 2013). 
AR splice variants (AR-Vs) represent another strategy adopted by PCa to progress to 
CRPC (Hörnberg et al. 2011). AR-Vs are alternately spliced isoforms of the AR mRNA 
that encode the NTD and DBD but lack the CTD (Qu et al. 2015); Approximately 20 AR-
Vs have been identified in cell lines and clinical specimens, of which several are 
constitutively active and can signal in the absence of androgen (Jernberg, Bergh & 
Wikström 2017; Kallio et al. 2018).  
Besides AR alterations, continued AR signalling is maintained by increased expression 
of steroidogenic enzymes within the tumour, which enhances intratumoral synthesis of 
testosterone and DHT from adrenal androgens (Armandari et al. 2014; Montgomery et 
al. 2008). Collectively, mechanisms of resistance to ADT in PCa highlight the central 
role that AR plays in PCa progression. 
Yet another adaptive mechanism in CRPC is the activation of GR signalling (Arora et al. 
2013). The GR can act as a surrogate AR by occupying AR DNA binding sites and 
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regulating expression of some AR target genes to promote therapeutic resistance (Arora 
et al. 2013).  
 
1.8.2 “AR indifferent” PCa 
 
A subset (20-25%) of prostate tumours are known to shed their reliance on AR and its 
associated pathways and progress to an “AR indifferent” state, in which AR expression 
may or may not be retained (Bluemn et al. 2017). The major “AR indifferent” prostate 
cancer subtypes is neuroendocrine prostate cancer  (Ellis & Loda 2018). Neuroendocrine 
prostate cancer that arises after failure of second generation AR-targeted therapies (i.e. 
Enzalutamide, Abiraterone) is referred to as treatment emergent NEPC (T-NEPC) 
(Davies, Beltran & Zoubeidi 2018). T-NEPC is highly aggressive and generally causes 
death within 2 years from diagnosis (Davies, Beltran & Zoubeidi 2018). Similar to 
neuroendocrine cells, NEPC express NE markers, such as synaptophysin (SYP), 
chromogranin A (CHGA), neuronal-specific enolase (NSE) and are defined by loss of 
AR expression (Beltran et al. 2011). NEPC tumours also originate as de novo primary 
cancers from prostatic neuroendocrine cells but are very rare (~1%).  
T-NEPC tumours are suggested to arise as an adaptive response to ADT via lineage 
plasticity. Lineage plasticity or cellular plasticity refers to the ability of a differentiated 
cell to revert to a less differentiated state or change to an alternative differentiated state 
(Aggarwal et al. 2014; Ellis & Loda 2018; Le Magnen, Shen & Abate-Shen 2018). In 
concordance with this hypothesis, androgen deprivation has been shown to reprogram 
AR-positive PCa cell lines into a metastable cancer-stem cell like state that can 
differentiate into a neuroendocrine phenotype (Nouri et al. 2017). Additionally, lineage 
tracing has determined that neuroendocrine (NE) cells transdifferentiate from prostate 
luminal cells (Zou et al. 2017). Furthermore, epithelial mesenchymal transition (EMT), a 
transdifferentiation process utilized by cancer cells for metastasis, has also been 
associated with T-NEPC (Esposito et al. 2015; McKeithen et al. 2010). 
AR targeting therapies have been shown to contribute to the emergence of NEPC via 
upregulation of AR-repressed genes that can promote transdifferentiation. For example, 
BRN2 is a neural transcription factor repressed by AR that is upregulated by the AR 
antagonist Enzalutamide (Bishop et al. 2017). BRN2 is required for T-NEPC and acts 
30 
 
partly by regulating SOX2, a transcriptional factor required for pluripotency and self-
renewal (Bishop et al. 2017). SOX2, which is also directly repressed by the AR, promotes 
lineage plasticity in NEPC (Mu et al. 2017).  
In addition to de-repressed AR signalling, multiple genetic, epigenetic and transcriptional 
events converge to promote plasticity and transdifferentiation in T-NEPC. Common 
genetic events include allelic loss of RB1 and PTEN, Tp53 mutations and amplification 
of AURKA and MYCN (Mosquera et al. 2013; Tan et al. 2014). RB1 loss often occurs in 
conjunction with PTEN and Tp53 mutations (Tan et al. 2014). Mechanistically, this de-
represses the expression of SOX2 and EZH2, to enable lineage switching (Ku et al. 2017). 
EZH2 is a histone methyltransferase that regulates cell pluripotency by altering gene 
expression via methylation of histone H3 lysine 27 (H3K27). Other factors implicated in 
progression to T-NEPC also act via SOX2- and EZH2-regulated gene networks. For 
instance, MYCN has been shown to drive progression to NEPC by activation of an EZH2 
mediated transcriptional program (Dardenne et al. 2016). Besides EZH2, other epigenetic 
regulators upregulated in NEPC include the RNA splicing factor SRRM4, and non-
coding RNAs such as miR-100-5p, miR-652 and lncRNA-p21 (Lee et al. 2018; Luo et 
al. 2019; Nabavi et al. 2017; Nam et al. 2018).  
Another AR indifferent prostate cancer subtype, called double negative prostate cancer 
(DNPC), is negative for both AR and NEPC markers (Bluemn et al. 2017). DNPC arises 
in patients after treatment with AR antagonists and is associated with elevated autocrine 
FGF MAPK signalling which allows these tumours to bypass the requirement for AR 
signalling(Bluemn et al. 2017) . The DNPC subtype has been suggested to be a transition 
state to NEPC (Bluemn et al. 2017).  
At present, treatment options for AR-indifferent PCa are limited to chemotherapy 
regimens. Novel molecular targeting therapy against EZH2 and AURKA are currently 




MicroRNAs (miRNAs) are a class of small non coding RNA molecules that post-
transcriptionally regulate expression of target genes by (Bartel 2004). miRNAs were first 
discovered in the nematode Caenorhabditis elegans where they were found to interact 
31 
 
with the 3’UTR of developmental genes and negatively regulate their expression (Lee, 
Feinbaum & Ambros 1993; Reinhart et al. 2000).  
miRNA genes encoded in the human genome are located either intergenically or within 
the introns of protein coding genes (Lee et al. 2004). Approximately 25% of human 
miRNA genes are organized in clusters of two or more genes (Kabekkodu et al. 2018). 
Clustered miRNA are co-expressed and transcribed as a single polycystronic unit 
(Baskerville & Bartel 2005). Transcription of individual or clustered intergenic miRNA 
genes is generally initiated from their own transcription initiation sites whereas intronic 
miRNA are either transcribed as part of their host genes or from upstream regulatory 
elements independent of the host gene (Lee et al. 2004; Monteys et al. 2010; Ozsolak et 
al. 2008).  
Like mRNA, most miRNA are transcribed by RNA polymerase II (Lee et al. 2004). 
Primary miRNA transcripts (pri-miRNA) are 5’ capped and 3’ polyadenylated hairpin 
structures that can range from a few hundred to a few kilobase pairs in size. Within the 
nucleus, pri-miRNA are processed into a 60-70bp pre-miRNA hairpins by a complex 
known as the microprocessor, consisting of Drosha and DGCR8 proteins (Figure 1.7) 
(Han et al. 2004). Pre-miRs are exported into the cytoplasm by the Exportin5 complex 
where they are processed into 18-22bp mature miRNAs by Dicer (Ha & Kim 2014; Lee 
et al. 2003; Lund et al. 2004). Mature miRNA are then incorporated into an RNA-induced 
silencing complex (RISC) along with Argonaute proteins. The RISC ribonucleoprotein 
complex recognizes and binds to target transcripts by Watson-Crick base pairing between 
the 5’ end of the miRNA and complementary sequences mainly in 3’UTR of the target 
transcript (Bartel 2009). Gene expression is repressed via transcript degradation or 
translational repression (Pratt & MacRae 2009). In humans, miRNA-encoding genes 
make up >5% of the human genome but regulate nearly 60% of protein coding genes 
(Friedman et al. 2009). As regulators of gene expression, miRNAs play critical roles in 














1.9.1 MiRNA in PCa 
 
miRNAs were first linked with tumorigenesis when miR-16-1 and 15a were found to be 
located in a chromosomal region deleted in B cell chronic lymphocytic leukaemia (Calin 
et al. 2002). Both these miRNA target the anti-apoptotic protein Bcl2 and their loss 
inhibits apoptosis (Cimmino et al. 2005). Since this initial discovery, dysregulation of 
miRNAs has been reported in all cancer types (Peng & Croce 2016). Dysregulation of 
miRNAs in cancer is often a consequence of alteration of miRNA gene loci such 
amplification, deletion, translocations, copy number variation and epigenetic changes, 
perturbation of upstream transcriptional regulators or defects in biogenesis (Peng & 
Croce 2016). Cancer-associated miRNA are either oncogenic (oncomiRs) i.e. they 
downregulate the expression tumour suppressor genes or act as tumour suppressors by 
targeting oncogenes (Pang, Young & Yuan 2010).  
In PCa, studies comparing miRNA expression in normal prostate epithelium, BPH, 
primary tumours, metastases, hormone sensitive tumours and CRPC as well as work in 
animal and cell line models have implicated miRNAs in PCa initiation, progression, 
therapy resistance, and metastatic dissemination. (Ambs et al. 2008; Goto et al. 2015; 
Hart et al. 2014; Jalava et al. 2012; Martens-Uzunova et al. 2012; Porkka et al. 2007; 
Walter et al. 2013). Mechanistically, PCa associated miRNA mediate these effects by 
regulating cell cycle, apoptosis, migration, invasion and other related pathways. For 
instance, the oncogenic miR-221/222 family promotes PCa proliferation by repressing 
the cell cycle inhibitor p27 and inhibits apoptosis by repressing Caspase-10 (Galardi et 
al. 2007; Wang, Liu, et al. 2015). Other examples of oncomiRs in PCa include miR-21, 
which targets the cell cycle inhibitor p57(Mishra et al. 2014), miR-9, which regulates 
metastasis via SOCS5 and CDH1, (Seashols-Williams et al. 2016), miR-32, which 
regulates the cell cycle and apoptosis via BTG2 (Jalava et al. 2012), and miR-194, which 
regulates metastasis via SOCS2 (Das et al. 2017). Tumour suppressive miRNAs that have 
frequently been reported as downregulated in PCa include the let-7 family that targeting 
cell cycle regulators E2F2 and CCDN2 (Dong et al. 2010), the miR-15a-16-1 cluster 
targeting the cell cycle regulator CCND1 and WNT pathway signalling ligand WNT3A 
(Bonci et al. 2016), and miR-34a which inhibits proliferation by targeting and MYC 
(Yamamura et al. 2012).  
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Importantly, the downregulation of a number of AR targeting miRNA is partly 
responsible for increased AR expression and activity in PCa. Conversely, the AR 
signalling axis induces expression of oncogenic miRNA and represses tumour suppressor 
miRNA. This interplay between the AR signalling axis and miRNA is important in 
driving PCa growth and progression.  
 
1.9.2 Interplay between the AR signalling axis and microRNAs in PCa  
 
This section of the introduction was published as a review article. 
Interplay between the androgen receptor signalling axis and microRNAs in prostate 
cancer. (2019). Fernandes RC, Hickey TE, Tilley WD, Selth LA. Endocr Relat Cancer. 



























The androgen receptor (AR) signaling axis is critical for normal prostatic development 
and maintenance and is the major driver of prostate cancer (PCa) growth and disease 
progression. Androgens such as testosterone and its more active metabolite, 
dihydrotestosterone (DHT), bind to the AR in the cytoplasm of prostate epithelial cells, 
which elicits its translocation into the nucleus. Ligand-activated AR binds to specific 
DNA sequences termed AR response elements (AREs) in regulatory regions of target 
genes, resulting in transcriptional activation or, less commonly, repression (Wang, et al. 
2009). In normal prostate epithelial cells, a key function of AR target genes is to maintain 
luminal differentiation; by contrast, in malignant prostate cells an aberrant AR 
transcriptional program promotes cell proliferation and survival (Coutinho, et al. 2016).  
 
Given the critical role of AR in PCa, androgen deprivation therapy (ADT) is the primary 
treatment for metastatic disease (Feldman and Feldman 2001). ADT encompasses 
multiple agents that: i) decrease circulating androgen levels by inhibiting pituitary signals 
that stimulate testicular androgen production i.e. lutenizing hormone releasing hormone 
(LHRH) and gonadotropin releasing hormone (GnRH) agonists that; ii) diminish 
biosynthesis of androgens i.e. inhibitors of androgen biosynthetic enzymes; and/or iii) 
inhibit AR activity i.e. agents that block androgen binding to the AR, termed AR 
antagonists. Unfortunately, these treatments inevitably fail, normally after a period of 2-
3 years. The resultant disease is termed castration-resistant prostate cancer (CRPC) 
(Scher, et al. 2004). AR remains the key driver of most cases of CRPC. Maintenance of 
AR activity despite low levels of circulating androgens can be achieved through 
amplification or mutation of the AR gene, alternative splicing to produce constitutively-
active AR splice variants, altered expression of AR co-regulators and/or enhanced intra-
tumoral androgen production (Coutinho et al. 2016).  
 
MicroRNAs (miRNAs) are a class of small non-coding RNAs, approximately 22nt in 
length, that post-transcriptionally silence target messenger RNAs (mRNAs). An 
estimated 60% of all protein coding mRNAs are targeted by miRNAs (Friedman, et al. 
2009), highlighting the powerful influence these small transcripts can have on the 
transcriptome and how it is interpreted by the cell. Primary transcripts of miRNA genes 
(pri-miRNAs), transcribed primarily by RNA polymerase II, can be encoded by 
sequences within (intragenic) or outside of (intergenic) protein-coding genes (Lee, et al. 
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2004; Rodriguez, et al. 2004). Following transcription of a miRNA gene (or host gene), 
pri-miRNAs are processed into precursor miRNAs (pre-miRNAs) that fold into a stem 
loop structure and are exported from the nucleus (Kim 2005). Within the cytoplasm, pre-
miRNAs are cleaved into a miRNA duplex that is then separated; one strand is the final 
mature form of approximately 22bp and the other strand is degraded (Kim 2005). As part 
of the RNA induced silencing complex (RISC) that includes Argonaute (Ago) proteins, 
miRNAs bind to target mRNAs and promote transcript degradation and/or translational 
inhibition (Fabian and Sonenberg 2012). MiRNAs generally bind to the 3’UTR of their 
target genes through complementarity with a region called the seed sequence, consisting 
of nucleotides 2-8 on the 5′ to 3′ ends of a miRNA sequence (Lewis, et al. 2005), although 
an increasing number of studies have also identified functional miRNA seed sites in the 
coding and 5’UTR regions of genes (Brummer and Hausser 2014; Ito, et al. 2017; Zhang, 
et al. 2018; Zhou and Rigoutsos 2014).  
 
Dysregulated miRNA expression is a hallmark of cancer development and metastasis 
(Calin and Croce 2006; Jackson, et al. 2014). PCa-associated miRNAs were initially 
reported by Porkka and colleagues, who identified differential expression of miRNAs 
between benign and malignant prostatic tissue (Porkka, et al. 2007). MiRNAs have since 
been implicated in all aspects of prostate carcinogenesis and progression to metastatic 
and therapy-resistant disease (Kojima, et al. 2017; Luu, et al. 2017). Moreover, since 
some PCa-associated miRNAs exist stably in the circulation of patients, there is 
considerable interest in their utility as blood-based biomarkers to improve PCa diagnosis, 
prognosis and treatment management (Fabris, et al. 2016; Kanwal, et al. 2017; Matin, et 
al. 2018).  
 
In this review we explore the significance of the interplay between the AR signaling axis 
and miRNAs as it relates to PCa growth and progression. Finally, we speculate on the 
potential clinical applications of miRNAs implicated in the regulation of AR. 
 
2. REGULATION OF AR BY MICRORNAS  
Direct targeting of AR by miRNAs 
Mechanisms by which miRNAs influence the AR signalling axis are depicted in Figure 
1. One prominent feature of this interplay is direct targeting of the AR 3’UTR by 
miRNAs. Indeed, a recent study predicted that the AR 3’UTR is likely to be more heavily 
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regulated by miRNAs than all other PCa driver genes and in the top 5% of regulated 
genes overall (Hamilton, et al. 2016). This elegant work exploited photoactivatable 
ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein 
(Ago-PAR-CLIP) to identify 147 miRNA seed sides corresponding to 71 miRNA 
families in the AR 3’UTR (Table 1). Importantly, 4 of the miRNAs identified by Hamilton 
and colleagues – miR-9, miR-34c, miR-185 and miR-488 –had been previously 
discovered in 2 high-throughput screens aimed at identifying AR-targeting miRNAs 
(Kumar, et al. 2016; Östling, et al. 2011) (Table 1). In addition to these unbiased 
approaches, many other studies have characterized specific AR-targeting miRNAs in a 
more directed manner. Interestingly, in addition to classical targeting of the 3’UTR, 
miRNA regulation of the AR via 5’UTR (miR-31) and the coding region (miR-421, miR-
449a, miR-449b, miR-646, miR-371, miR-193a and miR-9) has also been reported 
(Kumar et al. 2016; Lin, et al. 2013; Östling et al. 2011). A list of putative AR-targeting 
miRNAs and their putative modes of action is provided in Table 1. 
 
We propose that the biological relevance of these AR-targeting miRNAs can be 
prioritized using a set of discrete parameters. First, miRNAs that have been identified in 
multiple studies using multiple in vitro models are likely to have greater biological 
relevance in PCa. Second, it is known that transfection of cells with miRNA mimics can 
yield non-physiological miRNA activity; therefore, we prioritize studies that have 
demonstrated AR targeting using both miRNA mimics and inhibitors. Third, given that 
prostate tumors are “addicted” to AR (Coutinho et al. 2016), one would expect oncogenic 
selection pressure to down-regulate biologically relevant AR-targeting miRNAs. Indeed, 
a number of AR-targeting miRNAs have been reported to be down-regulated in prostate 
tumors compared to non-malignant prostate tissues. However, it is worth noting that our 
own analyses of miRNA expression in The Cancer Genome Atlas (TCGA) and Memorial 
Sloan-Kettering Cancer Center (MSKCC) (Taylor, et al. 2010) often contradict the 
published associations with cancer (Figures 2A-B). Finally, it would be expected that 
biologically relevant miRNAs are inversely correlated with AR protein levels in clinical 
samples. Indeed, our analysis of the TCGA cohort revealed such a correlation for miR-
145, miR-205, miR-34a and miR-31 (Figure 2C). Using these parameters for 
prioritization and taking into account both published findings and our new analyses, we 
have generated a list of candidate AR-targeting miRNAs, shown in Table 2, which are 
ranked by predicted relevance in PCa. We propose that down-regulation of at least a 
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subset of these miRNAs is a key enabler of enhanced AR expression and activity in this 
disease. 
 
When considering targeting of AR by miRNAs, it is worth noting that the reference AR 
3’UTR sequence is annotated as being 6,777 nucleotides in length (NM_000044.4), but 
other isoforms have been reported. For example, LNCaP cells have been reported to 
express an AR isoform with the canonical ~6.8kb 3’UTR and another alternatively 
spliced version that lacks a 3kb region in the 3’UTR (Faber, et al. 1991). Moreover, 
Ostling and colleagues delineated a 6,680 nucleotide AR 3’UTR in VCaP cells, a 
sequence that was also identified in LNCaP, LAPC-4, 22Rv1, and MDA-PCa-2b cell line 
models (Östling et al. 2011). In addition to variation in length, 5 single nucleotide 
polymorphisms (SNPs) were identified in the AR 3’UTR in PCa cell lines (Waltering, et 
al. 2006). Interestingly, SNPs have been reported to influence miRNA targeting of 
multiple genes in PCa (Stegeman, et al. 2015a; Stegeman, et al. 2015b), although our 
analyses indicate that none of the AR 3’UTR SNPs occur within conserved miRNA 
recognition sequences (not shown). Nevertheless, we believe that reported variations in 
the length and sequence of the AR 3’UTR warrants further consideration in relation to 
interplay with miRNAs, especially since 3’UTR sequences are often overlooked in 
genomic and transcriptomic studies. 
 
Direct targeting of AR splice variants by miRNAs 
AR splice variants (ARVs) are truncated isoforms of the AR that lack part or all of the 
C-terminal ligand binding domain (LBD) (Antonarakis, et al. 2016). ARV mRNAs were 
first identified in PCa cell lines (Dehm, et al. 2008; Guo, et al. 2009) but have since been 
detected in patient specimens including primary tumors and metastases, circulating tumor 
cells and whole blood (Antonarakis, et al. 2014; Hornberg, et al. 2011; Hu, et al. 2009; 
Liu, et al. 2016). Recent RNA-seq data indicates the presence of at least 16 distinct ARV 
mRNA species in primary PCa (TCGA 2015) and 23 in metastatic CRPC (Robinson, et 
al. 2015). A subset of these ARVs are constitutively active (i.e. they can regulate 
transcription in the absence of androgen) and are therefore resistant to therapies that target 
the LBD (Chan, et al. 2015). Although the relevance of ARVs in driving the growth of 
CRPC remains to be definitively proven (Luo, et al. 2018), it is worth noting that high 
expression of certain ARVs, such as AR-V7 and AR-V9, correlates with resistance to 
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AR-targeted therapies and worse survival (He, et al. 2018; Kohli, et al. 2017; Qu, et al. 
2015).  
 
Given the clinical relevance of ARVs, it is important to understand how they are regulated 
by miRNAs in PCa. Of note, ARVs possess 3’UTR sequences distinct from the canonical 
AR transcript (Hu, et al. 2011; Shi, et al. 2015) (Figure 3A). Recent studies have begun 
to decipher miRNA regulation of ARVs. Interestingly, a number of miRNAs regulate 
both canonical AR and specific ARVs through different target sites. For example, miR-
124 targets the AR transcript via a 3’UTR site that is distinct from another functional 
targeting site in the 3’UTRs of AR-V3, AR-V4 and AR-V7 (Figure 3B) (Shi et al. 2015; 
Shi, et al. 2013). Although the complete repertoires of ARV-targeting miRNAs remain 
to be determined, the identification of miRNAs that target both AR and ARVs via distinct 
sequences is intriguing and may suggest co-evolution of miRNAs and alternative AR 
splicing. Another mechanism by which miRNAs target both AR and ARV transcripts is 
via shared sequences in coding regions, as exemplified by translational regulation of AR 
and AR-V7 by miR-646, miR-371-3p and miR-193a-3p (Kumar et al. 2016).  
 
Importantly, differences in the 3’UTRs of ARVs and AR suggest that many of the 
identified AR-targeting miRNAs would not influence ARV expression, and vice versa. 
While this remains to be proven for most miRNAs, a recent study provided proof of 
concept by showing that miR-181c-5p effectively suppresses AR-V7 expression by 
targeting its 3’UTR but has no effect on the levels of the prototypical AR (Wu, et al. 
2019). Interestingly, AR-V7 and ARv567es exhibit greater post-transcriptional stability 
than AR in CRPC bone metastases (Hornberg et al. 2011); it is tempting to speculate that 
this may be (at least partly) explained by differential miRNA targeting. 
 
Indirect modulation of AR expression and activity by miRNAs  
As well as direct regulation of AR, miRNAs can indirectly influence the expression and 
activity of AR via multiple mechanisms (Figure 1), including targeting AR co-regulators. 
Approximately 200 AR co-regulators – broadly classed as co-activators and co-repressors 
– have been identified, comprising a highly complex and potent system for shaping AR 
function in PCa (Liu, et al. 2017) . The co-repressor small heterodimer partner (SHP) is 
downregulated by miR-141, which is frequently elevated in PCa, thereby indirectly 
contributing to activation of AR’s transcriptional activity (Xiao, et al. 2012). Another AR 
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corepressor, Prohibitin (PHB), is targeted by miR-27a, leading to increased expression of 
AR target genes and PCa cell growth (Fletcher, et al. 2012). Interestingly, miR-27a is an 
androgen-regulated miRNA, creating a feedback loop that represents a novel mechanism 
by which AR enhances its own activity. 
 
Concomitant with enhanced miRNA-mediated targeting of AR co-repressors in PCa is 
the frequent loss or down-regulation of miRNAs that target AR co-activators. For 
example, miR-137 targets a suite of AR co-activators and is progressively lost with tumor 
grade due to DNA methylation of the MIR137 locus (Nilsson, et al. 2015). Loss of miR-
331-3p, which targets the ERBB2 (HER2) oncogene, another AR co-activator (Craft, et 
al. 1999), also enhances AR signaling in PCa (Epis, et al. 2009). The AR co-activators 
p300/CBP-associated factor and bromodomain containing 8 isoform 2 are targeted by 
miR-17-5p and miR-185, respectively, leading to reduced AR transcriptional activity in 
PCa cells (Jiang, et al. 2016; Xiao et al. 2012). Interestingly, miR-185 also directly targets 
AR, enabling this miRNA to mediate a dual mode of inhibition of the AR signaling axis 
(Jiang et al. 2016). 
 
Another mechanism by which miRNAs indirectly influence the AR signaling axis is by 
targeting factors that regulate AR gene expression. For example, miR-let-7c targets the 
oncogenic transcription factor Myc, thereby indirectly down-regulating AR expression 
(Nadiminty, et al. 2012). Similarly, by directly targeting fibronectin type III domain 
containing 1, miR-1207-3p reduces fibronectin 1 and subsequently AR expression (Das, 
et al. 2016). Todorova and colleagues reported that miR-204 targeting of the DNA 
methyltransferase DNMT1 results in decreased methylation of, and hence increased 
transcription from, the AR gene promoter (Todorova, et al. 2017). The nuclear matrix 
protein hnRNPH1, which is upregulated in prostate tumors and promotes expression of 
AR and AR-V7, AR transactivation and binding to AREs, is a target of miR-212 (Yang, 
et al. 2016); miR-212 is downregulated in prostate tumors and its ectopic expression in 
PCa cell lines results in decrease in hnRNPH1 and AR expression (Yang et al. 2016). In 
summary, targeting AR co-regulators and upstream regulators of AR expression allows 
miRNAs to exert an additional layer of regulation on this key oncogenic signaling axis 





3. REGULATION OF MICRORNAS BY THE AR SIGNALING AXIS 
Direct regulation of miRNA gene expression by AR 
The AR can directly regulate the PCa “miRNAome” by binding to androgen response 
elements (AREs) within cis-regulatory regions that regulate miRNA gene expression 
(Figure 4). The integration of AR genome-wide DNA binding profiles (“cistromes”) with 
androgen-regulated transcriptomes has greatly facilitated the identification of direct 
miRNA target genes (e.g. (Pasqualini, et al. 2015; Takayama, et al. 2011)). This strategy 
has been used successfully irrespective of whether miRNAs are encoded in an intragenic 
or intergenic manner (Pasqualini et al. 2015). In general, AR induces oncogenic miRNAs, 
which act as downstream effectors of AR signaling, and represses tumor suppressor 
miRNAs (Table 3), although exceptions to this rule exist (see paragraph immediately 
below). Key oncogenic miRNAs that are directly upregulated by AR’s transcriptional 
activation function include miR-19a, miR-27a, miR-133b and miR-185-5p, all of which 
can promote PCa cell growth and/or survival (Mo, et al. 2013; Yao, et al. 2016), whereas 
tumor suppressor miRNAs directly repressed by AR include miR-221/222 and miR-421 
(Gui, et al. 2017; Meng, et al. 2016).  
 
While AR is the major driver of PCa, it also plays an essential role in normal prostate 
physiology, where it primarily regulates a differentiative rather than proliferative 
transcriptional program (Coutinho et al. 2016). This concept may explain the observation 
that AR also promotes the expression of miRNAs that inhibit proliferation (e.g. miR-101, 
miR-135a and miR-1, which target the oncogenic factors EZH2, ROCK1/2 and SRC 
respectively (Cao, et al. 2010; Kroiss, et al. 2015; Liu, et al. 2015)) and promote epithelial 
differentiation (e.g. miR-200b, which targets factors that drive epithelial-mesenchymal 
transition, such as ZEB1 (Williams, et al. 2013)).  
 
Indirect regulation of miRNA expression and/or activity by the AR signaling axis 
Indirect regulation of miRNAs by the AR can occur through a variety of mechanisms 
(Figure 4). First, AR appears to play an important regulatory role in miRNA biogenesis 
(Fletcher et al. 2012) by upregulating expression of DICER (Mo et al. 2013) and also, at 
least for certain miRNA transcripts, modulating the activity of Drosha (Fletcher et al. 
2012). The latter mechanism was elegantly elucidated by Fletcher and colleagues, who 
demonstrated a dual mode by which AR regulates miR-27a: AR induced expression of 
the primiR-23a27a24-2 cluster and concomitantly accelerated Drosha-mediated 
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processing of this cluster to generate mature miR-27a (Fletcher et al. 2012). The 
biological significance of AR’s role in regulating the PCa miRNAome was highlighted 
by the observation that treatment of LNCaP cells with the AR antagonist Enzalutamide 
results in a ~25% reduction in the number of miRNAs associated with gene 3’UTRs 
(Hamilton et al. 2016).  
 
AR-mediated regulation of the epigenome – more specifically, interplay between the AR 
and DNA methylation machinery – also modulates miRNA expression. As an example, 
by negatively regulating DNMT1, AR elicits hypomethylation and activation of the 
MIR375 promoter (Chu, et al. 2014). Similarly, AR appears to regulate the DNA 
methylation levels of genomic elements that regulate the expression of miR-22 and miR-
29a, although the mechanism by which it achieves this is unclear (Pasqualini et al. 2015).  
 
Androgen receptor-mediated rewiring of microRNA/mRNA transcriptional networks  
The androgen-regulated transcriptome has been examined in many different PCa models 
and contexts (Massie, et al. 2011; Nelson, et al. 2002; Ngan, et al. 2009; Pomerantz, et 
al. 2015; Velasco, et al. 2004). However, it is often difficult to identify which of these 
transcripts are directly regulated by AR, largely due to the fact that AR often binds to 
enhancers that are distal to its target genes (Wang, et al. 2007). Carefully assessing the 
temporality of androgen-mediated gene regulation (Massie et al. 2011), integrating 
transcriptomic data with AR cistromes (Pomerantz et al. 2015) and/or using more 
sophisticated transcriptomic techniques such as global run-on sequencing (GRO-seq) 
(Toropainen, et al. 2016), which is designed to identify nascent transcription, have 
improved the detection of bona fide AR targets in PCa cell lines and tissues. Nevertheless, 
accurately differentiating direct versus indirect targets of the AR remains challenging.  
 
We propose that indirect regulation of protein-coding genes by androgens/AR is heavily 
influenced by the same genes being direct targets of AR-regulated miRNAs. Sun and 
colleagues explored this concept by evaluating the AR-repressed miR-99a/let7c/125b-2 
cluster and discovered significant enrichment of AR-induced genes that are putative 
targets of these miRNAs (Sun, et al. 2014). Importantly, this in silico finding was 
validated for select candidate targets of each miRNA (Sun et al. 2014). We have expanded 
on this earlier work by intersecting TargetScan-predicted targets (Agarwal, et al. 2015) 
of AR-induced miRNAs with a panel of androgen-repressed genes, and vice versa 
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(Massie et al. 2011) (Table 4). Androgen-repressed genes are significantly over-
represented in the putative targets of certain AR-induced miRNAs, whereas androgen-
induced genes are over-represented in the targets of certain AR-repressed miRNAs. Our 
analysis provides strong evidence that protein-coding genes can be regulated by AR 
signaling via AR-mediated rewiring of miRNA/mRNA transcriptional networks. This 
phenomenon should be considered when undertaking genomic analysis of AR activity as 
it may facilitate the elucidation of the direct versus indirect transcriptional regulation.  
 
Regulation of AR and miRNA expression by feedback loops 
Feedback loops are a common feature of the interplay between AR and miRNAs. For 
example, the MIR21 gene is directly activated by the AR; conversely, miR-21 increases 
expression of AR in PCa cell lines, potentially by targeting PTEN – although the precise 
mechanism remains unclear (Mishra, et al. 2014; Ribas, et al. 2009). Since miR-21 
potently stimulates prostate tumor growth and metastasis, this feedback loop is likely to 
play a key role in PCa progression by maintaining expression and activity of 2 oncogenic 
factors (i.e. AR and miR-21) (Bonci, et al. 2016; Li, et al. 2009; Reis, et al. 2012). 
Conversely, the AR-repressed miRNAs miR-31 and miR-421 both target the AR directly 
(Lin et al. 2013; Meng et al. 2016; Östling et al. 2011). In the case of miR-31, this 
negative feedback loop is shifted in favor of the AR during disease progression, since 
DNA hypermethylation and subsequent down-regulation of miR-31 is a feature of 
aggressive prostate tumors (Lin et al. 2013; Meng et al. 2016). 
 
Indirect regulatory loops between miRNAs and the AR also exist. For example, miR-
190a is directly repressed via an AR binding site in its promoter, and in turn it suppresses 
AR expression and activity by targeting the 3’UTR of YB1 (Xu, et al. 2015), a 
transcription factor that acts to enhance AR gene transcription and also as an AR co-
activator (Shiota, et al. 2011; Xu et al. 2015). 
 
4. MICRORNAS AS REGULATORS OF THERAPY RESISTANCE IN 
PROSTATE CANCER  
A key feature of CRPC is the acquisition of miRNA activity that promotes cell survival 
in androgen-depleted conditions. Given the central role of AR in CRPC, it is not 
surprising that many of these miRNAs act, at least in part, by enhancing AR expression 
and/or activity. The feedback loop between miR-21 and AR has already been described 
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above; in the context of CRPC, it is worth noting that over-expression of miR-21 alone 
is sufficient to impart androgen-independent growth (Ribas et al. 2009). Unlike miR-21, 
miR-221/22 is repressed by AR signalling, yet it plays a similar role in promoting CRPC 
growth; upon castration, it is immediately upregulated and acts to enhance the expression 
of key cell cycle genes (Gui et al. 2017). Another example of a CRPC-relevant miRNA 
that influences AR is miR-125b, which was found to be elevated in androgen-independent 
derivatives of the LNCaP model (Shi, et al. 2007). By targeting the AR co-repressor 
NCoR2, miR-125b enhances AR signalling and thereby promotes androgen-independent 
growth (Yang, et al. 2012) .  
 
Concomitant with gain of oncomiRs in CRPC is loss of miRNAs that inhibit survival, 
proliferation and other oncogenic properties, including: miR-146a, which targets the 
oncogene Rho activated protein kinase (Lin, et al. 2007; Lin, et al. 2008); let-7c, which 
targets the oncogenes Myc and Lin28 (Nadiminty et al. 2012); miR-145-3p, which targets 
cell cycle associated genes (Goto, et al. 2017); and the AR-targeting miRNAs miR-30c-
5p and 30d-5p (Kumar et al. 2016). 
 
While the aforementioned miRNAs appear to play important roles in the progression of 
PCa to a castration-resistant state, it is noteworthy that studies evaluating expression of 
miRNAs in CRPC tissues are poorly concordant. Nevertheless, by comparing miRNAs 
putatively associated with CRPC in 3 published genome-wide miRNA profiling studies 
(Goto, et al. 2015; Goto et al. 2017; Jalava, et al. 2012) and combining this with our own 
analysis of the Memorial Sloan-Kettering Cancer Center cohort (Taylor et al. 2010), we 
have identified a set of miRNAs that are reproducibly dysregulated in CRPC. MiRNAs 
that were not reproducibly altered in these studies may be false positives, or alternatively 
may simply reflect differences in experimental design; for example, one study compared 
miRNA expression between benign prostatic hyperplasia and CRPC (Jalava et al. 2012), 
while the others compare normal prostate tissues or hormone naïve PCa with CRPC (Goto 
et al. 2015; Goto et al. 2017; Taylor et al. 2010). Moreover, only the latest of these 
employed RNA-seq (Goto et al. 2017), while the earlier studies used PCR arrays (Goto 






5. CLINICAL POTENTIAL OF AR-ASSOCIATED MICRORNAS IN 
PROSTATE CANCER 
AR-associated miRNAs as biomarkers  
Circulating miRNAs can be detected in many body fluids – most notably serum, plasma 
and urine – and have shown promise as biomarkers for PCa diagnosis and prognosis and 
predicting therapy response. Since this topic has been comprehensively encapsulated in 
recent reviews (Fabris et al. 2016; Kanwal et al. 2017), here we will briefly touch on the 
relevance of the AR signalling axis to these putative biomarkers. Several PCa-associated 
circulating miRNAs are known to be regulated by AR, suggesting that – like the classic 
PCa marker prostate specific antigen (Catalona, et al. 1991) – their release into circulation 
is likely increased in PCa due to elevated AR activity. One prominent example is miR-
375, which has consistently been identified as a potential marker of PCa, with higher 
levels in serum or plasma being associated with shorter overall survival and metastasis 
(Brase, et al. 2011; Huang, et al. 2015; Mitchell, et al. 2008; Selth, et al. 2012). AR 
indirectly promotes miR-375 transcription by suppressing DNA methylation of its 
promoter (Chu et al. 2014), and we have previously shown that miR-375 levels are 
positively correlated with androgen signalling in multiple tumor datasets (Selth, et al. 
2017). The release of miR-375 from LNCaP cells into culture medium is stimulated by 
DHT (Gezer, et al. 2015; Tiryakioglu, et al. 2013), suggesting that its levels in the blood 
of patients would be increased in PCa due to elevated AR activity. Other AR-regulated 
miRNAs that have been proposed as potential serum- or plasma-based biomarkers of PCa 
include miR-21 (Zhang, et al. 2011), miR-125b (Fredsoe, et al. 2017), miR-141 
(Gonzales, et al. 2011), miR-19a (Stuopelyte, et al. 2016), miR-27a (Gao, et al. 2018) 
and miR-221/222 (Santos, et al. 2014).  
 
Potentially the most useful application of circulating miRNAs would be in predicting 
response to therapies for CRPC. Given that an important subset of circulating miRNAs 
are AR-regulated, it is conceivable that one or more of these may be useful in predicting 
response to AR-targeted therapies. Supporting this concept, elevated circulating miR-141 
could predict clinical progression in a small cohort of CRPC patients with a sensitivity of 
78.9% and specificity of 68.8%, although the therapies they received were mixed 
(chemotherapy, hormone therapy, or novel agents such as vaccines and kinase inhibitors) 
(Gonzales et al. 2011). Additionally, high levels of miR-221 in peripheral blood is 
predictive of early CRPC development (Santos et al. 2014). These examples suggest that 
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circulating miRNAs could be useful additions to the biomarker armamentarium, although 
robust retrospective and prospective validation studies are required to move this field 
forward (Tavallaie, et al. 2015; Wang, et al. 2016) 
 
Exploiting AR-modulating microRNAs as a therapeutic strategy 
MiRNA-based therapies are being actively pursued for a multitude of diseases, as 
eloquently described in several recent reviews (Hong, et al. 2016; Van der Ree, et al. 
2016; van der Ree, et al. 2017). In cancer, such therapies are focused on increasing levels 
of tumor suppressor miRNAs by delivery of miRNAs mimics or decreasing levels of 
oncogenic miRNAs by delivery of antisense oligonucleotides (termed antimiRs or 
antagomiRs) (D'Angelo, et al. 2016). Since a single miRNA can regulate multiple cancer-
related pathways, miRNA-based therapies possess considerable promise. However, like 
other nucleic acid-based strategies, issues related to stability in biofluids, delivery to the 
tissue of interest and toxicity of mimics and antimiRs have hindered their clinical 
development (Rupaimoole and Slack 2017). While recent advances in formulation and 
delivery have led to miRNA-based therapies being tested in a range of clinical studies 
(Matin, et al. 2016), it is worth noting that none are yet used in the treatment of patients.  
 
With these caveats in mind, the application of a miRNA-based therapy in PCa remains a 
distant goal. Nevertheless, it is clear that opportunities in this area exist, especially given 
the importance of the interplay between miRNAs and the AR. For example, miR-34a 
reduces PCa cell viability, at least in part by targeting AR (Östling et al. 2011), but it also 
downregulates the expression of >30 oncogenes across multiple oncogenic pathways 
(Beg, et al. 2017). Cancer therapies based on master tumor suppressor miRNAs such as 
miR-34 are attractive because they would be expected to have high efficacy and at the 
same time reduce opportunities for resistance to develop. In pre-clinical studies, systemic 
delivery of a miR-34a mimic to mice harbouring orthotopic PCa xenografts led to 
decreased tumor growth and metastasis (Liu, et al. 2011). A liposomal formulation of 
miR-34a, termed MRX34, was evaluated in a Phase 1 clinical trial of patients with 
primary liver cancer, advanced solid tumors and hematological malignancies. 
Unfortunately, this trial was terminated due to immune-related serious adverse side 
effects (Hong et al. 2016; Van Roosbroeck and Calin 2017). Nevertheless, the promising 
anti-tumor activity of MRX34 observed in a subset of patients (Beg et al. 2017) provides 
incentive to continue investigating miRNA-based therapies for cancer. Indeed, new 
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strategies to more precisely deliver miRNA-based payloads to solid tumors are already 
showing promise: exciting findings from a recent phase I clinical trial in mesothelioma 
demonstrated that miR-16-loaded, EGFR-targeted “minicells” demonstrated an 
acceptable safety profile and early signs of activity (van Zandwijk, et al. 2017).  
 
As an alternative to therapies based on miRNA mimics or antimiRs, other strategies to 
regulate miRNA expression can be envisioned. Indeed, epigenetic therapies are being 
intensively investigated for a multitude of diseases, and we propose that an important 
aspect of their activity relates to miRNA biology. As specific examples associated with 
the AR signalling axis, re-activation of miR-124 using DNA demethylating agents or 
miR-320a with the histone deacetylase inhibitor OBP-801 lead to decreased AR 
expression and activity in PCa (Sato, et al. 2016; Shi et al. 2013) 
 
SUMMARY 
MiRNAs and the AR are involved in an intricate dance mediated by direct interactions or 
complex indirect mechanisms involving transcription factors, co-regulators and 
epigenetic machinery (Figures 1 and 4). Despite the complexity of this interplay, one 
overarching theme is that miRNAs play a major role in enhancing and maintaining AR 
activity throughout the course of PCa progression; miRNAs that antagonize AR 
expression and activity are frequently lost, whereas miRNAs that facilitate AR signaling 
are frequently gained. This phenomenon may be particularly relevant in CRPC, where 
miRNAs can play key roles in establishing and maintaining resistance to AR-targeted 
therapies. With this in mind, and given the continued focus on targeting AR in PCa, we 
propose that exploitation of miRNAs – potentially as biomarkers or therapeutic targets – 
warrants further consideration as a strategy to manage and/or treat this common disease. 
Finally, since AR is a key player and being investigated as a target in other solid tumours, 
including breast, bladder and hepatocellular, the value of understanding its interplay with 
miRNAs is increased; indeed, recent studies indicate that such interplay may be crucial 
to the progression of these other cancer types (Xiao, et al. 2019; Xiong, et al. 2017; Yang, 
et al. 2018). 
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FIGURES AND LEGENDS 
 
Figure 1. Key mechanisms by which microRNAs regulate AR expression and activity in 
prostate cancer, including direct targeting of the AR transcript (1), targeting of AR co-







Figure 2. Expression of putative AR-targeting miRNAs in clinical samples. (A) 
Expression of putative AR-targeting miRNAs in matched normal and primary prostate 
cancers from The Cancer Genome Atlas (TCGA). TCGA miRNA expression data was 
obtained from Genomic Data Commons, which uses miRBase v21 as miRNA reference; 
miRNA names were derived miRBase v21 and converted where necessary. MiRNA 
abundance (reads-per-million-miRNA-mapped) was calculated by taking the sum of all 
counts per miRNA (unique MIMAT ID), and the MIMAT ID was then converted to its 
appropriate miRNA name. Only miRNAs that were expressed in more than 50% of 
samples were included in this analysis. P values were determined using paired t tests; *, 
p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. (B) Expression of putative AR-
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targeting miRNAs in normal and prostate cancer (primary and metastatic) in the 
Memorial Sloan-Kettering Cancer Center (MSKCC) cohort. Normalized miRNA 
expression data for the MSKCC cohort was obtained from cBioPortal 
(www.cbioportal.org). P values were determined using unpaired t tests; *, p < 0.05; **, 
p < 0.01; ***, p < 0.001; ****, p < 0.0001. (C) Correlation between putative AR-targeting 
miRNAs and AR protein levels in the TCGA cohort. AR protein levels are from reverse 
phase protein array data, obtained from the Broad Institute’s GDAC Firehose. RPPA data 
was available for 145 primary prostate tumors. Only AR-targeting miRNAs that exhibited 
a significant (p < 0.05) negative Pearson correlation with AR protein levels in these 145 






Figure 3. Differential 3’UTRs of AR and AR variants in prostate cancer influence their 
regulation by miRNAs. (A) Graphical representation of 3’UTR sequences for the 
canonical AR transcript and 6 AR variants. Genbank accession IDs are shown; 3’UTR 
length was calculated as the number of nucleotides from after to the stop codon to the 
end of the annotated transcript. (B) miR-124 target sites in the canonical AR transcript 






Figure 4. Key mechanisms by which AR controls the miRNAome in prostate cancer, 
including direct regulation of miRNA expression (1), regulating epigenetic machinery 
that modulates expression of miRNAs (2) and regulating the expression and activity of 
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Table 2. Assessing the biological relevance of microRNAs reported to target the androgen receptor 
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miRNA status 
in PCa tissues 
(Score: 1 if 
downregulated, 
0 if unknown) 
Reported role of 
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3 Hagman et al. 2013; 
Hamilton et al. 
2016; Kumar et al. 
2016 
Yes  Downregulated 




and protein   
Downregulated 
in PCa tissues  
Tumor suppressor 6 Gandellini et al. 2009; 
Hagman et al. 2013; 
Kumar et al. 2016 
miR-
145 
2 Hamilton et al. 
2016; Larne et al. 
2015 





Tumor suppressor 5.5 Larne et al. 2015 
miR-34a 2 Hamilton et al. 
2016; Östling et al. 
2011 
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Unknown Tumor suppressor 4.5 Leite et al. 2015; Liu et 
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2011 
miR-34c 4 Fang et al. 2016; 
Hamilton et al. 
2016; Kumar et al. 
2016; Östling et al. 
2011 
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transcript 
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Downregulated 
in PCa tissues 
Tumor suppressor 4 Hagman et al. 2010; 
Östling et al. 2011 
miR-
101-3p 
2 Hamilton et al. 
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miR-
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2 Hamilton et al. 
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miR-
371 
3 Kumar et al. 2016; 
Leite et al. 2015; 
Östling et al. 2011 
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Unknown 2 Leite et al. 2015 
mir-488 4 Hamilton et al. 
2016; Kumar et al. 
2016; Östling et al. 
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N/A N/A Unknown Unknown Tumor suppressor 2 Sikand et al. 2011 
miR-
449a 
2 Östling et al. 2011; 
Zheng et al. 2015 
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Zheng et al. 2015b 
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2 Fang et al. 2016; 
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miR-
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2 Kumar et al. 2016; 
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miR-
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2 Kumar et al. 2016; 
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miR-
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Table 4: Intersection between AR regulated miRNA (by binding to ARBS) and AR 
regulated genes.  
 
Overlap between miRNA upregulated by AR  and genes downregulated by AR 
miRNA No of predicted  miRNA target genes  Genes in overlap p value 
miR-19  1338 43 0.02581 
miR-21 384 13 0.12688 
miR-22 620 22 0.03987 
miR-27a 1421 56 0.00012 
miR-29a 1264 34 0.24447 
miR-32 1041 36 0.01505 
miR-133b 711 18 0.42141 
miR-135a 847 26 0.10774 
miR-148a 802 26 0.06667 
miR-182-5p 1329 44 0.011979 
miR-193a-3p 286 12 0.041 
miR-203 960 25 0.342 
miR-4496 5975 168 0.004 
Overlap between miRNA downregulated by AR  and genes upregulated by AR 
miRNA No of predicted targets Genes in overlap p value 
miR-221/222 504 26 0.023 
miR-421 450 27 0.003 
 
aPredicted target genes for each miRNA were downloaded from TargetScan (release 
7.2; Agarwal et al. 2015). bP values were calculated using hypergeometric probability 
tests. Genes in universe = 18,393 i.e. total number of genes in Targetscan database. AR-




Table 5. Dysregulated miRNA in CRPC 
 





miR-7 Upregulated 2 Jalava et al. 2012; Taylor et al. 2010 
miR-18a  Upregulated 2 Jalava et al. 2012; Taylor et al. 2010 
miR-23b Downregulated 3 Goto et al. 2015; Goto et al. 2017; 
Taylor et al. 2010 
miR-24 Downregulated 4 Goto et al. 2015; Goto et al. 2017; 
Jalava et al. 2012; Taylor et al. 2010 
miR-25 Upregulated 2 Jalava et al. 2012; Taylor et al. 2010 
miR-27a Downregulated 3 Goto et al. 2015; Goto et al. 2017; 
Taylor et al. 2010  
miR-30a* Downregulated 3 Goto et al. 2015; Jalava et al. 2012; 
Taylor et al. 2010 
miR-30b-3p Upregulated 2 Jalava et al. 2012; Taylor et al. 2010 
miR-30e-3p Downregulated 3 Goto et al. 2015; Goto et al. 2017; 
Taylor et al. 2010 
miR-95 Upregulated 2 Jalava et al. 2012; Taylor et al. 2010 
miR-99a Downregulated 4 Goto et al. 2015; Goto et al. 2017; 
Jalava et al. 2012; Taylor et al. 2010 
miR-100 Downregulated 3 Goto et al. 2017; Jalava et al. 2012; 
Taylor et al. 2010 
miR-125a-
5p 
Downregulated 3 Goto et al. 2015; Goto et al. 2017; 
Taylor et al. 2010 
miR-125b Downregulated 4 Goto et al. 2015; Goto et al. 2017; 
Jalava et al. 2012; Taylor et al. 2010 
miR-125b-
2* 
Downregulated 3 Goto et al. 2017; Jalava et al. 2012; 
Taylor et al. 2010 
miR-130b Upregulated 2 Jalava et al. 2012; Taylor et al. 2010 
miR-133a Downregulated 4 Goto et al. 2015; Goto et al. 2017; 
Jalava et al. 2012; Taylor et al. 2010 
miR-143 Downregulated 3 Goto et al. 2015; Goto et al. 2017; 
Taylor et al. 2010 
miR-143* Downregulated 3 Goto et al. 2017; Jalava et al. 2012; 
Taylor et al. 2010 
miR-145 Downregulated 3 Goto et al. 2017; Jalava et al. 2012; 
Taylor et al. 2010  
miR-145* Downregulated 3 Goto et al. 2015; Goto et al. 2017; 
Taylor et al. 2010 
miR-150 Downregulated 3 Goto et al. 2015; Goto et al. 2017; 
Taylor et al. 2010 
miR-152 Downregulated 3 Goto et al. 2015; Jalava et al. 2012; 
Taylor et al. 2010 
miR-181c Downregulated 3 Goto et al. 2017; Jalava et al. 2012; 
Taylor et al. 2010 
miR-182 Upregulated 2 Jalava et al. 2012; Taylor et al. 2010 
miR-183 Upregulated 2 Jalava et al. 2012; Taylor et al. 2010 
miR-185 Upregulated 2 Jalava et al. 2012; Taylor et al. 2010 
miR-196b Downregulated 3 Goto et al. 2015; Goto et al. 2017; 





Downregulated 3 Goto et al. 2017; Jalava et al. 2012; 
Taylor et al. 2010  
miR-205 Downregulated 4 Goto et al. 2015; Goto et al. 2017; 
Jalava et al. 2012; Taylor et al. 2010 
miR-214 Downregulated 3 Goto et al. 2017; Jalava et al. 2012; 
Taylor et al. 2010 
miR-221 Downregulated  4  Goto et al. 2015; Goto et al. 2017; 
Jalava et al. 2012; Taylor et al. 2010 
miR-222 Downregulated / 
Upregulated 
4  Goto et al. 2015; Goto et al. 2017; 
Jalava et al. 2012; Taylor et al. 2010 
miR-425 Upregulated 2 Jalava et al. 2012; Taylor et al. 2010 
miR-452 Downregulated 3 Goto et al. 2017; Jalava et al. 2012; 
Taylor et al. 2010 
miR-625 Upregulated 2 Jalava et al. 2012; Taylor et al. 2010 
aThe studies referred to in the above table encompass 32 CRPC (18 metastases and 14 
localized CRPC), 109 primary prostate tumor, 7 benign prostatic hyperplasia and 38 
normal prostate samples. Downregulated miRNA were listed in Table 5 if they were 
reproducibly altered in >50% i.e. 3 out of 4 studies. Upregulated miRNA were listed if 
they were reproducibly altered in >50% i.e. 2 out of 2 studies. Goto et al 2015 and Goto 
et al 2017 only report miRNA downregulated in CRPC and were excluded when listing 
upregulated miRNA. Comparisons were done between benign prostatic hyperplasia and 
CRPC (Jalava et al. 2012), normal prostate tissues or primary prostate tumours with 
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1.10.1 Genomic location and regulation of expression 
 
Mature miR-194 is derived from two precursors originating from the miR-215/miR-194-
1 cluster and the miR-192/miR-194-2 cluster, on chromosome 1 and 11 respectively 
(Hino et al. 2008). While the miR-215/194-1 cluster is located within an intron of the 
IARS2 gene, the miR-192/miR-194-2 cluster is encoded by the miR-194-2HG gene 
located ~1.25kb downstream of the ATG2A gene.  
As with many miRNA, miR-194 has context dependant roles in cancer, and its regulation 
reflects its role in that tumour type. In hepatocellular carcinoma for instance, where miR-
194 is tumour suppressive, its expression is downregulated by NF-κB mediated 
suppression of Hepatocyte nuclear factor-1 alpha (HNF-1α) (Bao et al. 2015). HNF-1α is 
a key transcriptional upregulator of miR-194 that induces expression by binding to a 
highly conserved element within the promoter region of the miR-192/miR-194-2 cluster 
(Hino et al. 2008; Krützfeldt et al. 2012; Wang et al. 2014). In multiple myeloma, 
hypermethylation of the miR-194-2-192 cluster corresponding to inhibition of expression 
has been reported (Pichiorri et al. 2010). Consistent with its tumour suppressive role in 
some cancers, both miR-194-containing clusters have response elements for the p53 
tumour suppressor protein (Braun et al. 2008; Pichiorri et al. 2010). In prostate cancer, 
where miR-194 is oncogenic, expression is upregulated by GATA2 (Das et al. 2017).  
Only a few factors that regulate the expression of miR-194 have been reported so far. In 
general, upstream signalling events either up/downregulate miR-194 expression based on 
its role in cancer. Elucidating other factors, like genetic alterations and dysregulation of 
biogenesis, is important for further understanding how miR-194 might be affected and 
affect carcinogenesis.  
 
1.10.2 miR-194 in PCa 
 
miR-194 is known to have cellular context-dependent role in tumorigenesis (Xu et al. 
2012; Zhang et al. 2014). Several studies have indicated that miR-194 acts as a tumour 
suppressor, with its downregulation being linked to hepatocellular carcinoma (HCC) 
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(Bao et al. 2015), bladder cancer (Zhang, Zhuang & Cui 2016), oral squamous cell 
carcinoma (Chia et al. 2015), renal cell carcinoma (Khella et al. 2013), gastric cancer 
(Song et al. 2012), non-small cell lung cancer (Zhou et al. 2016) and myelodysplastic 
syndrome (Choi et al. 2015). In certain other cancer types, like oesophageal and 
pancreatic cancer, upregulation of miR-194 contributes to increased tumour growth and 
invasion (Mathé et al. 2009; Zhang et al. 2014).  
Work from our laboratory and others have shown that in prostate cancer, elevated miR-
194 is associated with early biochemical recurrence, metastasis and poor prognosis (Selth 
et al. 2013; Tong et al. 2009). Tong et al reported a >40% increase in miR-194 in 
prostatectomy sections of individuals who relapsed after to surgery compared to those 
who did not (Tong et al. 2009). Selth et al showed that miR-194 is elevated in the serum 
of men who experienced early biochemical recurrence (BCR) after prostatectomy versus 
those who did not, suggesting its utility as a circulating prognostic biomarker (Selth et al. 
2013). This study also found that tumour miR-194 levels were prognostic for BCR and 
that miR-194 is more highly expressed in metastases compared to normal prostate or 
primary tumours (Selth et al. 2013).  
Based on these earlier finding from our laboratory, we further investigated the role of 
miR-194 in prostate cancer metastasis and progression. I contributed to this study (Das 
et al. 2017) , which was completed during the early stages of my PhD, by assessing levels 
of miR-194 and its targets in tumour tissues, analysing data and participating in 
discussions. In this study, we showed that in cell line models, overexpression of miR-194 
can enhance migration, invasion and stimulate epithelial-mesenchymal transition. MiR-
194 was found to mediate these effects partly by targeting SOCS2. SOCS2 inhibits 
metastasis in prostate cancer by suppressing the STAT3 and ERK signalling pathways 
(Das et al. 2017). Although this study  identifies one target through which miR-194 
promotes metastasis, a complete description of miR-194 regulated genes and signalling 
networks remains lacking and is necessary to better understand the molecular 







1.11 Hypothesis and aims 
 
Previous studies in our laboratory have defined an oncogenic, metastasis-promoting role 
for miR-194 in prostate cancer. While our previous study identified one target gene by 
which miR-194 promotes metastasis, miR-194 is likely to act via multiple genes and 
pathways. We hypothesised that identifying all miR-194 target genes and associated 
signalling pathways, would be crucial to understanding its role in EMT, metastasis and 
prostate cancer progression.  
 
Aims: 
1. Identify a complete set of miR-194 target genes (“targetome”) in prostate cancer  
2. Identify and validate pathways by which the miR-194 targetome promotes 
prostate cancer metastasis and progression 
























 2.1 Materials 
 
Table 2.1: Chemicals and reagents 
Reagent  Supplier  Catalogue number 





control LNA inhibitors  
Qiagen YI00199006-DFA 
Anti-microRNA FAM labelled   




Bradford assay reagent BioRad 500-0006 
BSA (bovine serum albumin) Sigma Aldrich A9647 
Cell Titre Glo reagent Promega G7572 
Chloroform  Sigma Aldrich C2432 
DMEM Thermo Fischer Scientific 11995073 
DMSO (dimethyl sulfoxide) BDG Laboratory Supplies D2650 
Ethanol, molecular grade Scharlau ET00110500 
FBS (fetal bovine serum) Sigma Aldrich 14M357 
Glycerol Chem Supply GA010-2.5L-P 
Glycine Sigma Aldrich G8898 
iScript cDNA synthesis kit BioRad 170-8891 
iQ SYBR Green Supermix BioRad 170-8885 
Lipofectamine RNA iMAX Thermo Fisher Scientific
  
13778150 
Matrigel Corning Scientific BD 354234 
Matrigel Growth Factor 
Reduced 
Corning Scientific BD 356231 
Methanol Chem Supply MA004-2.5L-P 





mirVana® miRNA mimic hsa-
miR-194-5p 
Ambion 4464066 
mirVana® miRNA mimic 
negative control  
Ambion 4464058 
Optimem Thermo Fisher Scientific 31985070 
PBS (phosphate buffered 
saline) 
Gibco 14190 
Ponceau S Sigma Aldrich P3504 
Pre-microRNA-194 precursors GenePharma B02001 
Pre-microRNA precursors 
negative control  
GenePharma B04002 
Propidium Iodide Sigma Aldrich  P4864 
RPMI 1640 liquid media Sigma Aldrich R8758 
RPMI 1640 phenol red free Sigma Aldrich R7509 
SDS (sodium dodecyl 
sulphate) 
Sigma Aldrich 75746 
Tris Sigma Aldrich T1378 
Triton-X 100 Sigma Aldrich T8787 
TRI Reagent Sigma Aldrich T9424 
Trypsin EDTA solution Sigma Aldrich T4049 
TrypLE Express Enzyme Gibco 12605010 









Table 2.2: Western Blot Buffers  
 
Buffer Name Buffer Components  
Loading Buffer (6x) for western blot  
 
 0.27M Tris base 
10.3%  SDS 
35% Glycerol 
6% β-mercaptoethanol 
0.05% bromophenol blue 
RIPA (Radioimmunoprecipitation assay) 
Buffer  
 
10 mM Tris base 
150 mM NaCl  
1 mM EDTA  
1% Triton X-100 
Volume to 500 mL with water 
pH 7.4 
Running Buffer (10x)  
 
77.5 g Tris base  
360 g Glycine  
25 g SDS  
Volume to 2.5 L with water  
TBS (Tris-buffered saline) (10x)  
 
151.5 g Tris base 
219 g NaCl  
Volume to 2.5 L with water  
pH 7.4  
TBST (Tris-buffered saline, 0.1% Tween 
20) (1x)  
 
2.5 mL Tween20  
250 mL 10x TBS  
Volume to 2.5 L with water  
Transfer Buffer (10x)  
 
77.5 g Tris base 
360 g Glycine  





Table 2.3: qPCR Primers 
 
Primer Name Sequence Annealing Temp 
AHR F AGTTATCCTGGCCTCCGTTT 55˚C 
AHR R TCAGTTCTTTAGGCTCAGCGTC  
ARHGAP1 F GCGGAAATGGTTGGGGATAG 62˚C 
ARHGAP1 R CCTTAAGAGAAACCGCGCTC  
ARL6IP5 F GATTTCTTCCCGGGTTCCGA 55˚C 
ARL6IP5 R GATTTCTTCCCGGGTTCCGA  
ATXN1 F GATCCAAAACAAGCCCCGTG 58˚C 
ATXN1 R GCACGATGCTCTGTAAAGTGT  
BTF34L F GATAGGGGGCAAGGGTACAG 55˚C 
BTF34L R TTGGCTTCTGCATGACCAGT  
BRN2 F ACACTGACCGATCTCCACGCAGTA 60˚C 
BRN2 R GAGGGTGTGGGACCCTAAATATGAC  
CHGA F CTCAAGAACCTCTGAGAGTTCATC 55˚C 
CHGA R CTCAAGAACCTCTGAGAGTTCATC  
CHGB F CGAGGGGAAGATAGCAGTGAA 60˚C 
CHGB R CAGCATGTGTTTCCGATCTGG  
DUSP6 F GAGTCTGACCTTGACCGAGACCCCAA 55˚C 
DUSP6 R TTCCTCCAACACGTCCAAGTTGGTGGAGTC  
EGR1 F CACGAACGCCCTTACGCT 60˚C 
EGR1 R CATCGCTCCTGGCAAACT  
ENO2 F CTGGCTAAATACAACCAGCTCA 60˚C 
ENO2 R CACAGCACACTGGGATTACG  
ER F ATCATCAACTGGGCGAAGAG 55˚C 
ER R GATCTCCACCATGCCCTCTG  
ERGIC2 F AAAGAGTGGCAGAGGATGCTG 55˚C 
ERGIC2 R TGCCTTGCCCACTGTTATGT  
ETV4 F CCACCAGGATCAAGAAGGAA 60˚C 
ETV4 R CCCTGAGGAGATGTGAAGGA  
EZH2 F TGCAGTTGCTTCAGTACCCATAAT 55˚C 
EZH2 R ATCCCCGTGTACTTTCCCATCATAAT  
FAM63B F TCTACACAGGCTCAGCAGGG 62˚C 
FAM63B R AGGAAATCAGGCACAGACGG  
FLRT2 F ACCCTTGGTTTTGTGACTGC 62˚C 
FLRT2 R AGGACCTTGGCACATGAAAC  
FOXA1 F GGGGGTTTGTCTGGCATAGC 60˚C 
FOXA1 R GCACTGGGGGAAAGGTTGTG  
GAPDH F TGCACCACCAACTGCTTAGC 55˚C 
GAPDH R GGCATGGACTGTGGTCATGAG  
IQGAP1 F GGAGCACAATGATCCAATCC 58˚C 
IQGAP1 R ATGGTTCGA GCATCCATTTC  
NACC2 F ACGCTGTGAAATTGTACTGTC 55˚C 
NACC2 R CAGCATGGACTTGATCTTGG  
MAPK1 F GAAGCATTATCTTGACCAGC 55˚C 
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MAPK1 R TCCATGGCACCTTATTTTTG  
MET F TGAAATTCATCCAACCAAATCTT 60˚C 
MET R AATAGAAAACTGACAATGTTGAGAGG  
PAK2 F TGGTCGGAACGCCATACTG 55˚C 
PAK2 R TTCTGGGGTTCCATTAGTTGC  
QKI F CCTTGCCTTTTCTCTTGCAG 55˚C 
QKI R TATTGCAGCAGTTGGGTGAG  
REEP5 F AAGAACTGCATGACTGACCTTC 55˚C 
REEP5 R GAGGCTCCATAACCGAACACC  
REST F GCCGCACCTCAGCTTATTATG 60˚C 
REST R CCGGCATCAGTTCTGCCAT  
RHEB F TACCGGTCTGTGGGGAAATC 62˚C 
RHEB R CCCGGCTGTGTCTACAAGTT  
STEAP2 F TGGAATGAGGAAGAAGTTTGGA 55˚C 
STEAP2 R GCAAGAACAAAGTTTGGTGGTGTA  
SYP F TTAGTTGGGGACTACTCCTCG 60˚C 
SYP R GGCCCTTTGTTATTCTCTCGGTA  
SSH2 F GGGGAAATGGCTCATCCACA 55˚C 
SSH2 R TTCCAGTCTTACAGCCAGCC  
TJP1 F GCCTCAGAAATCCAGCTTCACGAA 55˚C 
TJP1 R GCAGCTAGCCAGTGTACAGTATAC  
TRAF6 F GCGCACTAGAACGAGCAAG 55˚C 
TRAF6 R TTTCCAGGGGTGGGTCAAAC  
ZBTB10 F GCTGGATAGTAGTTATGTTGC 60˚C 


















Table 2.4: Published prostate cancer datasets  
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2.2.1 Cell culture 
 
2.2.1.1 Reviving, maintaining, passaging and freezing of cell lines 
The human prostate carcinoma cell lines 22Rv1, LNCaP, and PC-3, were obtained from 
the American Type Culture Collection (ATCC). The LNCaP-V16D, LNCaP-MR42D and 
LNCaP-MR49F cell lines were obtained from the Zoubeidi lab at the Vancouver Prostate 
Centre. 22Rv1, LNCaP-V16D LNCaP cell lines were maintained in RPMI-1640 
containing 10% Fetal Bovine Serum (FBS). PC3 cell line was maintained in RPMI-1640 
containing 5% FBS. LNCaP-MR42D and LNCaP-MR49F were maintained in RPMI-
1640 containing 10% Fetal Bovine Serum (FBS) and 10μM Enzalutamide. 
All cell lines cultures regularly underwent mycoplasma testing. All cell lines underwent 
verification by short tandem repeat profiling by CellBank Australia. 
 For revival of cell lines, vials from liquid nitrogen were rapidly thawed in a 37°C water 
bath and gently mixed with 9ml of appropriate cell culture media. Cells were centrifuged 
at 1500rpm for 5 minutes, pellets were resuspended in 8ml of media and transferred to a 
T25 culture flask. Flasks were incubated at 37°C and 5%CO2 and passaged when 80% 
confluency was reached.  
For passaging, media was removed from cell culture flask followed by a PBS wash. 
Harvest of cells for passaging was performed using 0.25% trypsin and incubating at 37˚C 
and 5%CO2 for 2 minutes or until cells detached from flask. Trypsin was neutralized with 
media containing FBS and collected in a 50ml tube. Cells were pelleted by centrifuging 
at 1500rpm for 5 minutes and reseeded at appropriate density in a new flask. 
For freezing cells, T75 or T150 flasks at 80% confluency were trypsinized and counted. 
Cells were pelleted by centrifuging at 1500rpm for 5 minutes and resuspended in freezing 
media (10% DMSO, 40% FBS, 50% culture media) at a concentration of 1-2 million 
cells/ml. 1ml of suspension was added to each labelled cryo-vial, and placed in an 
isopropanol filled freezing container at -80°C. Cells were transferred to liquid nitrogen 




2.2.1.2 MicroRNA (miR) mimic or inhibitor transfection 
Prostate cancer cells were transfected in solution with 20nM of pre-miR microRNA 
precursors or microRNA locked nucleic acid (LNA) inhibitors (6.25nM, 12.5nM or 
50nM depending on experiment) or negative controls using the RNAiMax transfection 
agent. Briefly, an RNAiMax -Opti-MEM mix was made and incubated for 10 min at RT. 
The miRNA precursors/inhibitors were diluted in Opti-MEM. RNAiMax-Opti-MEM 
mix was added to precursors/inhinitors and incubated for an additional 10 min at RT to 
form complexes. The transfection complexes were added drop-wise to the cell cultures 
at the time of seeding. The cells were incubated for 48h, 72h, 96h or longer depending 
on the assay being performed.  
2.2.2 Cell viability assay 
 
Growth assays were performed over a period of 7 days. Cells were transfected with miR-
194 LNA or negative controls and a known number of cells was seeded at into the wells 
of a 12 well plate. Cell numbers were counted at 2, 4 and 7 days to assess proliferation. 
Number of live cells was assessed using trypan blue exclusion assay. Briefly, 20µl of 
0.4% trypan blue solution was added to 20µl of cell suspension, mixed and loaded onto 
a haemocytometer. Cells were examined under a microscope. If cells take up trypan blue, 
they are considered non-viable. The number of unstained and stained cells were counted 
and total number of live cells was assessed as follows: 
Total cells/ml = Average number of cells in corner squaresdilution factor10000 
cells/ml  
2.2.3 Inverse invasion assay 
 
100μl of Matrigel diluted in a 1:1 ratio with ice-cold PBS was pipetted into 8μm pore, 
6.5mm diameter uncoated transwells. Matrigel was allowed to solidify by incubating for 
30 min at 37°C. Transwells were then inverted and 100μl of cell suspension with 5x105 
cells per mL was pipetted onto the underside of each transwell. Transwells were covered 
with the base of their 24 well culture plate and incubated inverted for 4 h to allow cells 
to adhere to the transwell membrane. Transwells were then returned to their original 
orientation and washed twice with 1mL serum free medium. Transwells were left to 
incubate in 1mL serum free media containing indicated treatments. 100μl appropriate 
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media containing 10% FBS was added to each transwell on top of the matrigel layer. 
Plates were incubated for 5 days at 37°C and 5% CO2. Cells were stained in culture wells 
filled with 1 mL PBS containing 10 μg per mL propidium iodide for 30 min at RT in the 
dark followed by PBS washes. Images were collected by confocal microscopy using the 
Leica SP5 microscope microscope. Transwells were placed onto a large coverslip 
covered in a small amount of PBS ensuring no bubbles were present for imaging with 
non-immersion 20x objective. 10 Z-stack sections of Matrigel were captured at set 
intervals beginning at the transwell membrane (0 μm). Florescence intensity of PI 
staining at individual z-stack sections was quantified by Image J software. Average 
measure of all slices was calculated and indicates proportion of cells that invaded. 
2.2.4 Organoid culture 
 
2.2.4.1 Reviving, maintaining, passaging and freezing of organoids 
The organoid cell lines 201.1 Dura and 201.2 Lung representing prostate adenocarcinoma 
and neuroendocrine prostate cancer respectively, were obtained from the Melbourne 
Urology Research Alliance (MURAL) and are described in (Lawrence et al. 2018). 
Organoid cell lines were generated from patient derived xenografts (PDX) of  CRPC 
metastases from rapid autopsy specimens. The 201. Dura and 201.2 Lung lines were 
derived from metastases in the dura and lung, respectively (Lawrence et al. 2018). 
201.1 Dura and 201.2 Lung cells were seeded in growth factor reduced, phenol red-free, 
LDEV-free Matrigel (Corning). 201.1 organoids were cultured in advanced DMEM/F-
12 media (Gibco) containing 0.1ml Primocin (Invivogen), 2 mM Glutamax (Sigma), 
10mM HEPES (Sigma), 1nM DHT (Sigma), 1.25mM N-acetylcysteine (Sigma), 5nM 
NRG1 Heregulinβ-1 (Peprotech), 500 nM A83-01, 10 mM nicotinamide (Sigma), 10μM 
SB202190 (Sigma), 2% B27 (Thermo), 10ng/ml FGF10 (Peprotech), 5ng/ml FGF2 
(Peprotech), 1μM prostaglandin E2 (Tocris), 10% noggin conditioned media and 10% R-
spondin conditioned media. 10μM Y-27632 dihydrochloride (Selleck Chemicals) was 
added to culture medium during organoid establishment and following passage. 
201.2 Lung organoids were grown were cultured in PrENR -p38i -NAC media (Beshiri 
et al. 2018), which is similar to the media described above with the following 
modifications: 5ng/ml EGF was added to the medium but NRG1 Heregulinβ-1, 
SB202190 and N-acetylcysteine were not added to this medium.  
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For revival, frozen vials were thawed in a 37°C water bath. Cell suspension was 
centrifuged at 1200rpm for 4 minutes, pellet was washed with organoid culture media. 
Pellets were resuspended in growth factor reduced Matrigel (Corning) at a concentration 
of 100,000-50,000 cells per 30μl of Matrigel in 24 well plates. Plates were inverted at 
37°C for 15 minutes to allow Matrigel to solidify, then overlaid with 500mL of human 
organoid culture medium containing 10μM Y27632. Media was replaced every 3-4 days.   
At the time of passage, organoids were washed in PBS, 250μl of TrypLE (GIBCO) was 
added and Matrigel broken up by pipetting. Plates were incubated at 37°C for 5 minutes. 
Once the Matrigel was digested, the cells were transferred to 1.5ml Eppendorf tubes and 
centrifuged to form a pellet, washed and reseeded in Matrigel. 
For freezing organoids, cells were digested out of Matrigel as described above and 
pelleted. Pellets were resuspended in freezing media (90% human organoid culture 
medium containing 10μM Y27632, 10% DMSO). 1ml of suspension was added to each 
labelled cryo-vial, and placed in an isopropanol filled freezing container at -80°C. Cells 
were transferred to liquid nitrogen once frozen. 
2.2.2.2 Organoid transduction 
Organoid cells were digested out of 3 Matrigel discs and centrifuged as described above. 
Cell pellets were washed and resuspended in 350ul of organoid culture media containing 
10μM Y27632 in one well of a 24 well plate. 100ul of pJS309 lentivirus was added and 
cells were incubated at 37°C , 5%CO2 overnight in suspension. The following day, cells 
were collected and spun down. The cell pellet was washed, resuspended in 90ul Matrigel 
and seeded out in 30ul matrigel discs. Plates were inverted at 37°C for 15 minutes to 
allow Matrigel to solidify, then overlaid with 500mL of human organoid culture medium. 
Cells were observed at 24h-48h post transduction for expression of Tomato. At 48h, 
2ug/ml puromycin was added to the media to select for transduced cells.  
2.2.2.3 Organoid transfection 
Organoid transfections were carried out essentially as described (Broutier et al. 2016). 
Organoid cells were digested out of Matrigel discs as described above, counted and 
resuspended in at appropriate concentration in 450µl of organoid culture media. The 
transfection mix was prepared by adding 25µl of Opti-MEM per tube to two 1.5ml 
microcentrifuge tubes for each transfection condition. 0.5µl of LNA at 50mM (for a final 
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concentration of 50nM) was added to one of the tubes and 1.5µl of RNAiMAX reagent 
to the other tube and incubated at room temperature (RT) for 5min. The contents of the 
two tubes were mixed together and incubated at RT for a further 5-15min. 50µl of the 
LNA:RNAiMAX mixture was added to 450µl of single cell suspension and centrifuged 
in a pre-warmed centrifuge at 32°C, 600g for 1h. Cells were then incubated in a tissue 
culture incubator at 37°C for 4h. Cells were collected in a 1.5ml centrifuge tube and 
centrifuged at 1200rpm for 5min at RT. Pellet was resuspended in 90ul Matrigel and 
seeded out in 30ul Matrigel discs. Plates were inverted at 37°C for 15 minutes to allow 
Matrigel to solidify, then overlaid with 500mL of human organoid culture medium.  
Organoid forming efficiency was assessed as described previously (Lawrence et al. 
2018). At seven days post transfection, ≥5 sets of images were taken per treatment. 
Images were taken at different depths in order to get all the organoids for each field of 
view. Number of organoids per µm2 was determined by manually counting number of 
organoids from each field of view and dividing by area. Images of the Matrigel disc were 
taken at 2x magnification with scale bar and diameter was estimated using measure 
function in ImageJ. Average number of organoids per µm2 was multiplied by area of disc 
to estimate average number of organoids per disc. Organoid forming efficiency was 
calculated as average number of organoids divided by number of cells originally seeded.  
2.2.2.4 Organoid viability using Cell Titer-Glo 
Oganoid cells were transfected as described above. Briefly, organoid were collected and 
50,000 cells were resuspended in 450µl of organoid culture media and 50μl of 
transfection mix containing RNAiMAX with 25, 100, and 250nM miR-194 or NC LNA 
inhibitor. Cells were centrifuged in a pre-warmed centrifuge at 32°C, 600g for 1h. After 
centrifuging, cells were incubated in a tissue culture incubator at 37°C for 2-4h and then 
collected in 1.5ml centrifuge tubes by centrifugation at 300 g for 5 min at room 
temperature. Cell pellets were resuspended in 5 μl Matrigel and seeded out in 10μl 
matrigel discs in 96-well plates. Plates were inverted and incubated at 37°C for 15 
minutes to allow Matrigel to solidify, then overlaid with 100mL of organoid culture 
medium. 
 Organoid viability was assessed at 7 days post-transfection using the Cell Titer-Glo® 
Luminescent Cell Viability Assay kit (Promega). Media was removed from wells and 
70μl fresh media was added to each well. 80μl of Cell Titer-Glo reagent was added to 
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each well and contents of the well were mixed by pipetting up and down several times. 
Plate was wrapped in foil and contents were then mixed on an orbital shaker for 5 
minutes. The plate was incubated at room temperature for 25 minutes. Luminescence was 
measured using a BMG Lumistar Optima luminometer. 
2.2.5 Western blotting 
 
2.2.5.1 Preparation of cell lysates 
Cells were generally grown in 6 well plates for protein extraction. Cells were washed 
with PBS, 100µl of RIPA buffer was added to each well followed by incubation on ice 
for 10 minutes. Cells were scraped from wells and collected in 1.5ml Eppendorf tubes. 
Lysates were centrifuged for 10 min at 10000g at 4°C and supernatant containing protein 
was collected. Protein concentration was assessed using Bradford assay. Lysates were 
stored at -80°C. 
2.2.5.2 Bradford assay 
Total protein concentration of cell lysates was determined using the Bradford assay. The 
assay was performed in 96 well flat bottomed culture plates. 1 µl of BSA standards from 
0-6mg/ml and samples were pipetted in duplicates into the plate. 20% Bradford reagent 
was added to each well to a total of 200μl. The plate was mixed and incubated at RT for 
5min before being read at 595 nm on a PolarStar microplate reader. The protein 
concentration of a test sample was calculated using a standard curve.  
2.2.5.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
Protein lysates containing 25ug of total protein were mixed with 6x loading dye and 
heated at 95°C for 5 minutes. Lysates were loaded on precast SDS-PAGE gels (Criterion 
or TGX) and run with appropriate running buffer at 100V for 1.5 hours using a Biorad 
Criterion electrophoresis cell or Biorad Mini-protean tetra cell. 8μl of Precision Plus 
Protein Dual Color Standards was used as size marker. 
2.2.5.4 Western Transfer and Immunoblot  
Proteins were transferred from SDS-PAGE gel to a nitrocellulose membrane with transfer 
buffer using a BioRad Criterion Blotter at 400 mA for 60 minutes. Ponceau staining was 
used to confirm transfer of proteins to the membrane. Membranes were de-stained by 
washing with 1x TBST for 10 minutes. Nitrocellulose membranes were then blocked for 
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60 minutes on a rocking tray using 3% skim milk powder dissolved in 1x TBST. 
Membranes were probed using primary and HRP-conjugated secondary antibodies. HRP-
conjugates were detected using ECL solution and imaged on a BioRad Chemidoc MP 
imaging system and processed using Image Lab Software. Protein expression was 
determined by densitometry using Image Lab Software. 
2.2.6 RNA extraction 
 
2.2.6.1 RNA extraction from tissues 
RNA samples in RNA later were thawed on ice. Samples were placed in a Precellys tube 
(Sapphire BioScience) on ice with 500μl Qiazol and homogenized in a Precellys24 
homogenizer: 2x 6500 – 2x30 – 30sec break i.e. samples were homogennized twice at 
6500rpm for two cycles at 30 seconds per cycle with a 30 second break between cycles. 
Homogenates were transferred to a 1.5ml tube and 200μl Qiazol was added for a total 
volume 700μl. Samples were incubated at RT for 5 minutes. 140 µl chloroform was 
added, shaken vigorously for 15s and incubated at RT for 3 minutes. Samples were 
centrifuged at 12000g at 4°C for 15 min and upper aqueous layer was transferred to a 
new tube, making sure not to disturb the interphase layer. 1.5 volume 100% ethanol was 
added and mixed thoroughly by pipetting. 700µl sample, including precipitate, was 
pipetted into an RNeasy® Mini column in a 2 ml collection tube. Lid was closed and 
centrifuged at ≥8000g for 15s at RT. Flow-through was discarded. Remainder of sample 
was pipetted into column and spun.700 µl Buffer RWT was added to the RNeasy Mini 
column and centrifuged for 15s at ≥8000g. Flow-through was discarded. Pipet 500 µl 
Buffer RPE was pipetted onto the RNeasy Mini column and centrifuged for 15s at 
≥8000g. Flow-through was discarded. 500 µl Buffer RPE was added to the RNeasy Mini 
column and centrifuged for 2 min at ≥8000 x g. Column was centrifuged at full speed for 
1 min to further dry the membrane. RNeasy Mini column was transferred to a new 1.5 ml 
collection tube. 30 µl RNase free water was added directly onto the RNeasy Mini column 
membrane. Columns were centrifuge for 1 min at ≥8000 x g to elute. This step was 
repeated to maximise amount of RNA eluted. RNA concentration and purity was 
determined by spectrophotometry using a Thermo Scientific NanoDrop 2000. 
2.2.6.2 RNA extraction from cells grown in 2D culture 
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Cells in 6 well plates were washed with 1x PBS and harvested using 1 mL Trizol per 
well. Trizol samples were incubated at 37°C for 15 minutes then mixed with 200μl of 
chloroform and shaken vigorously for 15s followed by incubation for 3 mins at RT. 
Samples were centrifuged at 12000rpm at 4°C for 15 min and upper aqueous layer was 
transferred to a new tube, making sure not to disturb the interphase layer. The aqueous 
layer was mixed with 2.5 volume 100% ethanol, 10mM MgCl2, 0.1 volume 5M NaCl and 
2μl Glyco-blue, mixed and for 2h to overnight at -20˚C. RNA was pelleted by 
centrifugation at 12000rpm at 4°C for 30 min, washed in 80% EtOH and resuspended in 
nuclease free water. RNA concentration and purity were determined by 




2.2.7.1 DNase Treatment  
RNA samples were DNase treated using TURBO DNA-freeTM DNase Treatment kits 
(Ambion cat#AM1907). 2μg RNA was diluted in RNase free water to a total volume of 
44μl, gently mixed with 5μl of 10xTurbo DNAse Buffer and 1μl TURBO DNasefree. 
Samples were incubated at 37°C for 30 min. 5μl of DNase inactivation reagent was added 
to each sample, mixed and incubated for 5 min at RT. Samples were centrifuged at 
10000g for 1.5 min and supernatant was collected. 50μl 75% isopropanol and 2μl 
Glycoblue was added to each sample. Samples were incubated overnight at -80˚C. RNA 
was pelleted by centrifugation at 12000rpm at 4°C for 30 min, washed in 80% EtOH and 
resuspended in nuclease free water. The resulting RNA concentration and purity were 
determined by spectrophotometry using a Thermo Scientific NanoDrop 2000. 
 2.2.7.2 Reverse Transcription  
After DNAse treatment, cDNA was made from RNA samples using the iScriptTM Reverse 
Transcription kit or TaqMan® MicroRNA Reverse Transcription Kit. For the iScript 
reaction, 500ng RNA was diluted with nuclease free water to a volume of 15μl. 5μl iScript 
reaction mix and 1μl of reverse transcriptase enzyme was added to each sample. A control 
containing all components except reverse transcriptase was also made to confirm 
complete DNAse treatment. iScript reactions were run in an iCycler thermocycler using 
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the following conditions: 25˚C for 5 min, 42°C for 30 min, 85°C for 5 min and 4°C hold. 
Resultant cDNA samples were diluted 1:4 and stored at -20°C until further use. For 
Taqman reactions, 100ng RNA was combined with 0.15μl dNTPs, 1μl MultiScribe 
Reverse Transcriptase, 1.5μl Reverse Transcriptase buffer , 0.19μl RNase inhibitor, 
0.75μl each of miRNA primers and NFW for a total volume of 15μl. Taqman reactions 
were run in the iCycler thermocycler using the following conditions: 16°C for 30 min, 
42°C for 30 min, 85°C for 5 min and 4°C hold. Resultant cDNA samples were diluted 
1:4and stored at -20°C until further use. 
2.2.7.3 Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR ) 
RNA expression was examined via qRT-PCR using a BioRad C1000 Thermal Cycler and 
CFX384TM Real-Time System. RNA expression of target genes was expressed relative 
to GAPDH as the reference gene. For SYBR Green based PCRs, reactions contained 
0.5μl  primer mix (Forward+reverse primer at 10pmol each) (Table 2.3), 5μl iQ SYBR 
Green Supermix, 2.5μl RNase free water, and 2μl cDNA. Three technical replicates were 
performed for all samples. qRT-PCR reaction conditions were as follows: 3 min at 95°C, 
40 cycles of 15 sec at 95°C, 15 sec at 55°C-62˚C (Annealing temperature-May change 
dependent on primer set used), 30 sec at 72°C and 1 cycle of 95°for 1 minute, 1 min at 
55°C and 10 sec at 60°C. Melt curve was determined by a temperature increase from 
60˚C to 95˚C in 0.5˚C increments. Data was analysed using CFX Manager Software 
Version 3.0 (Bio-Rad Laboratories, Inc.). 
For Taqman based PCRs, reactions contained 0.5μl primer (20x), 5μl TaqMan Universal 
Master Mix II, no UNG, 2.5μl RNase free water, and 2μl cDNA. Three technical 
replicates were performed for all samples. qRT-PCR reaction conditions were as follows: 
2 min at 50°C, 10 minutes at 95°C, 15 sec at 95˚C and 1 min at 60°C . Data was analysed 
using CFX Manager Software Version 3.0 (Bio-Rad Laboratories, Inc.). 
2.2.8 Computational analyses 
 
2.2.8.1 Gene set enrichment Analysis (GSEA) 
GSEA was performed using GSEA preranked module on GenePattern 
(https://cloud.genepattern.org/gp/pages/index.jsf). Ranked lists were generated from 
RNA-Seq counts using the signal-to noise metric. Genesets were obtained from MSigDB 






2.2.8.2 Single Sample Gene Set Enrichment Analysis (ssGSEA) 
ssGSEA was performed using ssGSEA Projection module on GenePattern 
(https://cloud.genepattern.org/gp/pages/index.jsf). GCT files were generated from 
relevant microarray or RNA-seq data. Genesets were obtained from MSigDB or 
generated specific published studies. Rank normalization was used to normalize gene 
expression data.  
2.2.8.3 Bioinformatic Analysis for HITS-CLIP and RNA-seq 
Detailed methods are described in Chapter 3 
2.2.9 Statistical analyses 
 
Results were analysed using GraphPad Prism 7.02 or appropriate functions in R. Detailed 



















Chapter 3: MicroRNA-194 promotes lineage plasticity 





The following chapter includes a manuscript submitted for publication to Nature 
Communications, followed by supplementary figures. Supplementary tables are available 
on Figshare https://adelaide.figshare.com/s/98cb3b341a7f554bae0d. This chapter makes 
up a significant proportion of the work completed as a part of this PhD. A general 
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MicroRNA-194 (miR-194) promotes prostate cancer metastasis, but the precise 
molecular mechanisms by which it achieves this are unknown. Here, by integrating 
cutting-edge molecular (Ago-HITS-CLIP and RNA sequencing) and bioinformatic 
(exon-intron split analysis) techniques, we defined a 163-gene miR-194 “targetome” in 
prostate cancer. MiR-194 target genes were predominantly down-regulated through 
canonical 3’UTR recognition sites and were enriched within pathways involved in 
cytoskeletal organisation and cell movement. In clinical prostate cancer samples, miR-
194 activity was inversely correlated with the androgen receptor (AR) signalling axis. At 
a mechanistic level, this inverse correlation was explained by down-regulation of miR-
194 expression by AR. Accordingly, miR-194 expression and activity was significantly 
elevated in neuroendocrine prostate cancer (NEPC), an aggressive AR-independent 
disease subtype. MiR-194 enhanced the transdifferentiation of prostate adenocarcinoma 
cells to a neuroendocrine-like state, at least in part by targeting FOXA1, a transcription 
factor with a key role in maintaining the prostate epithelial lineage. Importantly, a miR-
194 inhibitor effectively inhibited the growth of cell lines and patient-derived organoids 
with neuroendocrine features. Overall, our study reveals a novel post-transcriptional 
mechanism regulating the plasticity of prostate cancer cells and provides a rationale for 



















Cellular plasticity, also referred to as lineage plasticity or lineage switching, is a process 
whereby cells exhibit reversible changes in properties and phenotypes. Cancer cells 
exploit this phenomenon in response to a targeted therapy, acquiring the phenotypic 
characteristics of another lineage that does not depend on the drug target for survival1. 
This phenomenon allows cancer cells to adapt to new or stressful conditions and is 
increasingly recognised as a key feature of cancer progression2.  
As first-line treatment for metastatic prostate cancer (PCa), androgen deprivation 
therapy targets the exquisite dependence of tumours on the androgen receptor (AR) for 
their growth. While initially effective, patients inevitably develop resistance and progress 
to castration-resistant prostate cancer (CRPC). Most CRPC tumours exhibit adaptive 
changes that maintain AR activity despite the low androgen environment, an 
understanding that led to the development of highly potent second-generation AR-
targeted therapies (e.g. Enzalutamide and Abiraterone). However, response to these 
newer agents is also limited in most cases3. It has become increasingly clear that 
prolonged targeting of the AR, particularly with the more potent second-generation 
therapies, can drive cellular plasticity in CRPC. This plasticity is characterised by cells 
losing dependence on AR and gaining new phenotypes (i.e. aggressive variant PCa), with 
the most well recognised of these being a neuroendocrine (NE)-like state that is 
characterised by the expression of neuroendocrine, neuronal, developmental and 
stem cell markers1. Neuroendocrine prostate cancer (NEPC) is evident in ~15-25% of 
CRPC tumours4, 5 and exhibits aggressive clinical features; indeed, patients with NEPC 
have a median overall survival time of <1 year4. A deeper understanding of how AR-
targeted therapies promote lineage plasticity and the emergence of aggressive disease 
phenotypes such as NEPC is essential to improve patient outcomes. 
Genomic comparisons of NEPC and CRPC adenocarcinoma (CRPC-Adeno) have 
revealed surprisingly few genetic differences between these disease subtypes; 
reproducible alterations in NEPC include higher incidences of RB1 and TP53 loss and 
more frequent amplification of MYCN and AURKA6, 7. The similarities in mutational 
landscapes between NEPC and CRPC-Adeno suggest that the plasticity underlying 
transdifferentiation from adenocarcinoma to an NE-like state is predominantly mediated 
by changes in epigenetics, transcriptional programs and protein function in the tumour 
cells, as opposed to selection and outgrowth of rare genetic variants1.  
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In this study, we identified miR-194 as a novel post-transcriptional regulator of 
transdifferentiation in PCa. By targeting genes that suppress plasticity, such as FOXA1, 
miR-194 drives the emergence and growth of NEPC, a finding that justifies further 
investigation of miRNA-based therapies for this aggressive CRPC subtype.  
RESULTS 
Global identification of transcripts targeted by miR-194 in prostate cancer 
Our earlier work demonstrated that miR-194 can promote epithelial-mesenchymal 
transition (EMT) and metastasis, at least in part by targeting the tumour suppressor 
SOCS28. However, miRNAs target tens to hundreds of genes, so we hypothesised that 
elucidating additional miR-194 targets would shed further light on its oncogenic 
functions in PCa. Thus, we performed Ago-HITS-CLIP on control- and miR-194-
transfected 22Rv1 prostate cancer cells to decode miRNA-mRNA interactions. The 
22Rv1 model was chosen for this experiment since it exhibits increased metastatic 
capacity upon transient delivery of miR-1948. After immunoprecipitation of Argonaute, 
co-immunoprecipitating RNA was isolated and evaluated by high-throughput 
sequencing. Argonaute binding sites (i.e. peaks) that were enriched in cells transfected 
with miR-194 compared to control transfected cells were identified using MACS29, 
yielding 7,772 peaks associated with 3,326 genes (Supplementary Table S2). An example 
peak at the ZBTB10 gene is shown in Fig. 1a. Highlighting the robustness of the data, the 
vast majority (94%) of peaks were within genes, most commonly in exons, 3’UTRs and 
introns (Fig. 1b). Furthermore, unbiased de novo motif analysis revealed that the most 
strongly enriched sequence within the peaks was a seed recognition site for miR-194 
(Supplementary Table S3), which was concentrated within the centres of peaks (Fig. 1c).  
MiRNAs typically reduce the levels of their target mRNAs10. Therefore, we 
conducted RNA-seq of cells transfected with miR-194 mimic or a control. MiR-194 
elicited significant changes to the transcriptome, causing down-regulation of 2,626 and 
up-regulation of 2,485 transcripts (Fig. 1d). We identified a strong bias toward down-
regulation of mRNAs with miR-194 Ago-HITS-CLIP peaks in 3’UTRs, whereas mRNAs 
with peaks in coding regions were less strongly biased toward down-regulation and those 
with peaks in introns were collectively unchanged (Fig. 1e; Supplementary Fig. S1a). 
This is consistent with previous studies demonstrating that 3’UTRs are the key sequences 
through which miRNAs exert their activity10. Similarly, transcripts with 3’UTR peaks 
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containing miR-194 seed recognition sequences tended to be more robustly down-
regulated than those lacking such sequences (Fig. 1f; Supplementary Fig. S1b).  
 
miR-194 expression and activity is negatively correlated with AR signalling 
Gene ontology analysis of the miR-194 targetome revealed enrichment for genes 
associated with cytoskeletal remodelling, cell adhesion and cell motility (Supplementary 
Table S4), which likely relates to the ability of miR-194 to enhance prostate cancer cell 
migration and invasion and elicit an EMT8. To more specifically evaluate the targetome 
in clinical prostate cancer, we used single sample gene set enrichment analysis (ssGSEA) 
of our high-confidence targetome to generate miR-194 activity scores in clinical cohorts, 
which were then compared to equivalent scores generated from the same cohorts for the 
“Hallmark” biological gene sets13. Amongst other robust associations, one striking 
finding was that miR-194 activity was strongly inversely correlated with AR signalling 
across all cohorts examined (Fig. 2a; Supplementary Table S5). This observation was 
validated using a more refined set of AR target genes (Fig. 2b) recently generated by 
Sowalsky and colleagues14.  
The strength of this negative association led us to examine whether the miR-194 
targetome was enriched for AR target genes, but there was only a limited overlap between 
these gene sets (Fig. 2c). Moreover, our Ago-HITS-CLIP and transcriptomic data 
indicated that miR-194 does not target the AR transcript (Supplementary Fig. S2). An 
alternative (and/or additional) explanation for this inverse relationship could be that AR 
regulates the expression of miR-194. Indeed, levels of miR-194 in the androgen-sensitive 
LNCaP model were decreased by the potent androgen DHT but increased by the AR 
antagonist Enzalutamide (Fig. 2d). In accordance with these findings, extended culture 
of cells in androgen-depleted conditions led to upregulation of miR-194 (Fig. 2e). 
Collectively, these data reveal that AR represses expression of miR-194, which (at least 






Fig 1. Integrative omics identifies a miR-194 “targetome” in prostate cancer. (a) 
Example of an Ago-HITS-CLIP peak with a miR-194 seed recognition sequence in the 
ZBTB10 gene. Genome tracks depict the average read density of all replicates for each 
treatment condition (i.e. cells transfected with miR-194 (red) or a scrambled control 
(black)). (b) Distribution of 7,772 Ago-HITS-CLIP peaks mapped to their genomic 
regions. (c) Distribution of miR-194 recognition sequences within Ago-HIT-CLIP peaks. 
Background represents occurrence of the motif on the opposite strand of the peak. (d) 
Volcano plot showing expression of genes altered by miR-194 transfection in 22RV1 
cells. Blue dots indicate significantly downregulated genes and orange dots indicate 
significantly upregulated genes (FDR ≤ 0.05). (e) Cumulative distribution of log2 fold 
change for genes containing peaks in the 3’UTR, CDS and Introns compared to a 
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background of all genes with no peaks. (f) Cumulative distribution of log2 fold change 
for genes with a 3’UTR Ago-HITS-CLIP peak containing miR-194 seed matches or no 
seed matches in peaks compared to a background of all genes with no peaks. (g) 
Cumulative distribution of log2 fold change for all genes with a 3’UTR Ago-HITS-CLIP 
peak containing a miR-194 seed match (Ago-HITS-CLIP) or both a 3’UTR peak with 
miR-194 seed match and down-regulation at the post-transcriptional level (Ago-HITS-
CLIP + EISA). (h) Correlations between miR-194 expression and its “targetome” in 72 
primary and metastatic prostate cancers (MSKCC cohort11). For each target identified, 
the Pearson correlation coefficient and its q value was calculated and plotted as −log q 
(on y-axis) versus correlation coefficient (on x-axis). To indicate the bias towards 
negative correlations, the mean correlation coefficient is indicated by a vertical black line. 








Fig 2. MiR-194 expression is suppressed by AR. (a) Correlation of miR-194 activity 
score with activity scores of “Hallmark” biological gene sets in the TCGA, SU2C and 
MSKCC cohorts. P and r values were determined using Pearson’s correlation tests. Only 
gene sets that were significantly correlated (p < 0.05) in all three cohorts are shown in 
the heatmap. (b) MiR-194 activity is inversely correlated with AR activity in primary 
prostate cancer (TCGA cohort, left15), metastatic prostate cancer (SU2C cohort, centre16) 
and a cohort comprising both primary and metastatic prostate cancer (MSKCC cohort, 
right11). P and r values were determined using Pearson’s correlation tests. (c) Overlap 
between the miR-194 targetome and an AR target gene set14. (d) Relative miR-194 
expression in LNCaP cells treated with the androgen DHT and AR antagonist 
Enzalutamide (Enz). Cells grown in serum starved conditions were treated with vehicle 
control (Veh) or 10 nM DHT in the presence or absence of 10 μM Enz for 48 hours. Cells 
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grown in full serum were treated with vehicle (DMSO) or 10μM Enz for 48 hours. 
Expression of miR-194 was normalised to the reference small RNA U6. P values were 
determined using unpaired two-sided t tests (*, p < 0.05). (e) Relative miR-194 
expression in LNCaP cells grown in fetal calf serum (FCS) or charcoal stripped serum 
(CSS) for 4 or 8 days. Expression of miR-194 was normalised to the reference small RNA 





miR-194 activity and expression is elevated in neuroendocrine prostate cancer 
NEPC is associated with loss of canonical AR activity1. Given the inverse relationship 
between miR-194 and AR, we therefore hypothesised that its activity would be elevated 
in clinical NEPC. Indeed, miR-194 activity (estimated by ssGSEA) was significantly 
higher in NEPC compared to CRPC-Adeno tumours in clinical samples (Fig. 3a) and 
patient-derived xenograft (PDX) models (Supplementary Fig. S3). Moreover, miR-194 
activity was correlated with established NEPC gene sets (Fig. 3b).  
We next examined whether miR-194 itself was over-expressed in NEPC. In the 
absence of miRNA expression data from clinical samples, we turned to a panel of 13 
PDXs established through the Melbourne Urological Research Alliance (MURAL), 6 of 
which have features of NEPC17. Importantly, miR-194 expression was higher in the 
NEPC versus AR-positive adenocarcinoma PDXs (Fig. 3c), further demonstrating its 
association with this disease subtype.  
Loss of AR expression and/or activity during the transition to NEPC likely 
explains – at least partly - increased miR-194 expression in this disease state. However, 
since we have also noted elevated miR-194 expression and activity in metastases and 
“poor outcome” primary tumours18, we speculated that other alterations may underlie 
dysregulation of miR-194 in PCa. MiR-194 is encoded by two separate loci on 
chromosomes 1 and 11; the MIR194-1 gene clusters with MIR215 within intron 12 of the 
IARS2 gene on chromosome 1, while the MIR194-2 gene clusters with MIR192 
approximately 3kb downstream of the ATG2A gene on chromosome 11. By interrogating 
clinical genomic datasets, we found that MIR194-1/IARS2 and MIR194-2/ATG2A are 
more frequently gained/amplified in metastatic compared to primary PCa and in NEPC 
compared to CRPC-Adeno (Fig. 3d). Importantly, gain/amplification of these loci were 
associated with elevated levels of miR-194 (Fig. 3e). These data suggest that copy 
number gain can result in increased miR-194 expression in aggressive prostate tumours 
and NEPC.  
 
miR-194 promotes the emergence of a neuroendocrine features in prostate cancer 
To determine whether miR-194 can directly influence the emergence of a NE-like state, 
we examined the response of adenocarcinoma PCa cells to transfection with a miR-194 
mimic. Exogenous miR-194 led to upregulation of NE marker genes (Fig. 4a) and 
increased neurite length in LNCaP cells (Fig. 4b), an effect that was recapitulated in the 
22Rv1 cell line model (Fig. 4a-b, Supplementary Fig. S4).  
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The ability of miR-194 to enhance NE transdifferentiation was further tested 
using a locked nucleic acid (LNA) inhibitor that specifically inhibits the activity of this 
oncogenic miRNA. In these experiments, we exploited the fact that the LNCaP model 
can be transdifferentiated from adenocarcinoma-like to NE-like cells by androgen 
deprivation19. As expected, growth of cells in charcoal-stripped serum (CSS) resulted in 
upregulation of NE markers ENO2 (encoding neuron-Specific Enolase) and SYP 
(encoding synaptophysin) and increased the length of neurite-like extensions (Fig. 4c-d). 
Importantly, the miR-194 LNA inhibitor effectively blocked this transdifferentiation 
(Fig. 4c-d). Collectively, these data reveal that miR-194 can drive the acquisition of NE 






Fig 3. MiR-194 is associated with the AR independent NEPC subtype. (a) MiR-194 
activity is higher in neuroendocrine prostate cancer (NEPC) compared to 
adenocarcinoma CRPC (CRPC-Adeno) in 2 distinct cohorts6, 20. Dashed middle line, 
median; dotted lines above and below, upper and lower quartiles. P values were 
determined using unpaired two-sided t tests (*, P < 0.05; ****, P< 0.0001). (b) 
Correlation between miR-194 activity and published NEPC associated gene signatures21, 
22, 23, 24, 25, 26. P and r values were determined using Pearson’s correlation tests (*, p < 0.05; 
**, p < 0.01; ***, p < 0.001; ****, p < 0.0001). (c) Expression of miR-194 is higher in 
NEPC PDXs compared to PDXs derived from AR-positive adenocarcinoma tumours. 
Expression of miR-194 was normalised to two reference small RNAs (U6 and RNU44). 
Dashed middle line, median; dotted lines above and below, upper and lower quartiles. P 
value was determined using an unpaired two-sided t test (**, P < 0.01). (d) MIR194-
1/IARS2 and MIR194-2/ATG2A are more frequently gained/amplified in metastatic 
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compared to primary PCa and in NEPC compared to CRPC-Adeno. Copy number data 
is combined from multiple clinical cohorts24, 27, 28, 29, 30. (e) Expression of miR-194 is 
higher in primary prostate tumours with MIR194-1/IARS2 or MIR194-2/ATG2A copy 
number gain or amplification compared to tumours with no change in copy number 
(diploid). Data is from the TCGA cohort. Dashed middle line, median; dotted lines above 
and below, upper and lower quartiles. P values were determined using unpaired two-sided 







Fig 4. MiR-194 promotes prostate cancer transdifferentiation. (a) Expression of 
NEPC marker genes is upregulated in response to transfection of a miR-194 mimic in 
LNCaP and 22RV1 cells. Gene expression was normalised to GAPDH. Expression for 
the negative control (NC) was set to 1, and error bars are SEM. (b) MiR-194 increases 
neurite length in LNCaP and 22RV1 cells compared to cells transfected with a negative 
control miRNA mimic (NC). Expression for NC was set to 1, and error bars are SEM. P 
values were determined using unpaired two-sided t tests (**, p < 0.01).  Representative 
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phase contrast images (on the right) are of LNCaP cells transfected with miR-194 mimic 
or NC. Neurite outgrowths are traced on images in magenta. Scale bars, 25 μm. (c) A 
miR-194 inhibitor (194i) blocks neuroendocrine transdifferentiation of LNCaP cells 
mediated by androgen deprivation, as determined by expression of Neuron specific 
enolase (ENO2), Synaptophysin (SYP) and changes in neurite length. Gene expression 
was normalised to GAPDH. Gene expression or neurite length for cells grown in full 
serum were set to 1, and error bars are SEM. P values were determined using ANOVA 
(*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). (d) Representative phase 
contrast images of LNCaP cells grown in full or stripped serum conditions with or 
without a miR-194 inhibitor (194i) or negative control inhibitor (NCi). Neurite 




FOXA1, an inhibitor of neuroendocrine transdifferentiation, is targeted by miR-194  
To understand at a mechanistic level how miR-194 promotes PCa transdifferentiation, 
we searched the targetome for genes with a known role in PCa progression. Of particular 
interest was FOXA1, a transcription factor with a critical role in maintaining epithelial 
lineage in the prostate31. Consistent with this function, a recent report demonstrated that 
loss of FOXA1 leads to NE differentiation in prostate cancer32. Multiple miR-194 Ago-
HITS-CLIP peaks were found within the FOXA1 3’UTR, one of which contains a perfect 
7-mer seed match (Fig. 5a). We confirmed that miR-194 decreases the levels of FOXA1 
mRNA and FOXA1 protein in the LNCaP and 22Rv1 models (Fig. 5b-c). Importantly, 
the activity of FOXA1 and miR-194 is inversely correlated in clinical PCa (NEPC and 
primary PCa; Fig. 5d). Collectively, these findings reveal a functional interaction 
between miR-194 and FOXA1.  
A recently described mechanism by which FOXA1 suppresses NE differentiation 
is by directly repressing the IL8 gene, a chemokine elevated in NEPC, which results in 
dampening of the MAPK/ERK pathway, a known driver of NEPC32, 33. Supporting the 
relevance of this mechanism in miR-194’s mode of action, transfection of prostate cancer 
cells (LNCaP and 22Rv1) with miR-194 caused upregulation of IL8 (Fig. 5e). Moreover, 
miR-194 also enhanced MAPK/ERK pathway activity (Fig. 5f), and miR-194 activity 
was positively correlated with MAPK/ERK gene signatures in clinical NEPC (Fig. 5g 
and Supplementary Fig. S5). Collectively, these data reveal that miR-194 promotes the 
emergence of NEPC at least in part by targeting FOXA1, which leads to upregulation of 
IL8 and enhanced MAPK/ERK pathway activity.  
 
Targeting miR-194 suppresses the growth of prostate cancer with neuroendocrine 
features 
Although miR-194 mediates the acquisition of an NE-like phenotype in prostate cancer, 
whether it represented a therapeutic target in this disease context is unclear. To 
investigate this possibility, we measured the growth of PCa cells treated with the miR-
194 LNA inhibitor. Interestingly, the growth of all 4 cell line models tested could be 
suppressed by the inhibitor, but the models with NE features (PC3 and LNCaP-MR42D) 
were more sensitive than those with a more typical adenocarcinoma phenotype (LNCaP, 
LNCaP-MR49F) (Fig. 6a). The miR-194 inhibitor was cytotoxic as revealed by cell 
viability assays (Fig. 6b) and by counting dead cells (Fig. 6c).  
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To examine the potential of targeting miR-194 in a more clinically-relevant setting, we 
turned to patient-derived CRPC organoids recently described by our team17. Models 
201.1 and 201.2 were derived from dura and lung metastases, respectively, from a patient 
who died after receiving second-generation AR-targeted therapies (Enzalutamide, 
Abiraterone) and chemotherapies (Docetaxel, Cabazitaxel)17. 201.1 is a model of PSA-
positive adenocarcinoma that expresses a mutated form of the AR (C687Y and T878A) 
that mediates resistance to Enzalutamide. In contrast, 201.2 has no AR or PSA expression 
but exhibits high expression of a neuroendocrine gene signature, focal staining of CD56, 
and concurrent genomic loss of TP53, PTEN and RB117. Representative IHC images of 
the expression of various markers in each model are shown in Fig. 6D. As expected, miR-
194 levels were higher in 201.2 compared to 201.1 (Fig. 6e). The effect of the miR-194 
LNA inhibitor on the growth of these 2 patient-derived models was evaluated by 
measuring organoid forming efficiency (OFE) and cell viability. Both models exhibited 
reduced OFE and cell viability in response to transfection with the inhibitor (Fig. 6f-g). 
However, similarly to the cell lines, the AR-null, NEPC-like 201.2 model was more 
sensitive to miR-194 inhibition than the adenocarcinoma-like 201.1 model (Fig. 6f-g). 
Collectively, these findings - in both traditional cell lines and contemporary patient-
derived models - provide evidence that targeting miR-194 has potential as a novel therapy 







Fig 5. MiR-194 targets FOXA1 and activates the MAPK/ERK pathway. (a) Ago-
HITS-CLIP peaks (including one indicated with a miR-194 seed recognition) sequence 
in the FOXA1 gene. Genome tracks depict the average read density of all replicates for 
each treatment condition (i.e. cells transfected with miR-194 (red) or a scrambled control 
(black)). (b) Western blot showing FOXA1 protein levels following transfection of a 
miR-194 mimic or negative control mimic (NC) in 22RV1 and LNCaP cells. (c) 
Expression of FOXA1 mRNA, as determined by qRT-PCR, following transfection of 
miR-194 mimic or NC in 22RV1 and LNCaP cells. Gene expression was normalised to 
GAPDH. Expression for NC was set to 1, and error bars are SEM. P values were 
determined using unpaired two-sided t tests (*, p < 0.05). (d) FOXA1 activity is 
negatively correlated with miR-194 activity in clinical cohorts6, 15. P and r values were 
determined using Pearson’s correlation tests. (e) Expression of IL8 is upregulated in 
response to miR-194 in 22RV1 and LNCaP cells. Gene expression was normalised to 
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GAPDH. Expression for NC was set to 1, and error bars are SEM. P values were 
determined using unpaired two-sided t tests (*, p < 0.05). (f) MiR-194 causes increased 
MAPK activity in 22Rv1 cells, as determined by GSEA. The MAPK activation signature 
has been described previously34. (g) MAPK/ERK activity is positively correlated with 
miR-194 activity in a clinical cohort comprised of NEPC and CRPC-Adeno samples6. P 











Fig 6. Inhibiting miR-194 blocks the growth of NEPC. (a) Blocking miR-194 activity 
with an LNA inhibitor (miR-194i) supresses the growth of cell lines with neuroendocrine 
features (LNCaP-MR42D, PC3) more potently than AR-driven adenocarcinoma cell lines 
(LNCaP-MR49F, LNCaP), as determined by Trypan blue growth assays. Error bars are 
SEM. Negative control inhibitor, NCi. (b) Blocking miR-194 activity with an LNA 
inhibitor supresses cell viability more potently in neuroendocrine-like LNCaP-MR42D 
cells compared to LNCaP adenocarcinoma cells, as determined by Cell Titer Glo cell 
viability assay. P values were determined using unpaired two-sided t tests (**, p < 0.01; 
****, p < 0.0001). (c) Proportion of live and dead cells in LNCaP-MR42D and LNCaP 
cells transfected with 194i or NCi. P values were determined using unpaired two-sided t 
tests (*, p < 0.05). (d) Representative phase contrast, haematoxylin and eosin (H&E) and 
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immunohistochemistry (IHC) of 201.1 and 201.2 organoid models growing as colonies 
in Matrigel. Scale bars: phase images = 100 μm; H&E and IHC = 50 μm. (e) Levels of 
miR-194 in 201.1 and 201.2 organoids. Expression of miR-194 was normalised to 2 
reference small RNAs (U6 and RNU44). P value was determined using an unpaired two-
sided t test (*, p < 0.05). (f-g) Blocking miR-194 activity with 194i inhibits organoid 
forming efficiency (f) and organoid viability (g) of the 201.1 and 201.2 models. P values 






Epigenetic and transcriptional alterations are known to mediate prostate cancer cell 
plasticity during adenocarcinoma-neuroendocrine transdifferentiation. Most drivers of 
these alterations identified to date are transcription factors and chromatin modifiers, such 
as SOX235, 36, EZH235, REST37, BRN238 and FOXA239. By identifying miR-194 as a 
mediator of this transdifferentiation, our work reveals that post-transcriptional gene 
regulation is another mechanism by which transcriptional networks are altered during 
progression to NEPC. 
Our study suggests that miR-194 is elevated in NEPC via 2 key mechanisms. 
First, by evaluating PCa cells treated with androgens and anti-androgens, we found that 
miR-194 is negatively regulated by the AR signalling axis. Interrogation of published 
cistromic data revealed no evidence for association of AR with regulatory elements 
proximal to MIR194 genes (data not shown); thus, we do not believe that the inverse 
relationship between AR and miR-194 represents a direct mode of transcriptional 
repression. Rather, we hypothesise that AR indirectly inhibits miR-194 expression 
through a mechanism that is yet to be elucidated. One possibility is that the transcription 
factor GATA2 serves as an intermediary: expression of GATA2 is known to be down-
regulated by AR40, and we previously demonstrated that GATA2 enhances the levels of 
miR-1948. Future studies should investigate the role of this putative pathway in NEPC, 
particularly since GATA2 has been identified as a mediator of PCa metastasis and drug 
resistance previously41. Second, we found that gain or amplification of genomic regions 
encompassing the MIR194 genes is another mechanism that can result in elevated 
expression of miR-194 in aggressive forms of prostate cancer, including NEPC. MiR-
194 is unusual in that it is encoded by 2 genes (MIR194-1 and MIR194-2), and the 
observation that both are frequently gained further supports the relevance of this miRNA 
in disease progression.  
 Using an integrative approach that exploited cutting-edge biochemical (Ago-
HITS-CLIP), molecular (RNA-seq) and bioinformatics (EISA) techniques, we identified 
~160 genes that miR-194 putatively targets in PCa. Of note, gene signatures enriched in 
this targetome include those involved in cell movement, cytoskeletal organisation 
(including axon guidance) and focal adhesion. We propose that dysregulation of these 
networks by elevated miR-194 during PCa progression promotes EMT8 and 
transdifferentiation from an adenocarcinoma-like cell to an NE-like cell (this study). 
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While this hypothesis remains to be proven, we note the EMT and emergence of NE 
features are manifestations of cell plasticity that share many fundamental characteristics; 
indeed, it appears as if the re-activation of a developmental EMT program is a crucial 
strategy by which PCa cells evolve towards a NE lineage1, 42.  
In addition to a miR-194 targetome enriched for cell movement, structure and 
attachment, we identified FOXA1 as a key target gene via which miR-194 influences the 
emergence of NEPC. Supporting our findings, FOXA1 has been previously identified as 
a target of miR-194 in non-small cell lung cancer (NSCLC); interestingly, in this context 
it appeared to act as a tumour suppressor, with upregulation of miR-194 suppressing 
tumour proliferation, invasion and metastasis 43. The divergent outcomes of targeting 
FOXA1 by miR-194 in PCa and NSCLC reflects a common phenomenon in miRNA 
biology whereby context-dependent roles are mediated by the relative expression of key 
miRNA target genes in a particular cell or tissue environment. Our data suggest that 
targeting of FOXA1 by miR-194 in PCa leads to de-repression of IL8 and subsequent 
upregulation of the MAPK/ERK pathway32. Both IL8 and the MAPK/ERK pathway are 
known drivers of NEPC33, 44, 45; our work defines a new mechanism by which these 
factors are elevated in this disease context.  
The relevance of the miR-194:FOXA1 pathway in PCa likely goes beyond its 
consequent impact on IL8 and MAPK/ERK, since FOXA1 is a pioneer factor for AR and 
a major regulator of its transcriptional outputs46. Like FOXA1, AR is also vital for 
maintenance of the epithelial phenotype; therefore, the consequent disruption of AR 
signalling by down-regulation of FOXA1 could be another mechanism by which miR-
194 enhances lineage plasticity in PCa. Combined with our finding that miR-194 is 
repressed by AR signalling and the identification of up to 11 AR downstream genes as 
miR-194 targets (Fig. 2c), our study reveals a complex and intimate interplay between 
miR-194 and this key pathway in PCa. In addition to being the likely explanation for the 
extremely strong negative correlation between miR-194 and AR in clinical PCa, this 
interplay may also influence response to AR-targeted therapies.  
Given the increasing frequency of treatment-emergent NEPC tumours and their 
aggressiveness, the development of therapies that selectively target this CRPC subtype is 
critically important. Indeed, strategies to target AURKA (which promotes the activity of 
MYCN, a known driver of NEPC), EZH2 (which enhances adenocarcinoma-NEPC 
transdifferentiation) and the Wnt and NOTCH pathways (both of which promote stem 
cell maintenance in NE-like tumours) are being evaluated in clinical trials1. Our study 
126 
 
identifies miR-194 as a novel therapeutic target in this disease setting. Although a recent 
study found that miR-652 can promote the acquisition of NE features in PCa cells47, to 
our knowledge ours is the only study to date demonstrating that targeting a miRNA can 
inhibit NE transdifferentiation and block the growth of NEPC. Moreover, the sensitivity 
of patient-derived CRPC organoids and PCa cell lines to nanomolar doses of a miR-194 
inhibitor highlights the potential of such a therapeutic strategy. While miRNA-based 
therapies have proven difficult to translate to the clinic48, at least 2 antagomiRs are 
currently being evaluated in trials: a miR-122 antagomiR (“Miravirsen”) showed activity 
in a phase IIa trial of hepatitis C (in which no adverse side effects were reported), while 
a miR-155 antagomiR is in phase I trials for lymphoma49. The attraction of targeting 
miRNAs in cancer comes from the potential to concurrently modulate multiple pathways 
involved in tumour growth and progression. In the case of miR-194, an inhibitor could 
stabilise multiple plasticity suppressing factors (e.g. FOXA1) and tumour suppressors 
(e.g. SOCS28), leading to inhibition of multiple plasticity- and metastasis-promoting 
pathways (e.g. MAPK/ERK, IL8 and STAT3). We aim to undertake further pre-clinical 
evaluation of a miR-194-targeted therapy to treat NEPC and/or re-sensitise NEPC 
tumours to AR-targeted therapies.  
In addition to its potential as a therapeutic target, it is worth noting that miR-194 was 
first linked to PCa as a serum marker of poor prognosis in a patients with localised 
disease18. In this earlier disease context, high levels of serum miR-194 likely demarcates 
tumours with increased plasticity and hence a propensity to metastasize. However, 
whether miR-194 is a marker of advanced PCa and CPRC is unknown. Given the strong 
inverse correlation between miR-194 and AR activity, it is tempting to speculate that 
circulating miR-194 could be used to identify CRPC patients with AR-independent 
tumours (e.g. NEPC) and therefore guide therapy, but this concept remains to be tested 
in patient cohorts.  
 In summary, our study demonstrates that miR-194 can promote adenocarcinoma-
NE transdifferentiation and the growth of NEPC by targeting a network of genes 
including the lineage-defining transcription factor FoxA1. These findings deliver new 
molecular insights into lineage plasticity in PCa, and provide impetus to further 





MATERIAL AND METHODS 
 
Cell lines and cell culture 
LNCaP, PC3 and 22RV1 cell lines were purchased from the American Type Culture 
Collection (ATCC). LNCaP-MR42D and LNCaP-MR49F cell lines have been described 
previously38. LNCaP and 22RV1 cell lines were maintained in RPMI-1640 (Sigma) 
containing 10% Fetal Bovine Serum (FBS) (Sigma). PC3 cell lines were maintained in 
RPMI-1640 containing 5% FBS. LNCaP-MR42D and LNCaP-MR49F cells were 
maintained in RPMI-1640 containing 10% FBS and 10μM Enzalutamide. For serum 
starvation experiments, cells were grown in phenol red-free RPMI-1640 containing 10% 
dextran-coated charcoal (DCC) stripped serum. Cell lines were subjected to regular 
mycoplasma testing. All cell lines underwent verification by short tandem repeat 
profiling by CellBank Australia. 
Cell line transfections 
Transient transfection of cell lines were performed using RNAiMAX Transfection 
Reagent (Life Technologies) according to the manufacturer's instructions. For HITS-
CLIP and RNA-seq experiments, 22RV1 cells were transfected with 20nM miRVana 
mimic (miR-194 or negative control; Ambion). For all other experiments, cells were 
transfected with 20nM miRNA mimics from Shanghai GenePharma. For miR-194 
inhibition, cells were transfected with 12.5 or 6.25nM locked nucleic acid (LNA) miRNA 
inhibitors (miR-194 LNA inhibitor or negative control inhibitor; Qiagen).  
Argonaute high-throughput sequencing of RNA isolated by crosslinking 
immunoprecipitation (Ago-HITS-CLIP) 
The Ago‐HITS-CLIP method was adapted from published methods50, 51, incorporating 
modifications from eCLIP52, 53. 22RV1 cells were seeded in 10 cm cell culture dishes and 
transfected in suspension with 20 nM miRVana mimic (miR-194 or negative control, 3 
replicates of each; Ambion) using RNAiMAX (Life Technologies). After 24 h, 
transfected 22RV1 cells were rinsed once with ice-cold PBS and UV irradiated with 600 
mJ/cm2, 254 nm, in ice-cold PBS using a UV Stratalinker-1800 (Agilent). Cells were 
collected by scraping, and cell pellets stored at -80°C as one pellet per 100mm plate. One 
pellet per CLIP IP was lysed in 500 μl of 1 X PXL (1 X PBS, 0.1% SDS, 0.5% 
deoxycholate, 0.5% Igepal) + EDTA-free Complete protease inhibitor cocktail (PIC; 
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Roche) for 15 min on ice, followed by trituration through a 21G needle and syringe 5 
times. DNA was digested with 20 μl RQ1 DNAse (Promega) at 37°C for 10 min on a 
Thermomixer (750 rpm, Eppendorf). RNA was partially digested with RNase 1 
(ThermoFisher) by adding 5 μl of 1:40 diluted RNase 1 in 1 X PBS at 37°C for 5 min on 
a Thermomixer (750 rpm), then returned to ice. Lysates were centrifuged at 21,000 g for 
20 min at 4°C and supernatant transferred to a fresh tube. 
AGO-RNA complexes were immunoprecipitated using mouse IgA2 monoclonal 
anti-Ago2 antibody 4F954; hybridoma sourced from University of Florida ICBR) with a 
mouse IgA antibody (GeneTex S107) used as a control. Antibodies (8 μg) were 
conjugated to 20 μl protein L Dynabeads (ThermoFisher, 88849) in PBS-Tw (1 X PBS, 
0.05% Tween-20) for 45 min and washed three times with 1 X PXL (1 X PBS, 0.1% 
SDS, 0.5% sodium deoxycholate, 0.5% Igepal) before resuspending the beads with 450 
μl of prepared lysate and rotating for 2 hr at 4°C. Bound AGO-RNA complexes were 
washed twice each consecutively with ice cold 1 X PXL, 5 X PXL (5 X PBS, 0.1% SDS, 
0.5% sodium deoxycholate, 0.5% Igepal), and 1 X PNK (50 mM Tris-Cl pH 7.5, 10 mM 
MgCl2, and 0.5% Igepal). Beads were first treated with T4 PNK (NEB, M0201L; 20 U 
in 80 μl reaction volume) in the absence of ATP (37°C, 850 rpm for 20 min) to 
dephosphorylate 3’ RNA ends followed by washes with 1 X PNK, 5 X PXL, and two 
washes with 1 X PNK at 4°C. The 3’ preadenylated linker (NEBNext 3’SR adaptor for 
Illumina; /5rApp/AGA TCG GAA GAG CAC ACG TCT /3AmMO/) was ligated to the 
RNA fragments on bead using T4 RNA ligase 2 truncated KQ (NEB M0373; 100 U in a 
40 μl reaction volume, 12% PEG8000, 1x RNA ligase buffer, 0.125 μM adaptor) in the 
absence of ATP at 16°C, overnight with periodic mixing. Beads were washed 
consecutively with ice cold 1 X PXL, 5 X PXL, and twice with 1 X PNK. Bound RNAs 
were then labelled with P32 γ-ATP using T4 PNK, 20 min at 37°C, and washed as above.  
AGO-RNA complexes were eluted with 40 μl 1 X Bolt LDS sample buffer 
(ThermoFisher) + 1% β-mercaptoethanol at 70°C for 10 min on a Thermomixer (1200 
rpm). Samples were separated through Bolt 8% Bis-tris Plus gels (ThermoFisher) using 
BOLT MOPS SDS running buffer at 200 V for 75 min. Complexes were then transferred 
to nitrocellulose (Schleicher&Schuell, BA-85) by wet transfer using 1 X BOLT transfer 
buffer with 10% methanol. Filters were placed on a phosphor screen and exposed using 
a Typhoon imager (GE). 115-160 kDa regions (corresponding to RNA tags > 30 nt) were 
excised from the nitrocellulose. RNA was extracted by proteinase K digestion (2 mg/mL 
proteinase K, 100 mM Tris-HCl pH 7.5, 50 mM NaCl, 10 mM EDTA, 0.2% SDS) at 
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50°C for 60 min on a Thermomixer (1200 rpm) followed by extraction with acid phenol 
(ThermoFisher, AM9712) and precipitation with 1:1 isopropanol:ethanol. RNA was 
pelleted by centrifugation then separated on a 15% denaturing polyacrylamide gel (1:19 
acrylamide, 1 X TBE, 7 M urea). The wet gel was wrapped in plastic wrap and exposed 
to a phosphor screen and imaged using a Typhoon. Gel slices were cut corresponding to 
the expected size of the cross-linked RNA eluted by the “crush and soak” method as 
previously described51.  
Reverse transcription, 5’ linker ligation and amplification were performed 
essentially as previously described52 using SR-RT primer for reverse transcription (IDT, 
AGACGTGTGCTCTTCCGATCT) with SuperScript IV, and a custom synthesised 5’ 
linker (IDT, 5’SRdeg /5Phos/NN NNN NNN NNG ATC GTC GGA CTG TAG AAC 
TCT GAA C/3SpC3/). Products were amplified for 20 cycles using a common forward 
primer (NEBNext SR primer for Illumina) and barcoded reverse primers for each sample 
(NEBNext Index primers for Illumina). PCR products were purified using Qiagen 
Qiaquick PCR purification kit, separated on an 8% acrylamide (29:1) TBE non- 
denaturing gel, stained with SYBR Gold nucleic acid gel stain (ThermoFisher) and 
imaged on a ChemiDoc (BioRad). Products corresponding to an insert size of ~30 – 70 
nt were excised from the gel and extracted by the “crush and soak” method as previously 
described51. Library quality and quantity was assessed by Bioanalyzer (Agilent) and 
qPCR, pooled and sequenced on an Illumina NextSeq 500 (1 x 75bp). 
RNA libraries generated by HITS-CLIP were sequenced on the Illumina Nextseq 
500 platform using the single end protocol with a read length of 75. Raw reads were 
adapter trimmed and filtered for short sequences using cutadapt v1.8.155 setting 
minimum-length option to 18, error-rate 0.2, and overlap 5. The resulting FASTQ files 
(averaging 41.6 million reads per sample) were analysed and quality checked using the 
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) program. Filtered 
reads were mapped against the human reference genome (hg19) using the Tophat2 
alignment algorithm (version 2.0.9 with default parameters)56, returning an average 
alignment rate of 43.8%. Unique molecular identifiers (UMIs) were used to de-duplicate 
reads that mapped to the same start site, possessed identical CIGAR strings and UMI 
barcodes sequences ≤1 edit distance apart. Enriched regions of the genome were 
identified from Samtools quality-filtered alignments57 (-q 5) with the MACS2 peak caller 
(version 2.1.1)9 (setting; --nomodel, --shift -15, --extsize 50, -B,  --slocal 0, --llocal 0, --
fe-cutoff 10, -q 0.05). Peak calling was performed using pooled alignment files and 
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carried out separately for each strand. The resulting peak files from each strand were 
merged. Features in the vicinity of peak loci and enrichment of motifs within peaks were 
determined and analysed using Homer58. Alignments were visualised and interrogated 
using IGV59. 
CLIP using a control antibody was performed on a single biological replicate of 
control transfected cells but yielded very little sequence data and was excluded from the 
analysis. 
RNA sequencing 
22RV1 cells were seeded in 6-well plates and transfected in solution with 20nM miRVana 
mimic (miR-194 or negative control; Ambion) using RNAiMAX (Life Technoloies). At 
36 hours post-transfection, cells were collected in Qiazol (Qiagen) and total RNA was 
extracted using a miRNeasy Mini Kit (Qiagen) according to the manufacturer's 
instructions. RNA seq was performed on 4 biological replicates each of 22RV1 cells 
transfected with miR-194 or negative control. RNA sequencing libraries were constructed 
with the mRNAseq Library prep kit and libraries were sequenced on the Illumina 
NextSeq 500 platform.  
RNA-seq libraries were multiplexed and sequenced on the Illumina NextSeq 500 
platform using the stranded, paired-end protocol with a read length of 150. Raw reads 
were adapter trimmed and filtered for short sequences using cutadapt v1.8.155, setting 
minimum-length option to 18, error-rate 0.2, quality cut-off 28, overlap 5 and trim N's 
on. The resulting FASTQ files (averaging 60.2 million read pairs per sample) were 
analysed and quality checked using the FastQC program 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Reads were mapped 
against the human reference genome (hg19) using the STAR spliced alignment 
algorithm60 (version 2.5.3a with default parameters and --chimSegmentMin 20, --
quantMode GeneCounts), returning an average unique alignment rate of 92.9%. 
Differential expression analysis was evaluated from TMM normalised gene counts using 
R (version 3.2.3) and edgeR61 (version 3.3), following protocols as described62. Graphical 
representations of differentially expressed genes were generated using Glimma63. 
Alignments were visualised and interrogated using the Integrative Genomics Viewer 
v2.3.8059.  
Exon Intron Split analysis (EISA) was performed as described previously64. To 
refine the miR-194 targetome, only post-transcriptionally downregulated genes (i.e. 
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genes with log2FC(dExon-dIntron) < 0) and a FDR cutoff of 0.05) were considered as 
targets. 
Gene set enrichment analysis  
Genes were ranked according to expression using the Signal2Noise metric. Gene Set 
Enrichment Analysis (Preranked analysis)65 was implemented using the Broad Institute’s 
public GenePattern server with default parameters.  
Analysis of miR-194 activity in published datasets single sample GSEA (ssGSEA) 
Expression data was downloaded from GEO (Kumar 2016 (GSE77930)20), cBioportal 
(MSKCC29 and SU2C66), TCGA67 and dbGAP (Beltran 201624). ssGSEA68 was 
implemented using the Broad Institute’s public GenePattern server, using rank 
normalisation and default parameters. Since miRNAs repress expression of their target 
genes, miR-194 activity was calculated as the inverse value of ssGSEA scores for the 
miR-194 targetome.  
RNA extractions from cell lines and patient-derived xenograft (PDX) tissues  
Total RNA from cell lines was extracted using TRI Reagent (Sigma), as described 
previously8. PDX tissues preserved in RNALater were provided by the Melbourne 
Urology Research Alliance (MURAL)17. Tissues were homogenised in Qiazol (Qiagen) 
with a Precellys24 Tissue Homogeniser (Bertin Technologies) and total RNA was 
extracted using a miRNeasy Mini Kit (Qiagen), according to the manufacturer's 
instructions.   
Quantitative RT-PCR (qRT-PCR) analysis of mRNA 
Total RNA was treated with Turbo DNA-free kit (Invitrogen), and reverse transcribed 
using iScript Reverse Transcriptase Supermix kit (Bio-Rad). qRT-PCR was performed in 
triplicate as described previously69. GAPDH levels were used for normalization of qRT-
PCR data. Primer sequences are available on request. 
qRT-PCR analysis of miR-194 
Total RNA (100 ng) was reverse transcribed using the TaqMan MicroRNA Reverse 
Transcription Kit (Applied Biosystems) and Taqman Microarray Assays (Thermo Fisher 
Scientific). Quantitation of miR-194, U6 and RNU44 was done by qRT-PCR using 
Taqman Microarray Assays (Thermo Fisher Scientific) and TaqMan™ Universal Master 
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Mix II, no UNG (Applied Biosystems) on a CFX384 real-time PCR detection system 
(Bio-Rad). MiR-194 expression was normalised to expression of U6 (cell lines) or the 
geometric mean of U6 and RNU44 (PDX tissues). 
Proliferation and cell viability assays 
Proliferation curves for cell lines treated with LNA miRNA inhibitors were performed 
using the Trypan blue exclusion assay. Cells were seeded at 1104 (PC3) or 4.5104 
(LNCaP-MR42D, LNCaP-MR49F, LNCaP) in 12-well plates and transfected in 
suspension with 12.5 or 6.25 nM miR LNA inhibitor using RNAiMAX (Life 
Technologies). Live and dead cells were quantified at indicated time points using Trypan 
blue. 
For cell viability assays, LNCaP-MR42D or LNCaP cells were seeded at 4103 cells/well 
in 96-well plates and transfected in suspension with 12.5 or 6.25nM miR LNA inhibitor 
using RNAiMAX (Life Technologies). Cell viability was assesses using the Cell Titer-
Glo Luminescent Cell Viability Assay (Promega) according to manufacturer’s 
recommendations. 
Neurite length measurement 
Length of neurite extensions were measured using the Simple Neurite Tracer plugin 70 
for Fiji/ImageJ . Neurite lengths were measured from ≥ 3 images per replicate. 
Representative images with overlaid traces were generated using the NeuronJ plugin71 
for Fiji/ImageJ  
Western blots 
Protein extraction from cells using RIPA buffer and western blotting was done as 
described in 69. Primary antibodies used in western blotting were FOXA1 (Abcam, 
Ab23738) and GAPDH (Millipore, MAB374). Immunoreactive bands were visualised 
using Clarity Western ECL Substrate (Bio-Rad). 
Organoid culture and transfections 
PDXs were established by the Melbourne Urology Research Alliance (MURAL) 
(Monash University Human Research Ethics Committee approval 12287). The 
established PDXs were grown as subcutaneous grafts in male NSG mice supplemented 
with testosterone implants according to animal ethics approval (17963), as previously 
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described17, 72. PDXs were routinely authenticated using short tandem repeat profiling 
(GenePrint 10, Promega) at the Australian Genome Research Facility. Tissue from PDXs 
201.1 dura (adenocarcinoma) and 201.2 lung (AR-null) was digested and grown as 
organoids in growth factor reduced, phenol red-free, ldEV-free Matrigel (Corning). 201.1 
organoids were cultured in advanced DMEM/F-12 media (Gibco) containing 0.1 mg/ml 
Primocin (Invivogen), 1x Glutamax (Gibco), 10 mM HEPES (Gibco), 1 nM DHT 
(Sigma), 1.25mM N-acetylcysteine (Sigma), 5nM NRG1 Heregulinβ-1  (Peprotech), 500 
nM A83-01 (Sigma), 10 mM nicotinamide (Sigma), 0.5 μM SB202190 (Sigma), 2% B27 
(Thermo), 20 ng/ml FGF10 (Peprotech), 5 ng/ml FGF7 (Peprotech), 10ng/ml 
Amphiregulin (Peprotech), 1 μM prostaglandin E2 (Tocris), 10% noggin conditioned 
media and 10% R-spondin conditioned media. 201.2 Lung organoids were cultured in 
PrENR -p38i -NAC media73. 10 μM Y-27632 dihydrochloride (Selleck Chemicals) was 
added to culture medium during organoid establishment and following passage. 
Phase contrast images of organoids were obtained with a Leica DM IL LED 
microscope with Leica DFC425 C digital camera. For immunohistochemistry, organoids 
were pelleted in agar, then formalin-fixed and paraffin embedded. Sections were stained 
using a Leica BOND-MAX-TM autostainer with BondTM epitope retrieval 1 or 2 and 
the Bond Refine Detection Kit (Leica). Primary antibodies are listed in Supplementary 
Table S1. 
Organoids were transfected with miR LNA inhibitors essentially as described 
previously 74. Briefly, organoid were collected and 50,000 cells were resuspended in 
450µl of organoid culture media and 50μl of transfection mix containing RNAiMAX with 
25, 100, and 250 nM miR-194 or NC LNA inhibitor. Cells were centrifuged in a pre-
warmed centrifuge at 32°C, 600g for 1h. After centrifuging, cells were incubated in a 
tissue culture incubator at 37°C for 2-4h and then collected in 1.5ml centrifuge tubes by 
centrifugation at 300 g for 5 min at room temperature. Cell pellets were resuspended in 
50 ul Matrigel and seeded out in 10 μl matrigel discs in 96-well plates. Plates were 
inverted and incubated at 37°C for 15 minutes to allow Matrigel to solidify, then overlaid 
with 100mL of organoid culture medium. Organoid forming efficiency was determined 
at 7 days post-transfection as described previously17. Organoid viability was assessed at 
7 days post-transfection using the CellTiter-Glo® Luminescent Cell Viability Assay kit 





Statistical analysis for grouped quantitative data were carried out using two-tailed 
unpaired t-test or ANOVA (GraphPad Prism 7). The relationships between activity scores 
were determined using Pearson’s correlation coefficient (Graphpad Prism 7). 
DATA AVAILIBILITY 
Ago-HITS-CLIP and RNA-seq data have been deposited with NCBI’s Gene Expression 
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Chapter 4: Mechanisms underlying miR-194 







MiRNAs, as post-transcriptional regulators of gene expression, are key players in 
numerous biological processes. MiRNA precursors are processed in the nucleus and 
cytoplasm into mature miRNA, which are then incorporated into an RNA-induced 
silencing complex (RISC) (Ha & Kim 2014; Kobayashi & Tomari 2016). Target 
recognition depends on base pairing between complementary sequences in mRNA 
transcripts and mature miRNA in the RISC (Ha & Kim 2014).  
Structurally, mature miRNA strands can be divided into 5 domains: 5′ anchor (nucleotide 
1), seed sequence (nucleotides 2–8), central region (nucleotides 9–12), 3′ supplementary 
region (nucleotides 13–16) and 3′ tail (nucleotides 17–22) (Figure 4.1A) (Wee et al. 
2012). Canonical target recognition occurs via base pairing between miRNA seed 
sequences and conserved complementary sequences in the target transcript, although 
interactions with seed distal regions (i.e. 3’region of miRNA) can also be important for 
miRNA mediated silencing (Bartel 2009; Moore et al. 2015). Seed matches on target 
transcripts can be separated into 4 main types based on the extent of complementarity to 
the miRNA seed: “6mer” sites have perfect complementarity with the miRNA seed, 
“7mer-m8” sites match with the seed and nucleotide 8 on the miRNA, “7mer-A1” sites 
have a perfect seed math and a supplementary A across from nucleotide 1 on the miRNA 
and “8mer” sites have a match with nucleotide 8 and A at position 1 in addition to a 
perfect seed match (Figure 4.1B) (Grimson et al. 2007). Additional seed types include 
“offset 6mer” which have a perfect match with nucleotides 3-8 on the miRNA and “6mer-
A1” sites matching nucleotides 1-6 on miRNA (Ellwanger et al. 2011; Friedman et al. 
2009). Efficiency of target downregulation is generally dependent on the seed match type, 
with 8mer>7mer-m8>7mer-A1>6mer>offset-6mer>6mer-A1 (Agarwal et al. 2018; 
Grimson et al. 2007).  
Non-canonical targeting by miRNA includes imperfect seed matches or weak pairing at 
the 5’end supplemented by strong pairing at the 3’end (Figure 4.1C), bulged sites 
involving the nucleotide opposite position 6 bulging out (Figure 4.1D) (Liu et al. 2011) 
and centered sites where there is complementarity between nucleotides in the centre of 




Figure 4.1: (A) miR-194 sequence depicting different regions. (B) Types of miR-194 canonical 
seed sequences. (C-E). Putative non-canonical target recognition by miR-194 (B-D).  
MiRNA:mRNA interactions are usually characterized as occurring at the 3’UTR of target 
transcripts and resulting in post-transcriptional repression, however miRNAs can bind to 
other regions of a transcript and induce post-transcriptional upregulation in some 
instances (Chi et al. 2009; Forman & Coller 2010; Vasudevan 2012). An abundance of 
miRNA binding sites have been found in coding sequences (CDS) but generally do not 
lead to downregulation of target mRNAs as effectively as 3’UTR sites. As another point 
of difference, CDS sites appear to always act by repressing translation rather than 
destabilizing mRNA (Hausser et al. 2013). 
Predicting functional miRNA binding sites is difficult. A key component of 
computational prediction tools is that they also incorporate the evolutionary conservation 
of predicted sites; sites that are conserved are more likely to be biologically relevant 
(Bartel 2009). Besides conservation, prediction algorithms also rely on stringent seed 
pairing rules, free energy analysis of hybridization between miRNA and its target, and 
site accessibility (Peterson et al. 2014). Despite these features, predictions algorithms are 
associated with several drawbacks including high rate of false positives and negatives, a 
tendency to focus only on 3’UTR sites and canonical sites, and a failure to account for 
tissue specificity of miRNA (M Witkos, Koscianska & J Krzyzosiak 2011; Ovando-
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Vázquez, Lepe-Soltero & Abreu-Goodger 2016). To overcome these limitations, 
crosslinking immunoprecipitation (CLIP)-based methods combined with bioinformatics 
analysis are being used to experimentally map functional miRNA binding sites. One such 
method, Ago-HITS-CLIP (high-throughput sequencing of RNAs isolated by crosslinking 
immunoprecipitation), uses UV-irradiation to covalently crosslink 
miRNA:mRNA:Argonaute complexes within cells. These complexes are purified using 
antibodies against the Argonaute protein and bound mRNA fragments are identified by 
sequencing. Ago-HITS-CLIP has high specificity and low false positive and false 
negative rates (Chi et al. 2009; Neame 2009).  
CLIP in combination with gene expression changes following miRNA perturbation has 
been used to elucidate targetomes and functionally characterize specific miRNA and their 
role in disease (Bracken et al. 2014; Loeb et al. 2012; Xu et al. 2010). Changes in gene 
expression caused by miRNA overexpression or knockdown are often assessed using 
RNA sequencing (RNA-seq). One drawback of using this method, however, is that 
miRNAs alter levels of target genes transcripts at the post-transcriptional level but 
standard RNA-seq outputs do not distinguish if expression changes occur at the 
transcriptional or post-transcriptional  level. Standard RNA-seq is therefore unable to 
distinguish between direct and indirect effects of miRNA on gene expression. Exon 
Intron Split Analysis (EISA), a powerful computational method that can use sequencing 
reads for RNA-seq to identify transcriptional or post-transcriptional expression changes, 
can be used to overcome this issue (Gaidatzis et al. 2015). Across experimental 
conditions,  EISA quantitates the difference between intronic reads (dIntron) which is a 
measure transcriptional changes or between exon and intron reads (dExon-dIntron) a 
measure of post-transcriptional regulation (Gaidatzis et al. 2015). EISA has been 
previously used to determine direct post-transcriptionally downregulated miRNA target 
genes (Gaidatzis et al. 2015; Pillman et al. 2019).    
In the previous Chapter, I described how we used Ago-HITS-CLIP and EISA to identify 
miR-194 target genes in prostate cancer (PCa). In this Chapter, I examine this data in 





Materials and methods 
 
Details of cell lines, transfections, qPCR, HITS-CLIP, RNA-seq and EISA are described 
in Chapter 3. 
Identification of miR-194 non-canonical binding in the 3’UTR 
Genomic sequences for peaks without miR-194 seed matches (“seedless peaks”) were 
obtained from peak coordinates using bedtools GetFastaBed in Galaxy 
(https://usegalaxy.org/). Genomic sequences were assessed for presence of enriched 
motifs using the SeqPos motif tool in Cistrome (http://cistrome.org/ap/). In a set of 
sequences, SeqPos finds motifs enriched near the centre of the regions i.e. motifs enriched 
near peak summits. The FIMO tool in Meme Suite (http://meme-suite.org) was used to 
scan for de-novo motif identified by SeqPos and specific motifs in seedless peaks.  
ECDF curves and Kolmogorov–Smirnov (KS) tests 
Cumulative distribution function graphs, to represent changes in expression of genes of 
interest, were plotted using the ecdf function in R. Statistical significance of differences 
in cumulative distribution function were  calculated using the Kolmogorov–Smirnov 
(KS) test.  KS tests were performed in R. 
3’complementary binding analysis for CDS sites 
RNAduplex was used to determine base pairing interaction between miR-194 and CDS 
peak regions. Only interactions with a binding energy D of <-15 and base pairing of 6 







Functional effects of miR-194 binding sites identified by Ago-HITS-CLIP 
To identify miR-194:target interactions in PCa, we performed Ago-HITS-CLIP analysis 
on 22RV1 cells transfected with a miR-194 mimic or a control mimic, as described in 
Chapter 3. Genomic annotation of the peaks revealed that the majority occurred in the 
coding regions (36%), followed by the 3’UTR (23.4%) and introns (22%). Other regions 
with miR-194 binding included promoters (5.5%), transcription termination sites (TTS) 
(5.4%), intergenic regions (5.2%), 5’UTRs (1.5%), non-coding RNAs (0.6%) and 
pseudogenes (0.1%).  Since binding in the 3’UTR, 5’UTR, CDS and introns has been 
associated with miRNA functional effects (Bartel 2009; Hausser et al. 2013; Meng et al. 
2013; Ørom, Nielsen & Lund 2008), we have focussed primarily on these regions in this 
study. 
To determine the effect of miR-194 binding on transcript levels, we have used RNA-seq 
to compare changes in gene expression between 22RV1 cells transfected with a miR-194 
mimic or a control mimic. RNA-seq data was further processed by EISA to obtain post-
transcriptional changes (dExon-dIntron) in gene expression. Post-transcriptional changes 
in gene expression (from EISA) were used for all analyses in this chapter.  
Changes in transcript levels for genes with Ago-HITS-CLIP peaks in different regions of 
the transcript were plotted as a cumulative distribution. As expected, we found that genes 
with Ago binding sites in the 3’UTR have a very strong bias towards downregulation (p< 
2.21016), whereas CDS (p= 2.581012) and 5’UTR (2.8211005) peaks are associated 
with modest changes in transcript downregulation (Figure 4.2B). Interestingly, changes 
in gene expression for intron peaks (p=0.03196) had a small bias towards upregulation 
(Figure 4.2B).  
A panel of sixteen genes, with Ago-HITS-CLIP peaks in the 3’UTR and showing post-
transcriptional downregulation with EISA, were validated by qPCR in the 22RV1 cell 
line. 14 out of the 16 genes tested were downregulated with 9 genes showing significant 




Figure 4.2: miR-194 binding sites are associated with reduced transcript levels. (A) 
Cumulative distribution of log2 fold change for genes with peaks in the 3’UTR, CDS, 
Introns and 5’UTR compared to background of all genes with no peaks. Numbers in 
parenthesis indicate p value compared to background. P values were determined by KS 
test.  (B) Validation of miR-194 target genes identified by HITS-CLIP and EISA in the 
22RV1 cell line. Cell lines were transiently transfected with a miR-194 mimic or negative 
control (NC) for 36h. p-values were determined by two tailed student’s t test. (*, p < 0.05; 





Association of seed match with repression in 3’UTR and CDS binding sites 
 
The efficacy of miRNA downregulation often correlates with the target transcript’s seed 
type, with longer seed matches resulting in stronger repression (Grimson et al. 2007). To 
evaluate the impact of seed match on miR-194 target gene repression, we identified all 
canonical 8mer, 7mer and 6mer seed matches in Ago-HITS-CLIP peaks. Of the canonical 
miR-194 seed matches (Figure 4.3A), 7mer-A1 sites were the most enriched in both the 
3’UTR and the CDS (Figure 4.3A) (Table 4.1). In the 3’UTR, 8mer, 7mer-m8 and 6mer 
sites were almost equally enriched whereas 6mer-A1 sites were less common. In the CDS, 
7mer-m8, 6mer and 6mer-A1 sites were more common compared to 8mer sites (Figure 
4.3A). The CDS also had five offset 6mer sites which were not seen in the 3’UTR.  MiR-
194 seed matches were rare in 5’UTR and intron peaks. In the 5’UTR, only 7 out of 120 
peaks had miR-194 seed matches whereas in the intron, 84 out of 1730 peaks had seed 
matches.  5’UTR and intron seed matches were mainly 8mer, 7mer-m8 and 7mer-A1 
(Figure 4.3A) (Table 4.1). 
To test how different seed types were associated with changes in target mRNA levels, we 
plotted post-transcriptional changes in gene expression as cumulative distribution 
fractions for transcripts containing single seed matches (Figure 4.3C,D). All miR-194 
seed types in the 3’UTR were significantly associated with downregulation of target 
transcripts compared to background (KS test, p<10-5). Similar to what has been reported 
for other miRNAs (Bracken et al. 2014; Grimson et al. 2007), targets with 8-mer 3’UTR 
sites were associated with significantly more robust target downregulation compared to 
targets with 7mer-A1 (p=0.0001536) and 6-mer (p=0.006177) sites; there appeared to be 
a trend towards stronger repression of 8-mer sites compared to 7mer-m8 and 6mer-a sites, 
but the differences between these groups were not significant. In summary, for miR-194 
sites in the 3’UTR, seed associated repression efficacy was 8mer>7mer-m8=6mer-
A1>6mer>7mer-A1.  
Repression of target genes with seed matches in the CDS occurred to a much smaller 
extent than 3’UTR sites, with only 8mer (p=0.03007), 7-mer-m8 (p=0.004165) and 7-
mer-A1 (1.6610^0-5) sites significantly repressing target genes over background (Figure 
4.3B).   Both CDS 6mer and 6mer-A1 sites repress expression to a lesser extent than other 
seed matches, and as a whole do not significantly reduce transcript levels.  
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Seed matches occurred infrequently in the 5’UTR and introns. Out of 1,107 genes with 
intronic peaks, only 71 had a canonical seed match in these regions. More than half of 
these genes were downregulated (Table 4.1) but strong downregulation was only 
observed for genes that also had a 3’UTR or CDS peak. Only 7 out of 95 genes were 
associated with a canonical seed match in the 5’UTR (Table 4.1). 
In summary, although miR-194 can binds to the 3’UTR, CDS, 5’UTR and introns, the 
strongest effects on transcript levels are observed for binding at 8mer sites in the 3’UTR 































































2 (1DN) - - - 91 (37DN, 
34UP) 
Table 4.1: Distribution of genes with canonical seed matches or no seeds in the 3’UTR, 
CDS, introns and 5’UTR regions of transcripts. Number in parenthesis indicates number 
of genes that are post-transcriptionally downregulated (DN) or upregulated (UP). 




Figure 4.3: 3’UTR seed matches are more functional than CDS seed matches. (A) 
Distribution of miR-194 canonical seed matches in 5’UTR, CDS, 3’UTR and intron 
peaks. (B) Cumulative distribution of log2 fold change for genes with canonical seed 
matches in the 3’UTR. Numbers in parenthesis indicate p value compared to background. 
P values were determined by KS test. (C) Cumulative distribution of log2 fold change for 
genes with canonical seed matches in the CDS. Numbers in parenthesis indicate p value 





Multiple miR-194 sites work cooperatively to repress target genes 
The presence of multiple seeds within a single transcript has previously been shown to 
increase the effective of miRNA repression (Fang & Rajewsky 2011; Grimson et al. 
2007). Previous reports have found that 8mer seed matches in combination with other 
seed matches are more effective at reducing target mRNA stability than combinations of 
other seed types (Grimson et al. 2007). In addition, seed matches in the CDS have been 
shown to act additively with 3’UTR sites (Fang & Rajewsky 2011).  
We determined the number of canonical seeds in all miR-194 targets and found that the 
majority of target transcripts harbour single seeds in the 3’UTR or the CDS (Figure 4.4A), 
with only 16% and 12% of target transcripts having multiple seed sites in the 3’UTR and 
CDS, respectively. The presence of seeds in both the 3’UTR and CDS of a single 
transcript is much more uncommon (~2.5% of targets). In the 3’UTR, 7mer-A1 and 6mer 
seed matches are more likely to be present in combination with other seeds (Figure 4.4B). 
In the CDS, 7mer-a1 and 6mer sites are most likely to occur in combination with other 
sites (Figure 4.4C).  
To test if multiple miR-194 seed matches can act cooperatively to repress targets, we 
assessed changes in expression of genes containing 2 or more seed sequences vs genes 
with single sites (Figure 4.4D). 8mers in combination with 7mers or 6mers were not in 
general associated with stronger mRNA dysregulation than 8mers alone (p=0.4428) 
(Figure 4.4D), but it must be noted that there is only a few transcripts in this group (n=20). 
Combinations of 7 or 6-mer sites, however, were significantly more effective than single 
7-mer or 6-mer sites alone (p=0.008857). Multiple sites in the CDS moderately increased 
target repression compared to single CDS sites (p=0.005813) (Figure 4.4E). However, 
combination of a 3’UTR site and a CDS site do not significantly downregulate expression 








Figure 4.4: miR-194 binding sites work cooperatively to reduce target mRNA 
stability. (A) Distribution of transcripts with 1 or more miR-194 seeds in the 3’UTR and 
CDS. (B) Occurrence of different seed matches per transcript in the 3’UTR. (C) 
Occurrence of different seed matches per transcript in the CDS. (D) Cumulative 
distribution of log2 fold change for genes for genes with single or multiple seed matches 
in the 3’UTR of the same transcript. (E) Cumulative distribution of log2 fold change for 
genes for genes with single or multiple seed matches in the CDS. (F) Cumulative 
distribution of log2 fold change for genes for genes with a single 3’UTR seed match or 





MiR-194 is associated with non-canonical binding in the 3’UTR and CDS 
MiRNA CLIP experiments have helped identify a range of non-canonical miRNA: target 
interactions that do not rely on perfect seed matches but are associated with nucleation 
bulges, mismatches, wobbles, centred pairing and/ or complementarity with the 3’ and 5’ 
ends of miRNA. Non-canonical interactions are widespread and may occur for up to 60% 
of miRNA: target interactions in the 3’UTR (Helwak et al. 2013; Moore et al. 2015).  
Approximately 70% (1,314 peaks) of 3’UTR Ago-HITS-CLIP peaks did not have a 
canonical seed match for miR-194 (Figure 4.5A). To determine whether miR-194 was 
associated with non-canonical binding in these sites, we used the SeqPos tool on Cistrome 
(Liu et al. 2011) to search for enriched sequences. SeqPos identified 2 motifs (p-value > 
0.001), with the most significant motif (-log10 pvalue=102) resembling a miR-194 7mer-
m8 seed sequence with mismatches at nucleotide positions position 8 and 4 (Figure 4.5B). 
The other enriched motif (-log10 pvalue=74.929) (Figure 4.5C) did not correspond to any 
part of the miR-194 sequence. We next used the FIMO tool (Find Individual Motif 
Occurrences) on MEME suite (Bailey et al. 2009) to scan all 1314 “seedless” peaks for 
presence of the “mismatched” miR-194 motif, with a p-value filter of 0.001 for output, 
shown in Figure 4.5B, and found 199 occurrences. To assess effects of the mismatched 
motif on gene regulation, we evaluated expression of targets with one or more 
mismatched sites in the 3’UTR but no canonical 3’UTR seed sequence against 
background. Our results indicate that sites with a mismatched miR-194 seed sites are 
indeed functional based on reduced transcript levels (p=6.48210-5) (Figure 4.5D). The 
other identified motif (Figure 4.5C) was not associated with decreased transcript levels. 
In addition to mismatches, we used FIMO to scan for complementarity to the central 
region (centred sites) of the miRNA, nucleation bulges, and other possible mismatches 
to the miR-194 seed sequence that might occur at low frequency (Figure 4.5E). No 
evidence for centred pairing was found in any of the seedless peaks, suggesting that miR-
194 does not function through this mode of non-canonical binding. A perfect nucleation 
bulge was found in only 6 seedless peaks, indicating this is not a major mode of miR-194 
action. We also found evidence for multiple seed mismatch sequences at low frequency 
within seedless peaks. 
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A recent study has identified a novel miRNA recognition element in the CDS of target 
genes that is dependent on extensive binding to the 3’ end of the miRNA rather than the 
seed sequence and only functions in the context of the CDS (Zhang et al. 2018). This 
mode of miRNA regulation does not result in transcriptional repression but inhibits 
translation (Zhang et al. 2018). We found 106 sites that meet the criteria for this type of 
miRNA: target interaction in our HITS-CLIP dataset. An example of this type of 
interaction between miR-194 and the CDS of the LAPTM4A transcript is depicted in 
Figure 4.5F. Figure 4.5G depicts Ago-HITS-CLIP peaks in the non-canonical binding 
site in the LAPTM4A CDS. These transcripts showed a trend towards downregulation at 
the transcript level (p=0.07) compared to background (Figure 4.5H). The functional 
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Figure 4.5: miR-194 is associated with non-canonical binding to target genes. (A) 
Distribution of peaks with and without miR-194 seed motifs in the 3’UTR. (B) Motif 
found enriched in seedless peaks using the SeqPos tool represents a mismatched miR-
194 seed match sequence. (C) Motif found enriched in seedless peaks using the SeqPos 
tool that does not match any region of miR-194. (D) Cumulative distribution of log2 fold 
change for genes with a mismatched miR-194 seed match in the 3’UTR.Numbers in 
parenthesis indicate p value versus background. (E) Examples of other non-canonical 
miR-194 seed mismatches found in 3’UTR peaks. ‘N’ represents mismatched nucleotide. 
Numbers in parentheses represent number of peaks with corresponding mismatched site. 
(F) Example of non-canonical binding with extensive complementarity to the miRNA 3’ 
region for a site in the LAPTM4A CDS. Red strand represents miR-194, green strand 
represents mRNA. (G) Example of a CDS region with non-canonical 3’ binding. Genome 
tracks depict the average read density of all replicates for each treatment condition (i.e. 
cells transfected with miR-194 (red) or a negative control (NC) (black)).(H) Cumulative 
distribution of log2 fold change for genes with a non-canonical CDS seed match in the 







CLIP-based high-throughput studies combined with transcriptomic datasets are 
increasingly being used for high confidence detection of miRNA: target interactions 
(Hoefert et al. 2018; Loeb et al. 2012; Luna et al. 2017). This approach is advantageous 
over computational prediction tools, which are often limited to sites in the 3’UTR, cannot 
predict non-canonical interactions and do not take tissue specific miRNA interactions 
into account. In the present study, we have used an integrated approach combining Ago-
HITS-CLIP and transcriptomics to identify hundreds of functional binding sites for miR-
194 in PCa. We further refined our transcriptomic data using EISA, which allowed us to 
match miR-194 bound sites specifically with genes that were post-transcriptionally 
regulated. This strategy allowed us to ignore genes that were likely to be indirectly altered 
in response to miR-194 (i.e. downstream of direct targets). Notably, ours is one of only 
two studies (Pillman et al. 2019) that has used EISA to specifically identify direct miRNA 
targets.   
Consistent with other CLIP studies (Chi et al. 2009; Moore et al. 2015), we have found 
that miR-194 binds predominantly in the 3’UTR and CDS. MiR-194 target genes with 
3’UTR peaks were significantly more down-regulated at the mRNA level than targets 
with CDS sites. Strong 3’UTR-associated repressive effects on mRNA suggest that 
miRNA binding at this location is highly biologically relevant. The weaker repressive 
effects observed for genes with CDS binding sites are possibly due to CDS effects being 
mediated primarily at the translational rather than transcriptional level (Hausser et al. 
2013). We cannot assess translational effects as we have not evaluated the effect of miR-
194 on the proteome of PCa cells. Such an experiment would be extremely useful to more 
precisely dissect the mechanism by which miR-194 regulates its target genes.  
Besides CDS and 3’UTR binding, our study also identified extensive binding of miR-194 
to introns. Interestingly, genes associated with introns peaks show a small bias towards 
upregulation (Figure 4.2A). One reason for this could be that transcripts indirectly 
upregulated by miR-194 have been misannotated as intronic sequences. Alternately, miR-
194 could be downregulating a splicing factor responsible for intron retention, a process 
where specific introns are not spliced out of mRNA transcripts. Retained introns are often 
found in 3’UTRs and harbour numerous miRNA binding sites (Bicknell et al. 2012; 
Schmitz et al. 2017; Tan et al. 2007). Downregulation of a splicing factor that regulates 
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this process might result in introns not being retained in transcripts, resulting in loss of 
functional miRNA binding sites and consequently gene upregulation.  
Our study indicated that miR-194 does not follow the general hierarchy for seed 
repression but instead has a seed repression efficacy of 8mer>7mer-m8=6mer-
A1>6mer>7mer-A1. Such differences have been attributed to sequence of the miRNA 
which affects relative affinity with targets and thus affects efficacy of gene repression 
(McGeary et al. 2018).  
Our results indicate that multiple seed matches on a transcript are more potent than single 
seed matches. The occurrence of multiple seed match sites in single transcripts has been 
proposed to enhance miRNA-based repression, for at least 2 reasons: i) by increasing the 
probability of having at least one site bound at any one time, and ii) by one bound site 
promoting binding at the secondary site (Grimson et al. 2007). Interestingly, our data with 
miR-194 indicates that 7mer-A1 and 6mer sites, which are less efficient at gene 
repression than 8mer or 7mer-m8 sites, are more likely to occur in combination with 
another seed match on the same transcript within 3’UTRs and CDSs. When co-occurring 
in 3’UTRs, these combinations are nearly as effective at decreasing transcript levels as 
single 8mer sites.  
Canonical miR-194 seed sequences were only detected in ~30% of 3’UTR peaks, 
indicating that a significant fraction of interaction occur via non-canonical sites. Non-
canonical binding is widespread among miRNA and is made up of a variety of interaction 
types (Bartel 2009). While miR-194 is not associated with centered sites and very few 
nucleation bulge sites, mismatched sites appear to be a major form of miR-194 non-
canonical interaction. Besides their role in repressing gene expression, non-canonical 
sites have been suggested to act as evolutionary midpoints that will eventually form 
canonical sites (Loeb et al. 2012). 
In addition to a mismatch motif, our search in seedless peaks detected a motif (Figure 
4.5C) that does not have complementarity to the miR-194 sequence. Two previous studies 
have found non-functional sequences that bind to miRNA with high affinity but without 
significant complementarity (Leung et al. 2011; McGeary et al. 2018). The motif we 
identified did not reduce transcript levels and likely falls into this category. 
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Non-canonical miRNA binding has been primarily studied in the context of 3’UTR peaks 
(Loeb et al. 2012; Seok et al. 2016). Recently, however, a novel non-canonical miRNA 
recognition element (MRE) was reported for miR-20a binding in the CDS of its target 
genes (Zhang et al. 2018). This miRNA:target interaction relies on extensive binding at 
the 3’end of the miRNA, minimal pairing at the 5’seed region and results in translational 
repression with no effect on transcript levels (Zhang et al. 2018). We have found evidence 
for a similar MRE interaction in miR-194 “seedless” CDS peaks, which were associated 
with a trend towards decreased mRNA stability at the transcript level, but may be 
associated with stronger repression at the protein level and it remain to be experimentally 
validated.  
In summary, this work provides mechanistic insights into miR-194 and its interactions 
with target genes in the context of PCa. In particular, we demonstrate that effectiveness 
of different seed matches, co-operative repression by binding to multiple sites and show 
that miR-194 is associated with functional non-canonical binding. These findings raise 
the possibility of expanding the miR-194 targetome beyond canonical 3’UTR targets by 
further evaluating non-canonical and CDS binding sites. In addition to the miR-194 
specific findings, this study provides broader insights into how miRNA exert their 
actions, reinforcing earlier findings and providing further evidence for the utility of non-






























Breast cancer (BCa) is the most common cause of cancer in women and a leading cause 
of cancer mortality worldwide (Bray et al. 2018). Despite arising in different organs, BCa 
and prostate cancer (PCa) share many biological similarities. Like PCa, BCa is a hormone 
dependant malignancy that is driven by a steroid hormone receptor, the estrogen receptor 
(ER). AR and ER belong to the nuclear hormone receptor superfamily, have similar 
mechanisms of action and can be regulated by the same factors (Risbridger et al. 2010). 
These factors include SRC3, UBE3A (Risbridger et al. 2010) and FOXA1 (Bernardo et 
al. 2010; Jin et al. 2014). Therapies directed against hormone receptor signalling are the 
mainstays treatments for both cancers and mutations of AR/ER are major therapy 
resistance mechanisms (Coutinho et al. 2016; Jeselsohn et al. 2015).  
Based on gene expression profiling, BCa can be subdivided into several molecular 
subtypes. These subtypes largely cluster into the ER-positive and -negative groups (Perou 
et al. 2000). ER positive subtypes, which make up ~70% of all BCa cases, are termed 
luminal as they have expression signatures consistent with secretory epithelial cells that 
line the lumen of breast ducts (i.e. mammary luminal epithelial cells) (Perou et al. 2000). 
The luminal subtypes, called Luminal A and Luminal B, differ mainly in expression of 
the progesterone receptor (PR) and the oncogenic human epidermal growth factor 2 
(HER2) with Luminal B expressing lower levels of PR and higher levels of HER2 (Perou 
et al. 2000). The ER negative subgroups, which include HER2-enriched, basal-like, and 
normal breast-like, are more aggressive than the luminal subgroups (Perou et al. 2000). 
Breast cancers can be subtyped into the groups described above using  the PAM50 gene 
expression signature. The PAM50 signature was recently applied to cohorts of prostate 
tumours (Zhao et al. 2017). Based on PAM50 gene expression, PCa samples could be 
stratified into groups with expression profiles concordant with BCa (Zhao et al. 2017). 
Additionally, while luminal BCa is characterized by ER expression, luminal PCa 
demonstrated increased AR expression and signalling (Zhao et al. 2017). 
Although similarities between PCa and BCa are largely related to hormone receptor 
signalling, both cancers also share genetic features such as mutations in the BRCA1 and 
BRCA2 genes which predispose to breast cancer and are also linked to increased risk of 





5.2 Rationale for assessing the role of miR-194 in BCa 
 
The preceding sections of this thesis have focussed on the role and mechanisms of action 
of miR-194 in PCa. In those chapters, I identified a targetome for miR-194, discovered 
that miR-194 targets FOXA1 to promotes progression to an aggressive subtype of PCa 
and defined PCa specific miR-194:target gene interactions. Given the underlying 
biological parallels between BCa and PCa, including similar roles for FOXA1 in these 
malignancies, I hypothesized that miR-194 may be an oncomiR in BCa akin to its role in 
PCa. Supporting an oncogenic role for miR-194, high levels of miR-194 in serum and 
tissue are proposed to predict recurrence in BCa (Hironaka-Mitsuhashi et al. 2017; Huo 
et al. 2016). In this chapter, I aimed to determine if miR-194 played an oncogenic 




Materials and methods 
 
Analysis of miR-194 expression in clinical datasets 
miR-194 expression was analysed in The Cancer Genome Atlas (TCGA) cohort, 
GSE40525 and GSE22216. TCGA data was obtained from the TCGA data portal 
(https://gdac.broadinstitute.org/). GSE40525 and GSE22216 were retrieved from NCBI 
GEO (https://www.ncbi.nlm.nih.gov/geo/). The TCGA dataset consists of 995 primary 
breast cancer and 102 normal samples. 73% of tumours in the TCGA dataset were ER 
positive. The GSE40525 consists of 56 primary breast tumours with matched peritumour 
tissue, with 77% of the tumours showing ER expression. GSE22216 consists of 210 early 
primary breast cancers with 63% ER positivity. Recurrence free survival was assessed at 
10 years.  
Cell lines and transfections 
MCF7 and ZR-75-1 cell lines were purchased from ATCC. MCF7 cells were maintained 
in DMEM-High Glucose supplemented with 10% FBS. ZR-75-1 cells were maintained 
in RPMI supplemented with 10% FBS. Cell lines were subjected to regular mycoplasma 
testing. All cell lines were regularly checked for identity using STR testing by CellBank 
Australia.  
Detailed methods for transfection are provided in Chapter 2.  
Cell viability assay 
For cell viability assays, cells were seeded at 2×105 (MCF7) or 1.5×105 (ZR-75-1) 
cells/well in 6-well plates and transfected in suspension with 20nM miR-194 mimic using 
RNAiMax reagent. Live and dead cells were subsequently quantified at days 2, 4 and 6 
using Trypan blue and manual cell counting 
Detailed methods for cell viability assay are provided in Chapter 2. 
Inverse Invasion assay 






Total RNA was extracted from cells using TRIzol and qPCRs were done as described as 
in Chapter 2. Primer sequences are listed in Chapter 2.  
Western blot 
Protein extraction and western blotting was done as described in Chapter 2. Antibodies 
used in this study were FOXA1 (Abcam, Ab23738; 1:500), ER (Novocastra, NCL-ER-























miR-194 is upregulated in BCa and is a predictor of metastasis free survival 
To determine whether miR-194 is associated with BCa subtypes and clinic-pathological 
parameters, we assessed its expression in clinical cohorts with associated miRNA 
expression data. To determine the expression of miR-194 in breast tumours relative to 
non-tumour tissue, we made use of two clinical datasets: the GSE40525 cohort consisting 
of 56 matched tumour and peritumoural tissues; and the TCGA cohort, with 995 tumour 
samples and 102 normal breast tissue samples. We found that miR-194 is highly 
expressed in tumour tissue compared to normal /peritumoural tissues (Figure 5.1A, B).  
We next determined if miR-194 is associated with specific breast cancer subtypes in the 
TCGA cohort. We found that miR-194 expression is significantly higher in HER2-
enriched tumours compared to the basal and Luminal A subtypes (Figure 5.1C). Among 
luminal sub-groups, expression was higher in Luminal B tumours (Figure 5.1C).  
In PCa, we have found that increased miR-194 expression is associated with increasing 
tumour grade and poor metastasis-free survival (Das et al. 2017). To determine if such 
an association existed in BCa, we assessed miR-194 in GSE22216 (Buffa et al. 2011), a 
clinical cohort of 210 primary breast tumours that has associated grade and metastasis 
free survival information over a ten year follow-up period. In this cohort, miR-194 was 
lower in Grade 3 tumours compared to Grade 1 and 2 tumours (Figure 5.1D). 
Furthermore, high expression of miR-194 was associated with longer time to distant 
metastasis compared to patients with low expression of miR-194 (Figure 5.1E). 
Collectively, these data suggest that elevated expression of miR-194 may be associated 






Figure 5.1: miR-194 is upregulated in BCa and is a predictor of metastasis. (A) miR-
194 expression analysis in the GSE40525 dataset (Biagioni et al. 2012) containing 
matched patient peri-tumour and tumour samples. Middle dashed line represents median. 
Dotted lines above and below represent upper and lower quartiles. p-values were 
determined by two tailed student’s t test (****, p<0.00001). (B) miR-194 expression 
analysis between matched and unmatched normal and tumour samples in the TCGA 
dataset. Middle dashed line represents median. Dotted lines above and below represent 
upper and lower quartiles. p-values were determined by two tailed student’s t test (****, 
p<0.00001). (C) Differential expression of miR-194 occurs between the PAM50 breast 
cancer subtypes. Middle dashed line represents median. Dotted lines above and below 
represent upper and lower quartiles. p-values were determined by ANOVA (*, p < 0.05; 
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**, p < 0.01; ****, p<0.00001). (D) miR-194 expression in patients from the GSE22216 
dataset (Buffa et al. 2011) grouped according to tumour grade. Middle dashed line 
represents median. Dotted lines above and below represent upper and lower quartiles. p-
values were determined by ANOVA (*, p < 0.05). (E) Correlation between miR-194 
expression and metastasis free survival in patients with breast cancer from the GSE22216 







MiR-194 inhibits proliferation and invasion of ER-positive BCa cell lines 
To explore the functional effects of miR-194 in BCa, we assessed cell proliferation and 
invasion following transient transfection of a miR-194 mimic into the MCF7 and ZR-75-
1 cell lines. MCF7 and ZR-75-1 are models of Luminal A breast cancer expressing ER, 
PR and HER2. Luminal A models of breast cancer were chosen because (i) ER is the 
main driver of approximately 70% of breast cancers; (ii) Luminal breast cancers have a 
gene expression profile similar to AR-expressing prostate cancers (Zhao et al. 2017); and 
(iii) miR-194 has the lowest expression in this subtype. 
In both cell lines, the miR-194 mimic significantly inhibited proliferation, as measured 
by a trypan blue cell viability assay (Figure 5.2A, B). We next determined whether miR-
194 influenced invasion, a key measure of the metastatic capacity of cancer cells. The 
ability to invade is also a proxy measure of plasticity in cells since this requires cells to 
activate plasticity-related pathways such as epithelial mesenchymal transition (EMT). In 
the MCF7 cell line, transient expression of the mimic significantly inhibited invasion 
through Matrigel compared to a negative control (Figure 5.2C); there was a trend towards 
this phenotype in the ZR-75-1 cell line, but it was not significant (Figure 5.2D). 
Additionally, MCF7 cells did not undergo any morphological changes characteristic of 
acquisition of a plastic phenotype (Figure 5.2E). These results indicate that miR-194 
inhibits tumourigenic potential (growth, invasion) in BCa.  
MiR-194 targets FOXA1 in BCa 
We assessed expression of FOXA1 in our BCa cell line models in response to miR-194 
mimic transfection. Although we did not see a significant reduction of FOXA1 mRNA 
(Figure 5.3A), FOXA1 protein (Figure 5.3B) levels were reduced by miR-194 
overexpression in both cell lines. Since miRNAs can act by translational inhibition rather 
than transcript degradation (Hausser et al. 2013), these results support the concept that 
FOXA1 is a target of miR-194 in the context of the ER-positive subtype of breast cancer. 
Supporting this idea, transfection of a miR-194 locked nucleic acid (LNA) inhibitor 








Figure 5.2: The effect of miR-194 on proliferation and invasion of ER positive BCa 
cells. (A,B) Ectopic expression of a miR-194 mimic inhibits proliferation of MCF7 and 
ZR-75-1 cell lines compared to a negative control (NC). Error bars represent SEM. p-
values were determined by two tailed student’s t test ( **, p < 0.01;***, p<0.001; ****, 
p<0.00001). (C, D) Ectopic expression of a miR-194 mimic inhibits invasion of MCF7 
but not ZR-75-1 cells. Error bars represent SEM. p-values were determined by two tailed 
student’s t test ( **, p < 0.01). (E) MCF7 cells transfected with a miR-194 mimic or 




              
Figure 5.3: miR-194 targets FOXA1 in BCa. (A) FOXA1 mRNA levels following 
transient transfection of a miR-194 mimic or negative control (NC) into the MCF7 and 
ZR-75-1 BCa cell lines. Error bars represent SEM. (B) FOXA1 protein levels following 
transient transfection of a miR-194 mimic or negative control (NC) into the MCF7 and 
ZR-75-1 BCa cell lines. Normalized FOXA1 protein levels are shown below the lanes. 
(C) FOXA1 protein levels following transient transfection of a miR-194 locked nucleic 
acid (LNA) inhibitor (194i) or negative control inhibitor (NCi) into the MCF7 cell line. 
Normalized FOXA1 protein levels are shown below the lanes.  
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ER expression is downregulated by miR-194 
FOXA1 is an upstream regulator of ESR1 gene expression, binding to a regulatory 
element within the ESR1 promoter to promote expression of this gene (Bernardo et al. 
2010). Since overexpression of miR-194 reduced FOXA1 expression in our cancer cell 
line models (Figure 5.3C), we speculated that this would result in consequent reduction 
in ER expression. Indeed, overexpression of miR-194 significantly reduced expression 
of ER at both the protein and RNA level (Figure 5.4 A, B). ESR1 is not predicted to have 
a binding site for miR-194 in its 3’UTR, thus the downregulation we have observed is 






      
     
 
Figure 5.4: miR-194 downregulates expression of the estrogen receptor. (A) ESR1 
mRNA levels after transient transfection of a miR-194 mimic or negative control (NC) 
into two ER-positive BCa cell lines. Error bars represent SEM. p-values were determined 
by two tailed student’s t test (*, p < 0.05). (B) ER protein levels after transient transfection 











MiR-194 has context-dependent roles in different cancer types, and can act as an 
oncomiR or a tumour suppressor (Das et al. 2017; Wang, Shen, et al. 2015).  In PCa, 
miR-194 has been shown to have an metastasis-promoting role (Das et al. 2017). In this 
study, we aimed to determine if miR-194’s role in BCa mirrors its role in PCa. 
Similar to PCa, we have found that in clinical cohorts miR-194 expression is elevated 
compared to normal tissue. Unlike PCa, however, we show that miR-194 expression is 
reduced in higher grade tumours, and higher expression is associated with better 
outcomes. This suggests that while high levels of miR-194 is linked to the initial states 
of carcinogenesis it may repress disease progression in later stages. Such a phenomenon 
is not without precedent: for example, miR-221/-222 is reported to have oncogenic or 
tumour suppressive roles in different phases of prostate cancer (Gui et al. 2017). 
Supporting a tumour suppressive function of miR-194, we found that ectopic expression 
of miR-194 decreased growth and invasion in BCa cell line models. Altogether, these 
results suggest that miR-194 has dichotomous roles in PCa and BCa, acting as an 
oncomiR in the former and a tumour suppressor in the latter. 
In this study we have specifically assessed expression of FOXA1 as a miR-194 target in 
BCa. FOXA1 is a miR-194 target in PCa (Chapter 3) and is important for steroid receptor 
transcriptional function, acting as a pioneer factor for both AR and ER (Bernardo et al. 
2010; Clarke & Graham 2012; Sahu et al. 2013). Additionally, FOXA1 directly 
upregulates expression of ER in breast cancer (Bernardo et al. 2010). Since our study 
indicated that FOXA1 is a target of miR-194 in ER-positive BCa cell lines, we speculated 
it may have an effect on ER expression. Our study provides evidence for miR-194 
downregulating ER at the protein and RNA level. Since ESR1 is not predicted to have a 
binding site for miR-194 in its 3’UTR, downregulation is likely to be an indirect effect 
via FOXA1. ER is a key driver of luminal BCa, promoting proliferation, invasion and 
migration of cells (Fuqua 2001; Pike et al. 1993; Sanchez et al. 2010). The 
downregulation of ER by miR-194 therefore likely explains the effects we observe on 
growth and invasion as well as the positive outcomes for tumours expressing high levels 
of miR-194.  
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One of the major findings of our study in PCa was the role of miR-194 in mediating 
plasticity via EMT and promoting neuroendocrine transdifferentiation. While I did not 
address this in detail in relation to BCa in the current study, the invasion data as well as 
the inability of miR-194 to induce morphological changes in BCa cells suggests that this 
miRNA does not promote plasticity in ER-positive breast cancer cells.  
The obvious explanation for the differences in the action of miR-194 in PCa versus BCa 
are that it targets different genes in these 2 distinct cancer types. However, in the absence 
of transcriptomic data in response to miR-194 delivery to BCa cells,  we are unable to 
assess the extent to which our miR-194 PCa targetome (defined in Chapter 3) compares 
with its targetome in BCa. Determining the miR-194 targetome in BCa and its 
contribution to the divergent effects on this cancer type compared to PCa is an obvious 
avenue for future investigation.  
While my work indicates that miR-194 is tumour suppressive, earlier studies found it to 
have an oncogenic role in  BCa. For instance, elevated expression of miR-194 in tissue 
and serum from breast cancer patients has previously been associated with recurrence 
post-curative surgery (Hironaka-Mitsuhashi et al. 2017; Huo et al. 2016). This 
inconsistency may be explained by differences between the these cohorts and the Buffa 
et al cohort (Buffa et al. 2011) which was used in our study. Given our finding that miR-
194 expression varied significantly in different PAM50 subtypes, outcomes may be 
affected depending on the fraction of each subtype in the study cohorts assessed to date. 
The cohorts also differed in treatment administered to patients and median age, which 
may account for variable results across studies. MiRNA expression was recently shown 
to differ between patients with different ages of onset (Tsai et al. 2018). Since the 
Hironaka-Mitsuhasi cohort had patients under 35 years of age whereas the other cohorts 
had median ages between 45 and 50, this might be a factor in the differences in results.  
In summary, we show that miR-194 has dichotomous effects in breast and prostate 
cancers in terms of growth, invasion and prognosis. Tumour suppressive effects of miR-











6.1 General discussion of thesis findings 
 
MicroRNAs are negative regulators of gene expression that play critical roles in cancer 
initiation and progression. This thesis focussed on the role of miR-194 in prostate cancer 
(PCa). My interest in this topic stemmed from earlier work from my host laboratory 
demonstrating that miR-194 is a circulating marker prognostic of PCa prognosis (Selth 
et al. 2013). We subsequently showed that miR-194 promotes metastasis and epithelial 
mesenchymal transition (EMT) in PCa, at least in part by targeting the anti-metastatic 
SOCS2 gene (Das et al. 2017). In this study, we aimed to understand the molecular 
mechanisms responsible for miR-194’s oncogenic activity in PCa. Given that both breast 
cancer (BCa) and PCa are hormone dependant malignancies that share certain features, I 
have also assessed the role of miR-194 in BCa.  
MiR-194 is a driver of lineage plasticity 
Identification of miRNA targets relies primarily on computational prediction, assessment 
of gene expression changes following ectopic miRNA expression, crosslinking 
immunoprecipitation (CLIP) based methods and pull-down of labelled miRNA (Li & 
Zhang 2019). CLIP-based methods are preferred over computational prediction as they 
experimentally determine direct endogenous miRNA targets on a genome-wide scale. 
CLIP, especially in combination with gene expression analysis following miRNA 
perturbation, is a powerful tool for defining miRNA: target networks. 
In the first part of this thesis (Chapter 3), using an integrated approach that includes high-
throughput sequencing of RNA isolated by crosslinking immunoprecipitation (HITS-
CLIP), RNA sequencing and bioinformatics, I identified 163 targets of miR-194. This 
was a ground-breaking study since, at the time of commencement of my project, no 
complete miRNA targetomes in PCa had been identified. Since that time the only other 
miRNAs whose targetomes have been identified in PCa are miR-1271-5p and miR-26a-
5p (Kalofonou et al. 2019; Rizzo et al. 2017). Using the miR-194 targetome, I established 
that miR-194 activity was inversely related to AR activity. Consequently, using 
expression data from clinical cohorts and experiments in cell lines and PDX models, I 
have established that miR-194 promotes progression to a highly aggressive, metastatic, 
“AR-indifferent” neuroendocrine subtype of prostate cancer (NEPC).  
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NEPC is proposed to arise from prostate adenocarcinomas as an adaptive response to AR 
directed therapy via lineage plasticity (Akamatsu et al. 2018; Davies, Beltran & Zoubeidi 
2018). Lineage or cellular plasticity, a process by which differentiated cells can change 
their identity to a new phenotype, is essential for cancer progression and therapy 
resistance (Yuan, Norgard & Stanger 2019). The induction of plasticity on treatment with 
ADT is attributed in part to the upregulation of several AR repressed genes. Genes such 
as PEG10, SOX2, BRN2 and lncRNA-p21 are all repressed by direct AR binding to 
promoter or enhancer regions of these genes (Akamatsu et al. 2015; Bishop et al. 2017; 
Luo et al. 2019; Mu et al. 2017). By contrast, the MIR194 genes do not appear to have 
AR binding sites in their regulatory regions, and miR-194 is only downregulated at 48 
hours of androgen stimulation – therefore, we believe that it is not a direct target of AR. 
We have previously shown that GATA2 is a direct upstream regulator of miR-194 
expression (Das et al. 2017). Since GATA2 is also repressed by AR (He et al. 2014), it 
might serve as a link between AR signalling and miR-194, with AR-directed therapies 
upregulating the expression of GATA2 and consequently miR-194 (Figure 6.1). 
Although the exact mechanisms underlying ADT-induced lineage plasticity remain 
unknown, the process of EMT is thought to transition cells into a metastable stem cell-
like state that can then dedifferentiate into an AR indifferent state (Davies, Beltran & 
Zoubeidi 2018; Dicken, Hensley & Kyprianou 2019). Supporting a link between EMT 
and NEPC, EMT regulators have been found to be associated with NEPC. For instance, 
overexpressing the EMT transcription factor (EMT-TF) SNAIL in LNCaP cells induces 
neurite-like morphology and an increase in expression of neuroendocrine markers 
(McKeithen et al. 2010). Additionally, SNAIL and ZEB1, another EMT-TF, are 
upregulated during transition of a PDX model from adenocarcinoma to NEPC (Akamatsu 
et al. 2015). EMT is characterized by downregulated expression of epithelial markers and 
upregulated mesenchymal markers, reduced adhesion between cells and a more migratory 
phenotype (Pearson 2019). Our previous work has indicated that miR-194 promotes EMT 
by reducing expression of the epithelial markers CDH1 and ZO-1, and upregulating the 
mesenchymal marker CDH2 (Das et al. 2017). In addition, miR-194 promotes 
cytoskeletal rearrangements and increased migratory and invasive capacity, consistent 
with induction of EMT (Das et al. 2017). The STAT3 signalling pathway, which has been 
shown to promote the acquisition of stem cell features (Schroeder et al. 2014), is also 
activated by miR-194 (Das et al. 2017). My work implicating miR-194 in NEPC (Chapter 
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3), along with our earlier findings that link miR-194 to EMT and stem cell related 
pathways (Das et al. 2017), support the concept of miR-194 being a key hub regulating 
lineage plasticity.  
Mechanistically, my data suggests that  miR-194’s role as a plasticity regulator is in part 
via miR-194 mediated downregulation of FOXA1 (Figure 6.1), a transcription factor that 
is important for maintaining a cellular differentiated state (Kaestner 2010). FOXA1 is an 
inhibitor of EMT in PCa cells, acting by supressing the EMT-TF Slug (Jin et al. 2013). 
FOXA1 also inhibits transition to NEPC by suppressing IL8-MEK/ERK signalling (Kim 
et al. 2017), a pathway that I have found is upregulated on ectopic expression of miR-
194 in cell lines. Highlighting the importance of FOXA1 in NEPC, the R219 point 
mutation that leads to impaired FOXA1 activity is present in nearly 75% of NEPC 
tumours (Adams et al. 2019).  
While I propose that FOXA1 is an important target by which miR-194 promotes lineage 
plasticity, many other target genes are likely to be involved in this process and could 
constitute a miR-194 “plasticity supressing targetome” (Figure 6.1). Like FOXA1, 
several miR-194 target genes have been identified as inhibitors of EMT in prostate and 
other cancers. These include ZNF516 (Li et al. 2017), ATXN1 (Kang et al. 2017), 
MPZL2 (Ramena et al. 2016) and ARHGAP1 (Li, Liu & Yin 2017). Notably the EMT 
epithelial marker ZO-1 is a direct miR-194 target. Additionally, targets such as 
ARHGAP1 and TRAF6 are upstream inhibitors of IL8 and EZH2, both of which are 
important in NE transdifferentiation (Lu et al. 2017; Satterfield et al. 2017). Pathway 
analysis of the miR-194 targetome indicates that it is enriched for genes involved in 
cytoskeletal rearrangement, adhesion, junction formation and lamellopodia formation 
consistent with a role in regulating cellular invasion, migration and therefore plasticity. 
Besides directly downregulating genes, ectopic expression of miR-194 also strongly 
upregulated several oncogenes. MET, one of the most highly upregulated genes, is of 



























A key finding of this study was the cytotoxic and cytostatic effect of inhibiting miR-194 
in cell lines and patient derived models of NEPC, raising the possibility of exploiting 
miR-194 as therapeutic target in NEPC. miRNA-based therapeutics are comprised of 
antagomiRs, which bind to target miRNA preventing interactions with target mRNA, and 
miRNA mimics, which aim to replace disease-inhibiting miRNAs lost during disease 
progression (Simonson & Das 2015). MiRNA-based therapeutics are advantageous since 
they can be used to (i) modulate multiple oncogenic genes or pathways with a single 
molecule and (ii) target genes whose corresponding proteins are not targetable by 
conventional antibodies or inhibitors (Rupaimoole et al. 2011). However, targeting 
miRNAs as a therapeutic strategy remain associated with many challenges, including: 
redundancy, since many miRNA target the same genes and inhibiting one miRNA may 
not result in desired effects; delivery to target tissues; cellular toxicity due to pressure on 
the miRNA processing machinery; activation of a non-specific immune response; and the 
selection of appropriate doses to maximize therapeutic effects but prevent off-target 
effects (Chen et al. 2015). Despite these drawbacks, miRNA-based therapeutics have had 
success in recent clinical trials (Kreth, Hübner & Hinske 2018; Van der Ree et al. 2016). 
In case of advanced prostate cancer, I envision three potential strategies in which a miR-
194 inhibitor could be of benefit to treat advanced prostate cancer (Figure 6.2). First, as 
demonstrated in this study, targeting miR-194 using antagomiRs can be used to inhibit 
the growth of NEPC. Second, targeting miR-194 (likely in combination with 
conventional therapies) could prevent emergence of the neuroendocrine phenotype. 
Supporting this concept, transfection of a miR-194 inhibitor was able to prevent serum 
starvation induced neuroendocrine differentiation in LNCaP cells. Finally, a miR-194 
inhibitor could be used to revert NEPC tumours back to an adenocarcinoma phenotype 
that is responsive to conventional AR-targeted therapies. These are exciting 
opportunities, but taking them forward clearly requires further studies in in vitro models 
and in preclinical animal models. One key study would involve using genetically 
engineered mouse models of NEPC such as the NPp53 model. Treatment of NPp53 mice 
with the anti-androgen abitraterone results in progression to an NEPC phenotype that is 
similar to human NEPC (Zou et al. 2017). I propose treating NPp53 mice with miR-194 
locked nucleic acid inhibitors (LNA)  in vivo by injection during abiraterone treatment to 
assess if this prevents progression to NEPC or after progression to determine if miR-194 
inhibition  reduces tumour growth. 
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Besides being a therapeutic target, miR-194 may have utility as a serum biomarker. Initial 
interest in miR-194’s role in prostate cancer arose when this miRNA was identified as a 
circulating marker for disease recurrence (Selth et al. 2013). In advanced PCa, circulating 
levels of miR-194 could be used for tracking disease progression and informing treatment 
decisions. To assess this further, I propose a prospective study in individuals treated with 
ADT to determine if those who initially expressed higher levels of miR-194 are more 
likely to progress to CRPC and//or NEPC. Supporting such a study, I found that miR-194 
trended towards higher levels in the serum of mice harbouring NEPC PDXs compared to 
those with adenocarcinoma PDXs (Figure 6.3). Although these results were not 
significant, perhaps due to the small cohort size, they suggests that tumours expressing 


































































Insights into target gene regulation by miR-194 
Individual miRNAs differ in their mechanism of interaction with target transcripts, and 
the rules governing these interaction are not completely understood (Moore et al. 2015). 
Data from CLIP studies has been crucial to better understanding these miRNA:target 
interactions, revealing previously unknown widespread diversity in regions to which 
miRNAs bind and enabling the identification of non-canonical miRNA regulation of 
target transcripts (Chi et al. 2009; Loeb et al. 2012). In Chapter 4, I used Ago-HITS-CLIP 
and transcriptomic data to study functional miR-194: mRNA interactions.  
My results indicate that miR-194: more potently destabilized target mRNAs by binding 
in the 3’UTR compared to CDS sites; can more potently represses targets through 
multiple binding sites; and is associated with widespread non-canonical binding events. 
However, miR-194 does not follow the general miRNA repression hierarchy based on 
seed length and is not associated with common non-canonical seed types like nucleation 
bulges and centered sites. These findings highlight the fact that miRNAs can function 
through similar mechanisms, but each miRNA also has unique features. 
Non-canonical binding events forms the majority of miRNA:target gene interactions, but 
these are often overlooked in favour of canonical binding sites in the 3’UTR and CDS. 
This study and others (Helwak et al. 2013; Loeb et al. 2012) have found that such 
interactions in the 3’UTR are functional, although they have much smaller effects on 
mRNA stability than canonical seed matches. Importantly, non-canonical seed matches 
may play crucial roles within miRNA targetomes. For instance, in the case of miR-24, 
downregulation of targets with non-canonical seed matches is critical for mediating its 
antiproliferative effects (Lal et al. 2009). In addition to 3’UTR sites, non-canonical sites 
in the CDS are also of interest, given that these were recently discovered to be highly 
functional for miR-20a (Zhang et al. 2018) and also occur in miR-194 CDS targets 
(Chapter 4). Although we did not incorporate non-canonical targets into the miR-194 
targetome, I propose that this will be critical to comprehensively understand its function.  
One drawback of this study was a lack of proteomic data corresponding to the HITS-
CLIP and RNA-seq data since a significant component of miRNA regulation occurs 
through translational repression, particularly for non-3’UTR sites (Hausser et al. 2013). 
Stable Isotope Labelling by amino acids (SILAC)-based methods have previously been 
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used to determine changes to cellular proteomes following perturbation of miRNAs 
(Bargaje et al. 2012). Using this method to determine proteomic changes following 
ectopic expression of miR-194 would ensure a more accurate miR-194 targetome  hence 
gaining a more complete picture of its function in prostate cancer.   
The role of miR-194 in BCa 
BCa is a hormone driven malignancy in which the estrogen receptor (ER) is the key driver 
in approximately 75% of cases. In Chapter 5, I assessed the role of miR-194 in BCa and 
its effect on the expression of FOXA1 and ER. 
Overall, my results indicate that miR-194 is a tumour suppressor in ER-positive BCa, 
unlike its oncogenic role in PCa. Such context-dependant roles are common among 
miRNAs and depend on the genes targeted by the miRNA in that cell type (Erhard et al. 
2014). As an example, a previous study of HER2 (+/-ER) BCa reported that miR-194 
inhibited migration/invasion by targeting TLN2 (Le et al. 2012), but TLN2 was not a 
miR-194 target in PCa (Chapter 3). Differential gene targeting phenomena like these 
likely explain the dichotomous responses to miR-194 we observed in PCa versus BCa. 
Furthermore, even if the same gene is targeted in both cancers, observed phenotypes may 
be different depending on the role of the target gene in that context. For instance, while 
FOXA1 is targeted by miR-194 in both BCa and PCa, the downstream effects mediated 
by FOXA1 are different in these cancers. In PCa, FOXA1 represses the IL-8 gene (Kim 
et al. 2017), whereas in ER-positive breast cancer FOXA1 together with ER upregulates 
IL-8 (Fu et al. 2016). Additionally, downregulation of FOXA1 activates  pathways 
promoting plasticity in PCa (at least partly by upregulating IL-8), whereas in BCa my 
work indicates that loss of FOXA1 may suppress plasticity/invasion. In order to fully 
elucidate the dichotomy in miR-194’s roles in BCa and PCa, it would be crucial to 
identify a miR-194 targetome for BCa using an approach similar to that described in 
Chapter 3.  
Given the importance of ER in growth and progression of luminal BCa, targeting ER 
levels and function is the most common treatment strategy for this BCa subtype 
(Manavathi et al. 2012). My study, which indicates ER is an indirect target of miR-194, 
opens up the possibility of exploring miR-194 upregulation as a therapeutic strategy in 
luminal BCa. The potential of such a strategy is enhanced since miR-194 also impacts on 
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other targets such as FOXA1, which is currently being explored as a therapeutic target in 
ER positive breast cancer (Jozwik and Carroll 2012).  
6.2 Conclusions 
 
Collectively, the research in this thesis has expanded on previous knowledge on the role 
of miR-194 in PCa, and identified a novel role for this factor in BCa. Of greater 







Abida, W, Cyrta, J, Heller, G, Prandi, D, Armenia, J, Coleman, I, Cieslik, M, Benelli, M, 
Robinson, D & Van Allen, EM 2019, 'Genomic correlates of clinical outcome in advanced 
prostate cancer', Proceedings of the National Academy of Sciences, vol. 116, no. 23, pp. 11428-
11436. 
 
Abrahamsson, PA 1999, 'Neuroendocrine cells in tumour growth of the prostate', Endocr Relat 
Cancer, vol. 6, no. 4, Dec, pp. 503-519. 
 
Abrahamsson, PA & di Sant'Agnese, PA 1993, 'Neuroendocrine cells in the human prostate 
gland', J Androl, vol. 14, no. 5, Sep-Oct, pp. 307-309. 
 
Adams, EJ, Karthaus, WR, Hoover, E, Liu, D, Gruet, A, Zhang, Z, Cho, H, DiLoreto, R, 
Chhangawala, S, Liu, Y, Watson, PA, Davicioni, E, Sboner, A, Barbieri, CE, Bose, R, Leslie, CS 
& Sawyers, CL 2019, 'FOXA1 mutations alter pioneering activity, differentiation and prostate 
cancer phenotypes', Nature, vol. 571, no. 7765, Jul, pp. 408-412. 
 
Agarwal, V, Subtelny, AO, Thiru, P, Ulitsky, I & Bartel, DP 2018, 'Predicting microRNA 
targeting efficacy in Drosophila', Genome biology, vol. 19, no. 1, p. 152. 
 
Aggarwal, R, Zhang, T, Small, EJ & Armstrong, AJ 2014, 'Neuroendocrine prostate cancer: 
subtypes, biology, and clinical outcomes', Journal of the National Comprehensive Cancer 
Network, vol. 12, no. 5, pp. 719-726. 
 
AIHW 2019, Cancer in Australia 2019, Cancer series Australian Insttute of Health and Welfare 
, C AIHW. 
 
Akamatsu, S, Inoue, T, Ogawa, O & Gleave, ME 2018, 'Clinical and molecular features of 
treatment‐related neuroendocrine prostate cancer', International Journal of Urology, vol. 25, no. 
4, pp. 345-351. 
 
Akamatsu, S, Wyatt, AW, Lin, D, Lysakowski, S, Zhang, F, Kim, S, Tse, C, Wang, K, Mo, F & 
Haegert, A 2015, 'The placental gene PEG10 promotes progression of neuroendocrine prostate 
cancer', Cell reports, vol. 12, no. 6, pp. 922-936. 
 
Albala, DM 2017, 'Imaging and treatment recommendations in patients with castrate-resistant 
prostate cancer', Reviews in urology, vol. 19, no. 3, p. 200. 
 
Alberti, C & Cochella, L 2017, 'A framework for understanding the roles of miRNAs in animal 
development', Development, vol. 144, no. 14, pp. 2548-2559. 
 
Ambs, S, Prueitt, RL, Yi, M, Hudson, RS, Howe, TM, Petrocca, F, Wallace, TA, Liu, C-G, 
Volinia, S & Calin, GA 2008, 'Genomic profiling of microRNA and messenger RNA reveals 
deregulated microRNA expression in prostate cancer', Cancer research, vol. 68, no. 15, pp. 6162-
6170. 
 
Antonarakis, ES 2013, 'Enzalutamide: the emperor of all anti-androgens', Translational 
andrology and urology, vol. 2, no. 2, p. 119. 
 
Armandari, I, Hamid, AR, Verhaegh, G & Schalken, J 2014, 'Intratumoral steroidogenesis in 





Armenia, J, Wankowicz, SA, Liu, D, Gao, J, Kundra, R, Reznik, E, Chatila, WK, Chakravarty, 
D, Han, GC & Coleman, I 2018, 'The long tail of oncogenic drivers in prostate cancer', Nature 
genetics, vol. 50, no. 5, p. 645. 
 
Arora, VK, Schenkein, E, Murali, R, Subudhi, SK, Wongvipat, J, Balbas, MD, Shah, N, Cai, L, 
Efstathiou, E & Logothetis, C 2013, 'Glucocorticoid receptor confers resistance to antiandrogens 
by bypassing androgen receptor blockade', Cell, vol. 155, no. 6, pp. 1309-1322. 
 
Artibani, W, Porcaro, AB, De Marco, V, Cerruto, MA & Siracusano, S 2018, 'Management of 
biochemical recurrence after primary curative treatment for prostate cancer: a review', Urologia 
internationalis, vol. 100, no. 3, pp. 251-262. 
 
Ayala, AG, Ro, JY, Babaian, R, Troncoso, P & Grignon, DJ 1989, 'The prostatic capsule: does it 
exist? Its importance in the staging and treatment of prostatic carcinoma', The American journal 
of surgical pathology, vol. 13, no. 1, pp. 21-27. 
 
Bailey, TL, Boden, M, Buske, FA, Frith, M, Grant, CE, Clementi, L, Ren, J, Li, WW & Noble, 
WS 2009, 'MEME SUITE: tools for motif discovery and searching', Nucleic acids research, vol. 
37, no. suppl_2, pp. W202-W208. 
 
Balk, SP 2014, 'Androgen receptor functions in prostate cancer development and progression', 
Asian journal of andrology, vol. 16, no. 4, p. 561. 
 
Banerjee, PP, Banerjee, S, Brown, TR & Zirkin, BR 2018, 'Androgen action in prostate function 
and disease', American journal of clinical and experimental urology, vol. 6, no. 2, p. 62. 
 
Bao, C, Li, Y, Huan, L, Zhang, Y, Zhao, F, Wang, Q, Liang, L, Ding, J, Liu, L & Chen, T 2015, 
'NF-kB signaling relieves negative regulation by miR-194 in hepatocellular carcinoma by 
suppressing the transcription factor HNF-1o', Sci Signal, vol. 8, p. 387. 
 
Bardin, CW, BULLOCK, LP, SHERINS, RJ, MOWSZOWICZ, I & BLACKBURN, WR 1973, 
'Part II. Androgen metabolism and mechanism of action in male pseudohermaphroditism: a study 
of testicular feminization', Proceedings of the 1972 Laurentian Hormone Conference, Elsevier, 
pp. 65-109. 
 
Bargaje, R, Gupta, S, Sarkeshik, A, Park, R, Xu, T, Sarkar, M, Halimani, M, Roy, SS, Yates, J & 
Pillai, B 2012, 'Identification of novel targets for miR-29a using miRNA proteomics', PloS one, 
vol. 7, no. 8, p. e43243. 
 
Bartel, DP 2004, 'MicroRNAs: genomics, biogenesis, mechanism, and function', Cell, vol. 116, 
no. 2, pp. 281-297. 
 
Bartel, DP 2009, 'MicroRNAs: target recognition and regulatory functions', Cell, vol. 136, no. 2, 
pp. 215-233. 
 
Baskerville, S & Bartel, DP 2005, 'Microarray profiling of microRNAs reveals frequent 
coexpression with neighboring miRNAs and host genes', Rna, vol. 11, no. 3, pp. 241-247. 
 
Beltran, H, Prandi, D, Mosquera, JM, Benelli, M, Puca, L, Cyrta, J, Marotz, C, Giannopoulou, E, 
Chakravarthi, BV & Varambally, S 2016, 'Divergent clonal evolution of castration-resistant 




Beltran, H, Rickman, DS, Park, K, Chae, SS, Sboner, A, MacDonald, TY, Wang, Y, Sheikh, KL, 
Terry, S & Tagawa, ST 2011, 'Molecular characterization of neuroendocrine prostate cancer and 
identification of new drug targets', Cancer discovery, vol. 1, no. 6, pp. 487-495. 
 
Bernardo, GM, Lozada, KL, Miedler, JD, Harburg, G, Hewitt, SC, Mosley, JD, Godwin, AK, 
Korach, KS, Visvader, JE & Kaestner, KH 2010, 'FOXA1 is an essential determinant of ERα 
expression and mammary ductal morphogenesis', Development, vol. 137, no. 12, pp. 2045-2054. 
 
Beshiri, ML, Tice, CM, Tran, C, Nguyen, HM, Sowalsky, AG, Agarwal, S, Jansson, KH, Yang, 
Q, McGowen, KM & Yin, J 2018, 'A PDX/organoid biobank of advanced prostate cancers 
captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening', 
Clinical Cancer Research, vol. 24, no. 17, pp. 4332-4345. 
 
Biagioni, F, Ben‐Moshe, NB, Fontemaggi, G, Canu, V, Mori, F, Antoniani, B, Di Benedetto, A, 
Santoro, R, Germoni, S & De Angelis, F 2012, 'miR‐10b*, a master inhibitor of the cell cycle, is 
down‐regulated in human breast tumours', EMBO molecular medicine, vol. 4, no. 11, pp. 1214-
1229. 
 
Bicknell, AA, Cenik, C, Chua, HN, Roth, FP & Moore, MJ 2012, 'Introns in UTRs: why we 
should stop ignoring them', Bioessays, vol. 34, no. 12, pp. 1025-1034. 
 
Bishop, JL, Thaper, D, Vahid, S, Davies, A, Ketola, K, Kuruma, H, Jama, R, Nip, KM, Angeles, 
A & Johnson, F 2017, 'The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–
Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer', Cancer discovery, vol. 
7, no. 1, pp. 54-71. 
 
Bluemn, EG, Coleman, IM, Lucas, JM, Coleman, RT, Hernandez-Lopez, S, Tharakan, R, 
Bianchi-Frias, D, Dumpit, RF, Kaipainen, A & Corella, AN 2017, 'Androgen receptor pathway-
independent prostate cancer is sustained through FGF signaling', Cancer cell, vol. 32, no. 4, pp. 
474-489. e476. 
 
Bonci, D, Coppola, V, Patrizii, M, Addario, A, Cannistraci, A, Francescangeli, F, Pecci, R, Muto, 
G, Collura, D & Bedini, R 2016, 'A microRNA code for prostate cancer metastasis', Oncogene, 
vol. 35, no. 9, p. 1180. 
 
Bracken, CP, Li, X, Wright, JA, Lawrence, DM, Pillman, KA, Salmanidis, M, Anderson, MA, 
Dredge, BK, Gregory, PA & Tsykin, A 2014, 'Genome‐wide identification of miR‐200 targets 
reveals a regulatory network controlling cell invasion', The EMBO journal, vol. 33, no. 18, pp. 
2040-2056. 
 
Braun, CJ, Zhang, X, Savelyeva, I, Wolff, S, Moll, UM, Schepeler, T, Ørntoft, TF, Andersen, CL 
& Dobbelstein, M 2008, 'p53-Responsive micrornas 192 and 215 are capable of inducing cell 
cycle arrest', Cancer research, vol. 68, no. 24, pp. 10094-10104. 
 
Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA & Jemal, A 2018, 'Global cancer 
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 
185 countries', CA: a cancer journal for clinicians. 
 
Brinkmann, A, Jenster, G, Kuiper, G, Ris, C, Van Laar, J, Van der Korput, J, Degenhart, H, 
Trifiro, M, Pinsky, L & Romalo, G 1992, 'The human androgen receptor: structure/function 
relationship in normal and pathological situations', The Journal of steroid biochemistry and 
molecular biology, vol. 41, no. 3-8, pp. 361-368. 
 
Brinkmann, AO, Faber, P, Van Rooij, H, Kuiper, G, Ris, C, Klaassen, P, Van der Korput, J, 
Voorhorst, M, Van Laar, J & Mulder, E 1989, 'The human androgen receptor: domain structure, 
196 
 
genomic organization and regulation of expression', Journal of steroid biochemistry, vol. 34, no. 
1-6, pp. 307-310. 
 
Broutier, L, Andersson-Rolf, A, Hindley, CJ, Boj, SF, Clevers, H, Koo, B-K & Huch, M 2016, 
'Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D 
organoids and their genetic manipulation', Nature protocols, vol. 11, no. 9, p. 1724. 
 
Buffa, FM, Camps, C, Winchester, L, Snell, CE, Gee, HE, Sheldon, H, Taylor, M, Harris, AL & 
Ragoussis, J 2011, 'microRNA-associated progression pathways and potential therapeutic targets 
identified by integrated mRNA and microRNA expression profiling in breast cancer', Cancer 
research, vol. 71, no. 17, pp. 5635-5645. 
 
Burdick, MJ, Reddy, CA, Ulchaker, J, Angermeier, K, Altman, A, Chehade, N, Mahadevan, A, 
Kupelian, PA, Klein, EA & Ciezki, JP 2009, 'Comparison of biochemical relapse-free survival 
between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 
prostate cancer', International Journal of Radiation Oncology* Biology* Physics, vol. 73, no. 5, 
pp. 1439-1445. 
 
Buyyounouski, MK, Choyke, PL, McKenney, JK, Sartor, O, Sandler, HM, Amin, MB, Kattan, 
MW & Lin, DW 2017, 'Prostate cancer–major changes in the American Joint Committee on 
Cancer eighth edition cancer staging manual', CA: a cancer journal for clinicians, vol. 67, no. 3, 
pp. 245-253. 
 
Calin, GA, Dumitru, CD, Shimizu, M, Bichi, R, Zupo, S, Noch, E, Aldler, H, Rattan, S, Keating, 
M & Rai, K 2002, 'Frequent deletions and down-regulation of micro-RNA genes miR15 and 
miR16 at 13q14 in chronic lymphocytic leukemia', Proceedings of the National Academy of 
Sciences, vol. 99, no. 24, pp. 15524-15529. 
 
Cancer Genome Atlas Research, N 2015, 'The Molecular Taxonomy of Primary Prostate Cancer', 
Cell, vol. 163, no. 4, Nov 5, pp. 1011-1025. 
 
Chen, CD, Welsbie, DS, Tran, C, Baek, SH, Chen, R, Vessella, R, Rosenfeld, MG & Sawyers, 
CL 2004, 'Molecular determinants of resistance to antiandrogen therapy', Nature medicine, vol. 
10, no. 1, p. 33. 
 
Chen, Y, Clegg, NJ & Scher, HI 2009, 'Anti-androgens and androgen-depleting therapies in 
prostate cancer: new agents for an established target', The lancet oncology, vol. 10, no. 10, pp. 
981-991. 
 
Chen, Y, Zhao, H, Tan, Z, Zhang, C & Fu, X 2015, 'Bottleneck limitations for microRNA-based 
therapeutics from bench to the bedside', Die Pharmazie-An International Journal of 
Pharmaceutical Sciences, vol. 70, no. 3, pp. 147-154. 
 
Chi, SW, Zang, JB, Mele, A & Darnell, RB 2009, 'Argonaute HITS-CLIP decodes microRNA–
mRNA interaction maps', Nature, vol. 460, no. 7254, p. 479. 
 
Chia, K, O’Brien, M, Brown, M & Lim, E 2015, 'Targeting the androgen receptor in breast 
cancer', Current oncology reports, vol. 17, no. 2, pp. 1-6. 
 
Chmelar, R, Buchanan, G, Need, EF, Tilley, W & Greenberg, NM 2007, 'Androgen receptor 
coregulators and their involvement in the development and progression of prostate cancer', 




Choi, J-S, Nam, M-H, Yoon, S-Y & Kang, S-H 2015, 'MicroRNA-194-5p could serve as a 
diagnostic and prognostic biomarker in myelodysplastic syndromes', Leukemia research, vol. 39, 
no. 7, pp. 763-768. 
 
Chong, JT, Oh, WK & Liaw, BC 2018, 'Profile of apalutamide in the treatment of metastatic 
castration-resistant prostate cancer: evidence to date', OncoTargets and therapy, vol. 11, p. 2141. 
 
Cimmino, A, Calin, GA, Fabbri, M, Iorio, MV, Ferracin, M, Shimizu, M, Wojcik, SE, Aqeilan, 
RI, Zupo, S & Dono, M 2005, 'miR-15 and miR-16 induce apoptosis by targeting BCL2', 
Proceedings of the National Academy of Sciences, vol. 102, no. 39, pp. 13944-13949. 
 
Claessens, F, Alen, P, Devos, A, Peeters, B, Verhoeven, G & Rombauts, W 1996, 'The androgen-
specific probasin response element 2 interacts differentially with androgen and glucocorticoid 
receptors', Journal of Biological Chemistry, vol. 271, no. 32, pp. 19013-19016. 
 
Clarke, CL & Graham, JD 2012, 'Non-overlapping progesterone receptor cistromes contribute to 
cell-specific transcriptional outcomes', PloS one, vol. 7, no. 4, p. e35859. 
 
Cooke, PS, Young, P & Cunha, GR 1991, 'Androgen receptor expression in developing male 
reproductive organs', Endocrinology, vol. 128, no. 6, pp. 2867-2873. 
 
Coutinho, I, Day, TK, Tilley, WD & Selth, LA 2016, 'Androgen receptor signaling in castration-
resistant prostate cancer: a lesson in persistence', Endocrine-Related Cancer, vol. 23, no. 12, pp. 
T179-T197. 
 
Culig, Z, Hoffmann, J, Erdel, M, Eder, I, Hobisch, A, Hittmair, A, Bartsch, G, Utermann, G, 
Schneider, M & Parczyk, K 1999, 'Switch from antagonist to agonist of the androgen receptor 
blocker bicalutamide is associated with prostate tumour progression in a new model system', 
British journal of cancer, vol. 81, no. 2, p. 242. 
 
Cury, J, Coelho, RF & Srougi, M 2008, 'Well-differentiated prostate cancer in core biopsy 
specimens may be associated with extraprostatic disease', Sao Paulo Medical Journal, vol. 126, 
no. 2, pp. 119-122. 
 
D'Amico, AV, Whittington, R, Malkowicz, SB, Schultz, D, Blank, K, Broderick, GA, 
Tomaszewski, JE, Renshaw, AA, Kaplan, I & Beard, CJ 1998, 'Biochemical outcome after radical 
prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically 
localized prostate cancer', Jama, vol. 280, no. 11, pp. 969-974. 
 
Dardenne, E, Beltran, H, Benelli, M, Gayvert, K, Berger, A, Puca, L, Cyrta, J, Sboner, A, 
Noorzad, Z & MacDonald, T 2016, 'N-Myc induces an EZH2-mediated transcriptional program 
driving neuroendocrine prostate cancer', Cancer cell, vol. 30, no. 4, pp. 563-577. 
 
Das, R, Gregory, PA, Fernandes, RC, Denis, I, Wang, Q, Townley, SL, Zhao, SG, Hanson, AR, 
Pickering, MA, Armstrong, HK, Lokman, NA, Ebrahimie, E, Davicioni, E, Jenkins, RB, Karnes, 
RJ, Ross, AE, Den, RB, Klein, EA, Chi, KN, Ramshaw, HS, Williams, ED, Zoubeidi, A, Goodall, 
GJ, Feng, FY, Butler, LM, Tilley, WD & Selth, LA 2017, 'MicroRNA-194 Promotes Prostate 
Cancer Metastasis by Inhibiting SOCS2', Cancer Res, vol. 77, no. 4, Feb 15, pp. 1021-1034. 
 
Davies, AH, Beltran, H & Zoubeidi, A 2018, 'Cellular plasticity and the neuroendocrine 
phenotype in prostate cancer', Nature Reviews Urology. 
 
Dicken, H, Hensley, PJ & Kyprianou, N 2019, 'Prostate tumor neuroendocrine differentiation via 




Dong, Q, Meng, P, Wang, T, Qin, W, Qin, W, Wang, F, Yuan, J, Chen, Z, Yang, A & Wang, H 
2010, 'MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo 
by targeting E2F2 and CCND2', PloS one, vol. 5, no. 4, p. e10147. 
 
Donjacour, AA & Cunha, GR 1993, 'Assessment of prostatic protein secretion in tissue 
recombinants made of urogenital sinus mesenchyme and urothelium from normal or androgen-
insensitive mice', Endocrinology, vol. 132, no. 6, pp. 2342-2350. 
 
Eisermann, K, Wang, D, Jing, Y, Pascal, LE & Wang, Z 2013, 'Androgen receptor gene mutation, 
rearrangement, polymorphism', Translational andrology and urology, vol. 2, no. 3, p. 137. 
 
Ellis, L & Loda, M 2018, 'LSD1: A single target to combat lineage plasticity in lethal prostate 
cancer', Proceedings of the National Academy of Sciences, vol. 115, no. 18, pp. 4530-4531. 
 
Ellwanger, DC, Büttner, FA, Mewes, H-W & Stümpflen, V 2011, 'The sufficient minimal set of 
miRNA seed types', Bioinformatics, vol. 27, no. 10, pp. 1346-1350. 
 
Epstein, JI 2000, 'Gleason score 2–4 adenocarcinoma of the prostate on needle biopsy: a diagnosis 
that should not be made', LWW. 
 
Erhard, F, Haas, J, Lieber, D, Malterer, G, Jaskiewicz, L, Zavolan, M, Dölken, L & Zimmer, R 
2014, 'Widespread context dependency of microRNA-mediated regulation', Genome research, 
vol. 24, no. 6, pp. 906-919. 
 
Esposito, S, Russo, MV, Airoldi, I, Tupone, MG, Sorrentino, C, Barbarito, G, Di Meo, S & Di 
Carlo, E 2015, 'SNAI2/Slug gene is silenced in prostate cancer and regulates neuroendocrine 
differentiation, metastasis-suppressor and pluripotency gene expression', Oncotarget, vol. 6, no. 
19, p. 17121. 
 
Fang, Z & Rajewsky, N 2011, 'The impact of miRNA target sites in coding sequences and in 3′ 
UTRs', PloS one, vol. 6, no. 3, p. e18067. 
 
Forman, JJ & Coller, HA 2010, 'The code within the code: microRNAs target coding regions', 
Cell cycle, vol. 9, no. 8, pp. 1533-1541. 
 
Friedlander, TW & Ryan, CJ 2010, 'Adrenal Androgen Synthesis Inhibitor Therapies in 
Castration-Resistant Prostate Cancer', Drug Management of Prostate Cancer, Springer, pp. 91-
100. 
 
Friedman, RC, Farh, KK-H, Burge, CB & Bartel, DP 2009, 'Most mammalian mRNAs are 
conserved targets of microRNAs', Genome research, vol. 19, no. 1, pp. 92-105. 
 
Fuqua, SA 2001, 'The role of estrogen receptors in breast cancer metastasis', Journal of mammary 
gland biology and neoplasia, vol. 6, no. 4, pp. 407-417. 
 
Gaidatzis, D, Burger, L, Florescu, M & Stadler, MB 2015, 'Analysis of intronic and exonic reads 
in RNA-seq data characterizes transcriptional and post-transcriptional regulation', Nature 
biotechnology, vol. 33, no. 7, p. 722. 
 
Galardi, S, Mercatelli, N, Giorda, E, Massalini, S, Frajese, GV, Ciafrè, SA & Farace, MG 2007, 
'miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma 





Gao, N, Ishii, K, Mirosevich, J, Kuwajima, S, Oppenheimer, SR, Roberts, RL, Jiang, M, Yu, X, 
Shappell, SB & Caprioli, RM 2005, 'Forkhead box A1 regulates prostate ductal morphogenesis 
and promotes epithelial cell maturation', Development, vol. 132, no. 15, pp. 3431-3443. 
 
Gao, N, Zhang, J, Rao, MA, Case, TC, Mirosevich, J, Wang, Y, Jin, R, Gupta, A, Rennie, PS & 
Matusik, RJ 2003, 'The role of hepatocyte nuclear factor-3α (Forkhead Box A1) and androgen 
receptor in transcriptional regulation of prostatic genes', Molecular Endocrinology, vol. 17, no. 
8, pp. 1484-1507. 
 
Gleason, DF 1966, 'Classification of prostatic carcinomas', Cancer Chemother. Rep., vol. 50, pp. 
125-128. 
 
Gleason, DF 1992, 'Histologic grading of prostate cancer: a perspective', Human pathology, vol. 
23, no. 3, pp. 273-279. 
 
Gordetsky, J & Epstein, J 2016, 'Grading of prostatic adenocarcinoma: current state and 
prognostic implications', Diagnostic pathology, vol. 11, no. 1, p. 25. 
 
Gordon, K & Hodgen, GD 1992, 'Evolving role of gonadotropin-releasing hormone antagonists', 
Trends in Endocrinology & Metabolism, vol. 3, no. 7, pp. 259-263. 
 
Goto, Y, Kojima, S, Nishikawa, R, Kurozumi, A, Kato, M, Enokida, H, Matsushita, R, Yamazaki, 
K, Ishida, Y & Nakagawa, M 2015, 'MicroRNA expression signature of castration-resistant 
prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease 
progression marker', British journal of cancer, vol. 113, no. 7, p. 1055. 
 
Grasso, CS, Wu, Y-M, Robinson, DR, Cao, X, Dhanasekaran, SM, Khan, AP, Quist, MJ, Jing, 
X, Lonigro, RJ & Brenner, JC 2012, 'The mutational landscape of lethal castration-resistant 
prostate cancer', Nature, vol. 487, no. 7406, p. 239. 
 
Grimson, A, Farh, KK-H, Johnston, WK, Garrett-Engele, P, Lim, LP & Bartel, DP 2007, 
'MicroRNA targeting specificity in mammals: determinants beyond seed pairing', Molecular cell, 
vol. 27, no. 1, pp. 91-105. 
 
Grino, PB, Griffin, JE & Wilson, JD 1990, 'Testosterone at high concentrations interacts with the 
human androgen receptor similarly to dihydrotestosterone', Endocrinology, vol. 126, no. 2, pp. 
1165-1172. 
 
Gui, B, Hsieh, C-L, Kantoff, PW, Kibel, AS & Jia, L 2017, 'Androgen receptor-mediated 
downregulation of microRNA-221 and-222 in castration-resistant prostate cancer', PloS one, vol. 
12, no. 9, p. e0184166. 
 
Ha, M & Kim, VN 2014, 'Regulation of microRNA biogenesis', Nature reviews Molecular cell 
biology, vol. 15, no. 8, p. 509. 
 
Hamdy, FC, Donovan, JL, Lane, JA, Mason, M, Metcalfe, C, Holding, P, Davis, M, Peters, TJ, 
Turner, EL & Martin, RM 2016, '10-year outcomes after monitoring, surgery, or radiotherapy for 
localized prostate cancer', New England Journal of Medicine, vol. 375, no. 15, pp. 1415-1424. 
 
Han, J, Lee, Y, Yeom, K-H, Kim, Y-K, Jin, H & Kim, VN 2004, 'The Drosha-DGCR8 complex 
in primary microRNA processing', Genes & development, vol. 18, no. 24, pp. 3016-3027. 
 
Hart, M, Nolte, E, Wach, S, Szczyrba, J, Taubert, H, Rau, TT, Hartmann, A, Grässer, FA & 
Wullich, B 2014, 'Comparative microRNA profiling of prostate carcinomas with increasing 




Hausser, J, Syed, AP, Bilen, B & Zavolan, M 2013, 'Analysis of CDS-located miRNA target sites 
suggests that they can effectively inhibit translation', Genome research, vol. 23, no. 4, pp. 604-
615. 
 
He, B, Lanz, RB, Fiskus, W, Geng, C, Yi, P, Hartig, SM, Rajapakshe, K, Shou, J, Wei, L & Shah, 
SS 2014, 'GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor 
complex', Proceedings of the National Academy of Sciences, vol. 111, no. 51, pp. 18261-18266. 
 
Heinlein, CA & Chang, C 2002, 'Androgen receptor (AR) coregulators: an overview', Endocrine 
reviews, vol. 23, no. 2, pp. 175-200. 
 
Heinlein, CA & Chang, C 2004, 'Androgen receptor in prostate cancer', Endocr Rev, vol. 25, no. 
2, Apr, pp. 276-308. 
 
Helpap, B, Köllermann, J & Oehler, U 1999, 'Neuroendocrine differentiation in prostatic 
carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives', 
Urologia internationalis, vol. 62, no. 3, pp. 133-138. 
 
Helwak, A, Kudla, G, Dudnakova, T & Tollervey, D 2013, 'Mapping the human miRNA 
interactome by CLASH reveals frequent noncanonical binding', Cell, vol. 153, no. 3, pp. 654-
665. 
 
Hino, K, Tsuchiya, K, Fukao, T, Kiga, K, Okamoto, R, Kanai, T & Watanabe, M 2008, 'Inducible 
expression of microRNA-194 is regulated by HNF-1α during intestinal epithelial cell 
differentiation', Rna, vol. 14, no. 7, pp. 1433-1442. 
 
Hironaka-Mitsuhashi, A, Matsuzaki, J, Takahashi, R-u, Yoshida, M, Nezu, Y, Yamamoto, Y, 
Shiino, S, Kinoshita, T, Ushijima, T & Hiraoka, N 2017, 'A tissue microRNA signature that 
predicts the prognosis of breast cancer in young women', PloS one, vol. 12, no. 11, p. e0187638. 
 
Hoefert, JE, Bjerke, GA, Wang, D & Yi, R 2018, 'The microRNA-200 family coordinately 
regulates cell adhesion and proliferation in hair morphogenesis', J Cell Biol, vol. 217, no. 6, pp. 
2185-2204. 
 
Hörnberg, E, Ylitalo, EB, Crnalic, S, Antti, H, Stattin, P, Widmark, A, Bergh, A & Wikström, P 
2011, 'Expression of androgen receptor splice variants in prostate cancer bone metastases is 
associated with castration-resistance and short survival', PloS one, vol. 6, no. 4, p. e19059. 
 
Huggins, C & Hodges, CV 1941, 'Studies on prostatic cancer. I. The effect of castration, of 
estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the 
prostate', Cancer research, vol. 1, no. 4, pp. 293-297. 
 
Humphrey, PA 2004, 'Gleason grading and prognostic factors in carcinoma of the prostate', 
Modern pathology, vol. 17, no. 3, p. 292. 
 
Huo, D, Clayton, WM, Yoshimatsu, TF, Chen, J & Olopade, OI 2016, 'Identification of a 
circulating MicroRNA signature to distinguish recurrence in breast cancer patients', Oncotarget, 
vol. 7, no. 34, p. 55231. 
 
Isaacs, JT & Coffey, DS 1989, 'Etiology and disease process of benign prostatic hyperplasia', The 




Jalava, S, Urbanucci, A, Latonen, L, Waltering, K, Sahu, B, Jänne, OA, Seppälä, J, Lähdesmäki, 
H, Tammela, T & Visakorpi, T 2012, 'Androgen-regulated miR-32 targets BTG2 and is 
overexpressed in castration-resistant prostate cancer', Oncogene, vol. 31, no. 41, p. 4460. 
 
Jang, TL, Patel, N, Faiena, I, Radadia, KD, Moore, DF, Elsamra, SE, Singer, EA, Stein, MN, 
Eastham, JA & Scardino, PT 2018, 'Comparative effectiveness of radical prostatectomy with 
adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with 
advanced prostate cancer', Cancer, vol. 124, no. 20, pp. 4010-4022. 
 
Jenster, G, Trapman, J & Brinkmann, A 1993, 'Nuclear import of the human androgen receptor', 
Biochemical Journal, vol. 293, no. 3, pp. 761-768. 
 
Jenster, G, van der Korput, HA, van Vroonhoven, C, van der Kwast, TH, Trapman, J & 
Brinkmann, AO 1991, 'Domains of the human androgen receptor involved in steroid binding, 
transcriptional activation, and subcellular localization', Molecular Endocrinology, vol. 5, no. 10, 
pp. 1396-1404. 
 
Jeon, H-M & Lee, J 2017, 'MET: roles in epithelial-mesenchymal transition and cancer stemness', 
Annals of translational medicine, vol. 5, no. 1. 
 
Jernberg, E, Bergh, A & Wikström, P 2017, 'Clinical relevance of androgen receptor alterations 
in prostate cancer', Endocrine connections, vol. 6, no. 8, pp. R146-R161. 
 
Jeselsohn, R, Buchwalter, G, De Angelis, C, Brown, M & Schiff, R 2015, 'ESR1 mutations 
[mdash] a mechanism for acquired endocrine resistance in breast cancer', Nature Reviews Clinical 
Oncology. 
 
Jin, H-J, Zhao, JC, Ogden, I, Bergan, RC & Yu, J 2013, 'Androgen receptor-independent function 
of FoxA1 in prostate cancer metastasis', Cancer research, vol. 73, no. 12, pp. 3725-3736. 
 
Jin, H-J, Zhao, JC, Wu, L, Kim, J & Yu, J 2014, 'Cooperativity and equilibrium with FOXA1 
define the androgen receptor transcriptional program', Nature communications, vol. 5, p. 3972. 
 
Jozwik, KM & Carroll, JS 2012, 'Pioneer factors in hormone-dependent cancers', Nature Reviews 
Cancer, vol. 12, no. 6, p. 381. 
 
Kabekkodu, SP, Shukla, V, Varghese, VK, D'Souza, J, Chakrabarty, S & Satyamoorthy, K 2018, 
'Clustered miRNAs and their role in biological functions and diseases', Biological Reviews, vol. 
93, no. 4, pp. 1955-1986. 
 
Kaestner, KH 2010, 'The FoxA factors in organogenesis and differentiation', Current opinion in 
genetics & development, vol. 20, no. 5, pp. 527-532. 
 
Kallio, HM, Hieta, R, Latonen, L, Brofeldt, A, Annala, M, Kivinummi, K, Tammela, TL, Nykter, 
M, Isaacs, WB & Lilja, HG 2018, 'Constitutively active androgen receptor splice variants AR-
V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases', 
British journal of cancer, vol. 119, no. 3, p. 347. 
 
Kalofonou, F, Leach, D, Hamilton, M, Mcguire, SE, Fletcher, C, Waxman, J & Bevan, CL 2019, 
'MiR-1271-5p: An AR-modulatory microRNA with a distinct role in prostate cancer progression, 
through SND1 and MORF4L1 interaction', American Society of Clinical Oncology. 
 
Kang, A-R, An, H-T, Ko, J & Kang, S 2017, 'Ataxin-1 regulates epithelial–mesenchymal 




Kapatia, G, Attri, VS, Mete, UK & Rastogi, P 2018, 'Metastatic basal cell carcinoma of prostate 
in a young adult: A rare aggressive entity', African Journal of Urology, vol. 24, no. 4, pp. 287-
290. 
 
Kauffmann, G & Liauw, SL 2017, 'The use of Hormonal Therapy to Augment Radiation Therapy 
in Prostate Cancer: An Update', Current urology reports, vol. 18, no. 7, p. 50. 
 
Kemppainen, JA & Wilson, EM 1996, 'Agonist and antagonist activities of hydroxyflutamide and 
Casodex relate to androgen receptor stabilization', Urology, vol. 48, no. 1, pp. 157-163. 
 
Khella, HW, Bakhet, M, Allo, G, Jewett, MA, Girgis, AH, Latif, A, Girgis, H, Von Both, I, 
Bjarnason, GA & Yousef, GM 2013, 'miR-192, miR-194 and miR-215: a convergent microRNA 
network suppressing tumor progression in renal cell carcinoma', Carcinogenesis, vol. 34, no. 10, 
pp. 2231-2239. 
 
Kim, J & Coetzee, GA 2004, 'Prostate specific antigen gene regulation by androgen receptor', J 
Cell Biochem, vol. 93, no. 2, Oct 1, pp. 233-241. 
 
Kim, J, Jin, H, Zhao, JC, Yang, YA, Li, Y, Yang, X, Dong, X & Yu, J 2017, 'FOXA1 inhibits 
prostate cancer neuroendocrine differentiation', Oncogene, vol. 36, no. 28, p. 4072. 
 
Kobayashi, H & Tomari, Y 2016, 'RISC assembly: Coordination between small RNAs and 
Argonaute proteins', Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms, vol. 
1859, no. 1, pp. 71-81. 
 
Koivisto, P, Kononen, J, Palmberg, C, Tammela, T, Hyytinen, E, Isola, J, Trapman, J, Cleutjens, 
K, Noordzij, A & Visakorpi, T 1997, 'Androgen receptor gene amplification: a possible molecular 
mechanism for androgen deprivation therapy failure in prostate cancer', Cancer research, vol. 57, 
no. 2, pp. 314-319. 
 
Kreth, S, Hübner, M & Hinske, LC 2018, 'MicroRNAs as clinical biomarkers and therapeutic 
tools in perioperative medicine', Anesthesia & Analgesia, vol. 126, no. 2, pp. 670-681. 
 
Krützfeldt, J, Rösch, N, Hausser, J, Manoharan, M, Zavolan, M & Stoffel, M 2012, 'MicroRNA‐
194 is a target of transcription factor 1 (Tcf1, HNF1α) in adult liver and controls expression of 
frizzled‐6', Hepatology, vol. 55, no. 1, pp. 98-107. 
 
Ku, SY, Rosario, S, Wang, Y, Mu, P, Seshadri, M, Goodrich, ZW, Goodrich, MM, Labbé, DP, 
Gomez, EC & Wang, J 2017, 'Rb1 and Trp53 cooperate to suppress prostate cancer lineage 
plasticity, metastasis, and antiandrogen resistance', Science, vol. 355, no. 6320, pp. 78-83. 
 
Kumar, A, Coleman, I, Morrissey, C, Zhang, X, True, LD, Gulati, R, Etzioni, R, Bolouri, H, 
Montgomery, B & White, T 2016, 'Substantial interindividual and limited intraindividual 
genomic diversity among tumors from men with metastatic prostate cancer', Nature medicine, 
vol. 22, no. 4, p. 369. 
 
Labrie, F, BÉLANGER, A, CUSAN, L, SEGUIN, C, PELLETIER, G, KELLY, PA, REEVES, 
JJ, LEFEBVRE, FA, LEMAY, A & GOURDEAU, Y 1980, 'Antifertility effects of LHRH 
agonists in the male', Journal of Andrology, vol. 1, no. 5, pp. 209-228. 
 
Labrie, F, Belanger, A, Luu-The, V, Labrie, C, Simard, J, Cusan, L, Gomez, J & Candas, B 2005, 
'Gonadotropin-releasing hormone agonists in the treatment of prostate cancer', Endocrine 




Lal, A, Navarro, F, Maher, C, Maliszewski, LE, Yan, N, O'Day, E, Chowdhury, D, Dykxhoorn, 
DM, Tsai, P & Hofman, O 2009, 'miR-24 inhibits cell proliferation by suppressing expression of 
E2F2, MYC and other cell cycle regulatory genes by binding to “seedless” 3′ UTR microRNA 
recognition elements', Molecular cell, vol. 35, no. 5, p. 610. 
 
Lawrence, MG, Obinata, D, Sandhu, S, Selth, LA, Wong, SQ, Porter, LH, Lister, N, Pook, D, 
Pezaro, CJ & Goode, DL 2018, 'Patient-derived models of abiraterone-and enzalutamide-resistant 
prostate cancer reveal sensitivity to ribosome-directed therapy', European urology, vol. 74, no. 5, 
pp. 562-572. 
 
Le Magnen, C, Shen, MM & Abate-Shen, C 2018, 'Lineage plasticity in cancer progression and 
treatment', Annual review of cancer biology, vol. 2, pp. 271-289. 
 
Le, X-F, Almeida, MI, Mao, W, Spizzo, R, Rossi, S, Nicoloso, MS, Zhang, S, Wu, Y, Calin, GA 
& Bast Jr, RC 2012, 'Modulation of MicroRNA-194 and cell migration by HER2-targeting 
trastuzumab in breast cancer', PloS one, vol. 7, no. 7, p. e41170. 
 
Lee, AR, Gan, Y, Tang, Y & Dong, X 2018, 'A novel mechanism of SRRM4 in promoting 
neuroendocrine prostate cancer development via a pluripotency gene network', EBioMedicine, 
vol. 35, pp. 167-177. 
 
Lee, JJ, Thomas, IC, Nolley, R, Ferrari, M, Brooks, JD & Leppert, JT 2015, 'Biologic differences 
between peripheral and transition zone prostate cancer', The prostate, vol. 75, no. 2, pp. 183-190. 
 
Lee, RC, Feinbaum, RL & Ambros, V 1993, 'The C. elegans heterochronic gene lin-4 encodes 
small RNAs with antisense complementarity to lin-14', Cell, vol. 75, no. 5, pp. 843-854. 
 
Lee, Y, Ahn, C, Han, J, Choi, H, Kim, J, Yim, J, Lee, J, Provost, P, Rådmark, O & Kim, S 2003, 
'The nuclear RNase III Drosha initiates microRNA processing', Nature, vol. 425, no. 6956, p. 
415. 
 
Lee, Y, Kim, M, Han, J, Yeom, KH, Lee, S, Baek, SH & Kim, VN 2004, 'MicroRNA genes are 
transcribed by RNA polymerase II', The EMBO journal, vol. 23, no. 20, pp. 4051-4060. 
 
Leung, AK, Young, AG, Bhutkar, A, Zheng, GX, Bosson, AD, Nielsen, CB & Sharp, PA 2011, 
'Genome-wide identification of Ago2 binding sites from mouse embryonic stem cells with and 
without mature microRNAs', Nature structural & molecular biology, vol. 18, no. 2, p. 237. 
 
Li, J-p, Liu, Y & Yin, Y-h 2017, 'ARHGAP1 overexpression inhibits proliferation, migration and 
invasion of C-33A and SiHa cell lines', OncoTargets and therapy, vol. 10, p. 691. 
 
Li, J & Zhang, Y 2019, 'Current experimental strategies for intracellular target identification of 
microRNA', ExRNA, vol. 1, no. 1, p. 6. 
 
Li, L, Liu, X, He, L, Yang, J, Pei, F, Li, W, Liu, S, Chen, Z, Xie, G & Xu, B 2017, 'ZNF516 
suppresses EGFR by targeting the CtBP/LSD1/CoREST complex to chromatin', Nature 
communications, vol. 8, no. 1, p. 691. 
 
Linder, S, van der Poel, H, Bergman, AM, Zwart, W & Prekovic, S 2018, 'Enzalutamide therapy 
for advanced prostate cancer: efficacy, resistance and beyond', Endocrine-Related Cancer, vol. 
1, no. aop. 
 
Liu, T, Ortiz, JA, Taing, L, Meyer, CA, Lee, B, Zhang, Y, Shin, H, Wong, SS, Ma, J & Lei, Y 
2011, 'Cistrome: an integrative platform for transcriptional regulation studies', Genome biology, 




Loeb, GB, Khan, AA, Canner, D, Hiatt, JB, Shendure, J, Darnell, RB, Leslie, CS & Rudensky, 
AY 2012, 'Transcriptome-wide miR-155 binding map reveals widespread noncanonical 
microRNA targeting', Molecular cell, vol. 48, no. 5, pp. 760-770. 
 
Logothetis, CJ & Lin, S-H 2005, 'Osteoblasts in prostate cancer metastasis to bone', Nature 
Reviews Cancer, vol. 5, no. 1, pp. 21-28. 
 
Lonergan, PE & Tindall, DJ 2011, 'Androgen receptor signaling in prostate cancer development 
and progression', Journal of carcinogenesis, vol. 10, no. 1, p. 20. 
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